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ABSTRACT
Introduction and aim
It has been suggested that the employment of pharmacists in general practice
might moderate the growth in prescribing costs. However, empirical evidence for
this proposition has been lacking. The aim of this study was to evaluate a
controlled trial of pharmacist-led intervention in general practice to determine
whether intervention practices made savings relative to controls and if so, exactly
how these savings were made and whether quality of prescribing was maintained.
Since this process of rationalisation has implications for patients, an additional
aim was to explore the views of patients on changes made to their medication.
Methods
The study was an evaluation of an initiative set up by Doncaster Health
Authority. Eight practices received intensive input from five pharmacists for one
year (September 1996 to August 1997) at a cost of £163 000. Changes in
prescribing patterns were investigated using Prescribing Analysis and CosT
(PACT) data by comparing these practices with eight individually matched
controls for both the year of the intervention and the previous year. A postal
survey of 314 patients who had undergone a change in medication between
October 1997 and January 1998 was used to explore patient views.
Results
The evaluation showed that the rise in prescribing costs for intervention practices
was significantly lower than for control practices (p=0.02S). Had the cost growth
of the intervention group been as high as that of the controls, their total
prescribing expenditure would have been around £347 000 higher. Detailed
analysis showed that these savings were achieved by controlling both prescribing
volume and cost per unit volume in areas believed to be without detriment to
patient care. The majority of patients were reasonably satisfied or very satisfied
with the way in which they found out about their medication change and
satisfaction was positively associated with being told why the change was taking
place, being given a choice and being told by the GP, a practice pharmacist or by
letter.
Conclusions
Compared with previous studies, this evaluation has advantages in the fact that a
control group was used to compare changes in prescribing patterns. The
evaluation has shown that the use of pharmacists controlled prescribing
expenditure sufficiently to off-set the costs of their employment. Results of the
patient survey indicated that patients were not so much concerned about changes
in medication per se, but rather the manner in which it was conveyed to them.
These results have important implications for the control of prescribing costs in
primary care. However, this study took place in motivated practices that had
relatively high prescribing costs and this may limit the generalisability of the
results.
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1.1 INTRODUCTION
The aims of this chapter are to explain the context of the studies presented in the
thesis, explain how the project was established, give the main aim and objectives
of the research and outline the content of the other chapters in the thesis.
1.2CONTEXT
In 1993/4 Doncaster Health Authority had the highest general practice
prescribing costs per patient of all health authorities in the country. It was
recognised that, although there might be good reasons for these high costs (such
as patient morbidity), the continued upward trend in drug budget overspend had
to be addressed, particularly as existing measures had met with limited success.
The decision was made that a more radical approach was needed. The Health
Executive Team (HET) challenged the Professional Advisers to design a strategy
to tackle the problem. Realising that the problem could not be tackled without
funding, they were prepared to commit a significant portion of development
monies to the initiative.
The strategy decided upon by Doncaster Health was to provide prescriber support
in the form of a pharmacist resource dedicated to each practice. The initial aims
were to:
• bring drug expenditure in Doncaster to within acceptable financial limits
• provide on-going, independent practice-based prescriber support
• maxmuse health gain to the people of Doncaster within the resources
available
• maximise effectiveness, minimise risk, minimise costs and respect patients'
choices
Three possible resources were identified for providing prescriber support. These
were practice-based pharmacists; community pharmacists or general practice
20
(GP) prescribing associates; it was decided that practice-based pharmacists would
be best placed to achieve the desired results.
During their training, pharmacists learn all aspects of the action and uses of
medicines, from the origin and preparation of drugs, to the laws and standards
applying to pharmacy. To qualify as a pharmacist in the UK it is necessary to
complete a four year degree course followed by one year's practical training in
pharmacy (pre-registration training) and then pass an examination to register with
the Royal Pharmaceutical Society of Great Britain, which acts as the regulatory
and professional body for pharmacists in England, Scotland and Wales.
Doncaster Health Authority believed that pharmacists had the necessary skills
and knowledge to provide the type of prescriber support required for the project.
The more difficult question was deciding on the type of intervention the
pharmacists were to deliver. The role of the pharmacist has traditionally been that
of dispensing and advice giving working in settings such as high street
community pharmacy and hospitals. Although the possibility of collaborating
with local pharmacists was raised, potential conflicts of interests with community
pharmacists over remuneration systems for drug dispensing, and the amount of
pharmacist time required to deliver the intervention, contributed to the decision
that the pharmacists should be practice-based rather than working on an
"outreach" basis.
In 1996, all general practices in the Doncaster Health Authority area were invited
to take part in the Prescriber Support Project (PSP) and a workshop, accredited
for Post Graduate Education Allowance, was held to provide more information.
Eight practices (including four fundholders, two single-handed general practices
and one dispensing practice) and a total purchasing pilot (Primary Care 2000)
were recruited. The practices covered 30% of the population in the Doncaster
Health Authority area. There were no entry criteria for these practices (apart from
a willingness to work with a practice-based pharmacist) and so all interested
practices were included. All practices were volunteer practices and none were
coerced into participating.
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The period of employment for the pharmacists was to be for one year in the first
instance, and the Health Authority was to provide ongoing development in the
form of education, training and prescribing information. There was agreement
that while the Health Authority would pay the salaries of the pharmacists,
fundholding practices would pay towards these costs from any savings that they
had made on their budgets during the year of the intervention.
Pharmacists were recruited by local and national advertisements. The Authority
was seeking pharmacists with at least 5 year's experience who were appropriate
for appointment at a senior/principal pharmacist grade (Whitley Council scale D-
F). Of the many applicants, 20 fulfilled the criteria and five of these were
employed. A pharmacist was seconded from the local acute Trust to cover the
purchasing pilot.
The five pharmacists who were appointed had a wide range of skills and
experiences. Two came from community pharmacy, one came from an academic
post and the other two had hospital backgrounds. The skills and experiences of
the pharmacists were taken into consideration when assigning them to the
different practices. Also, a certain amount of "personality matching" took place.
The total purchasing pilot was covered by 0.7 whole time equivalent (WTE) of
pharmacist time while the other eight practices were covered by 5 WTE of
pharmacist time (the amount of time per practice being dependent on list size).
In total, two of the pharmacists worked full-time in two of the practices, one
pharmacist worked half-time in two of the practices and the four remaining
practices were covered by two pharmacists each working 0.6 WTE and 0.4 WTE
in two practices.
The intended role of the pharmacists was to work with the practices to help
control prescribing costs while maintaining or improving prescribing quality,
The Health Authority provided the practices with feedback on their prescribing
and each practice decided on its own priorities for action in conjunction with the
pharmacist assigned to that practice. It was felt that the scheme would not require
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a large time commitment from GPs, because the pharmacists were capable of
making agreed changes to patients' medications and dealing with patients'
questions and concerns.
1.2.1Training and support for pharmacists
Pharmacists were provided with the following options for training and support:
• an introduction to the Project with an information pack
• half day training sessions on aspects of therapeutics at the University of
Sheffield
• regular meetings with other pharmacists involved in the Project to share ideas
and gain support
At the introductory session, pharmacists were provided with background
information on the Project. They were supplied with information on the wide
range of prescribing data that they could request from the Health Authority on
their practices and given information on the analysis of Prescribing and CosT
(PACT) data. Inaddition, they received an information pack that included:
• feedback on the prescribing of their practices based on PACT data
• a glossary of terms used for the interpretation of PACT data
• information on prescribing indicators
• an example of a "pharmacist's diary"
The pharmacists were asked to keep a diary in which they would record any
actions that they or their practice took to review or alter prescribing during the
course of the project. These diaries were then returned for analysis by Doncaster
Health Authority staff.
The half-day training sessions at the University of Sheffield took place in the
Department of Pharmacology and Therapeutics under the direction of Professor
Ramsay. Eight sessions were organised and each of these focused on different
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therapeutic areas. There was strong emphasis on evidence-based medicine in the
sessions.
The pharmacists met regularly (approximately monthly) following the
introductory session. These meetings provided a forum for the exchange of
information, ideas and strategies for managing change in the practices. The
meetings also provided an environment where the pharmacists could support
each other. It was felt that with the pharmacists coming from different
backgrounds, there was much that they could learn from each other.
1.2.2 The intervention
Although each practice decided on its own priorities for action in conjunction
with the pharmacist assigned to that practice, analysis of the pharmacist diaries
showed that a range of strategies were employed by the pharmacists and these are
summarised below:
• Repeat prescription review
• Generic substitution
• Nursing and residential home reviews
• Formulary review
• Review of gastro-intestinal drugs
• Review of cardiovascular drugs
• The establishment of pharmacist-run asthma clinics
Further details can be found in Appendix 6.
1.2.3 Key personnel involved in the Project at Doncaster Health
The establishment of the Prescriber Support Project required considerable input
from a number of personnel at Doncaster Health and the key roles are outlined
below:
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1. Medical Adviser
The Medical Adviser led and co-ordinated the whole project. He acted as a
major driving force to get the project up and running.
2. Pharmaceutical Adviser
The Pharmaceutical Adviser gave professional guidance and helped to draw
up the strategy, employ the pharmacists, liaise with the Local Pharmaceutical
Committee (LPC) and devise the information packs to guide the pharmacists.
3. Assistant to the Advisers
The assistant to the Advisers had an essential role in dealing with enquiries
from the pharmacists and in helping to provide information including
feedback on prescribing. He had a significant role in dealing with personnel
issues.
4. Finance and Personnel
Input from Health Authority staff with expertise in finance and personnel
issues was very important. Initially the pharmacists were to be employed by
the practices themselves with the Personnel Department at Doncaster Health
acting in an advisory capacity. However, it was eventually decided that
Doncaster Health would act as an 'agency' for the pharmacists, with the GPs
paying for services and then claiming for those services from General Medical
Services monies.
1.3 RATIONALE FOR THE STUDY
In evaluating the Prescriber Support Project, Doncaster Health decided to seek
help from an academic partner. Doncaster Health were keen to collaborate with
an academic partner with a track record in prescribing research and so they
approached Professor Tony Avery, then Senior Lecturer, at the Division of
General Practice, Nottingham. At the time, I was employed as a Research
Associate to work with Professor Avery on the Department of Health funded
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study "NHS Prescribing Research Initiative: identifying how some general
practices control their prescribing costs" (Avery et al. 2000). Itwas decided that I
would take the lead for this evaluation and register, initially, for the degree of
MPhil, and then latterly for the degree of PhD, with Professor Avery acting in the
role of supervisor.
By September 1996 the pharmacists had started working with the eight
intervention practices and for the purposes of the evaluation, this date was taken
as the beginning of the first year's intervention. The total purchasing pilot was
not included in the evaluation. The total cost of the scheme including
employment of the pharmacists, training and set-up was £163 000.
1.4 AIM OF THE STUDY
The main aim of the study was to evaluate the pharmacist-led intervention to
determine whether this helped general practices to control their prescribing costs.
Although there was evidence to suggest that there were benefits to employing
pharmacists in general practice (Burton, Duffus and Williams, 1995; Corbett,
1995; Jenkins, 1996; Macgregor et al. 1996), little had been done by way of
economic analysis. In cases where financial gains had been cited (Bradley, 1996;
Speak and Gibson, 1996), it was difficult to say whether the savings had been
made as a result of the employment of the practice pharmacist, rather than any
other factors. This is why a control group was used in this study and it was this
factor, in conjunction with the type of analysis done, which contributed to the
originality of the work.
In order to achieve the overall aim of the study a series of research questions was
devised. The research questions, which form the basis of my thesis, were:
1. Do intervention practices make savings in prescribing costs compared with
matched controls?
2. Do any savings cover the costs of the intervention?
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3. What changes do intervention practices make in their prescribing patterns
compared with matched controls?
4. Is the quality of prescribing maintained on the basis of any changes In
prescribing patterns?
5. What are the views of patients on changes made to their medication?
1.S STUDY DESIGN AND THESIS STRUCTURE
The research questions were addressed in three discrete studies. Each study has
been presented as a separate chapter in this thesis, containing an introduction,
aims, methods, results and summary of main findings. To avoid repetition,
discussion of methodological issues and key findings from each study has been
presented in the final discussion chapter. A brief summary of the contents of each
chapter is given below.
Chapter 2: Literature review
A review of international policy and peer-reviewed literature was undertaken at
the beginning of the study and updated as new publications appeared. This
chapter places the study in context of this literature and identifies the gaps in the
knowledge that this thesis set out to examine.
Chapter 3: Changes in prescribing costs of intervention and control
practices
An observational study was conducted to assess differences in prescribing costs
of intervention and control practices using Prescribing Analyses and CosT
(PACT) data from the Prescription Pricing Authority (PPA).
Changes for overall prescribing costs and prescribing costs within chapters and
subchapters of the British National Formulary (BNF) were assessed using PACT
standard reports (pACTline) for each of the intervention and control practices.
This data contains an analysis of general practitioner (GP) prescribing and, at the
time of data collection, was transferred electronically to the health authority on a
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monthly basis. The results of this analysis made it possible to determine whether
the intervention practices made relative savings in prescribing costs compared
with their matched controls and whether any relative savings were sufficient to
cover the costs of the intervention.
Chapter 4: Changes in prescribing patterns of intervention and control
practices
In order to assess the types of changes that took place, a second observational
study was carried out which entailed a much more detailed analysis of PACT
catalogues (Level 3 PACT) using specially designed computer software
(Optimise). Level 3 PACT catalogues contain detailed feedback on a practice's
prescribing down to the level of formulations, doses and quantities given and, at
the time of the study, came on paper from the PPA on request. Results of this
analysis made it possible to examine changes in prescribing volume and costs per
unit volume right down to individual drug and preparation level. The calculation
of potential savings that could be made through generic substitution of brand-
named products was also possible. Proxy measures of prescribing quality using
Level 3 PACT data were used to assess whether quality of prescribing was being
maintained (or improved) by the intervention practices.
Chapter 5: Patient satisfaction with changes in their medication
Assessing the views of patients was seen to be an important part of the
evaluation, and this chapter presents the results of a questionnaire survey of
patients who had undergone a change in their medication in the intervention
practices. The aims of the survey were to explore patients' satisfaction with
changes in their medication and identify levels of satisfaction in relation to the
way in which the change was carried out.
Chapter 6: Discussion
Methodological issues and key findings from each of the three studies are
discussed in this final chapter in light of recent national policy and peer-reviewed
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literature. Policy implications of the findings and future areas for research are
also discussed.
1.6 ETHICAL CONSIDERATIONS AND DATA PROTECTION
Ethical approval for the analysis of PACT data was not required at the time of the
study. However, approval was required for the patient satisfaction survey and was
obtained from the Local Research Ethics Committee (LREC) at the start of the
study. All data were stored with strict adherence to Data Protection Act (1998)
regulations. All electronic data were stored in password protected files on a
computer used solely by the researcher and was recognisable only by its
Prescription Pricing Authority (PPA) number. This number, assigned by the PPA,
is unique to each practice. All paper-based data, completed questionnaires and
correspondence relating to the study were stored in a locked filing cabinet
accessed only by the researcher. At the end of the study all data were archived in
accordance with the 1998 Data Protection Act.
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CHAPTER2
LITERATURE REVIEW
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2.1 INTRODUCTION
This chapter presents the background to the study and places it the context of
international peer-reviewed literature. It focuses on the variation in, and the need
to control, the rise in GP prescribing costs, and the various methods which have
been employed to improve prescribing practice. The growing collaboration
between GPs and pharmacists is discussed and a number of studies where this
collaboration has been used to rationalise prescribing are highlighted. This
process of rationalisation has implications for patient outcomes in terms of
satisfaction with health services and compliance with medications. These issues
are addressed in light of the growing body of literature surrounding the move
towards shared decision-making in the doctor-patient relationship. The gaps in
the literature that this thesis set out to examine are identified.
A great deal has happened since the time of this study and there have been many
developments in the role of the pharmacist. A number of studies evaluating a
range of pharmacist interventions in general practice to improve prescribing
outcomes have taken place, and publications from this thesis (Rodgers et al.
1999; Rodgers, Avery and O'Neill, 2000) have contributed to this body of work.
This chapter therefore concludes with a summary of the recent developments in
the field and highlights those studies relevant to this thesis.
2.1.1 How the literature was identified
The literature was identified by searching computerised databases (e.g. Medline
and Cochrane library, Web of Science, BIDS etc) and journals such as the British
Medical Journal, British Journal of General Practice, Pharmaceutical Journal,
International Journal of Pharmacy Practice, Journal of the American Medical
Association and Quality in Health Care. Key words used in the searches can be
found in Appendix 1. In addition reference lists of relevant articles were hand
searched.
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The information presented is not the result of a structured systematic review, and
in many cases, where more than one study had similar findings, only one study
has been referenced. Due to the volume of published work in this field, in many
cases, details of individual studies have not been given. However, details have
been given of those studies thought to be particularly relevant to the thesis. Only
articles published in English have been included in the review and due to
differences in the organisation of health care systems, the review has mainly been
confined to work conducted in the United Kingdom (UK), although reference is
made to studies conducted in the United States of America (USA), Canada,
South Africa and Europe.
2.2 BACKGROUND
Drug treatment is extremely common in general practice with an estimated 60%
to 75% of patients receiving a prescription on consulting their GP (Bligh and
Walley, 1992). In 1994,456 million prescription items were dispensed at a cost
of £3 404 million, an increase of 5.9 % in real tenus compared to the previous
year (Department of Health Statistical Bulletin, 1995). The number of
prescription items dispensed has now risen to 650 million and the costs incurred
more than doubled to £7 510 million in the year 2003 (Department of Health,
2004). When it is considered that 83% of the prescription items dispensed in
2003 were free to patients (Department of Health Statistical Bulletin, 2004), it is
understandable why the control of prescribing costs is of great concern to the
government.
In 1990 the Audit Commission became responsible for external audit of National
Health Service (NHS) bodies in England and Wales, including health authorities.
At the time, health authorities were responsible for overseeing primary care
delivered by GPs and dispensing by community pharmacists.
In 1994 the Commission published the results of its study of prescribing in 54
practices, located in ten health authorities (HAs), in the report "A prescription for
improvement: towards more rational prescribing in general practice" (Audit
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Commission, 1994). The study found great variation in prescribing costs between
health authorities and individual practices and deemed much of this prescribing
as unnecessary and wasteful. Repeat prescribing was highlighted as a particularly
problematic area. The report concluded that the NHS could save up to £425
million per year if general practitioners agreed to change their prescribing habits
by:
• increasing prescribing of the "top 20" generic drugs
• substituting comparable but cheaper drugs
• more appropriate use of expensive preparations
• prescribing fewer drugs of limitedclinical therapeutic value
I
• using less drugs often over prescribed /
Although the strategies proposed by the Audit Commission were viewed as
potentially useful for cost control, there was little evidence that the strategies
were being used to control the rise in prescribing costs. There was therefore a
need to influence prescribing behaviour and it was hoped that this could be
achieved by encouraging GPs to "rationalise" their prescribing.
2.2.1 Rational prescribing
Rational prescribing has been defined by Manojlovic and colleagues (see Buetow
et al. 1997) as the "application of an appropriate drug by a correct route in an
adequate dose over a sufficiently long period of time" and has been described as
the process whereby prescribing decisions are made (Buetow et al. 1997).
According to Parish (1973) rational prescribing should be "appropriate, safe,
effective and economic." In other words, rational prescribing should take into
consideration whether the patient's problem is best solved by taking a medicine
(appropriate), and if it is, deciding whether the drug will work (effective),
whether it will do more harm than good (safe) and whether there is a cheaper
alternative which would be just as effective (economic). In 1995, Barber
proposed a wider definition of what a prescriber should be trying to achieve
which included the right of patients to make choices in treatment: a 'good'
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prescriber should aim to maximise effectiveness, minimise risks and costs, and
respect the choices of patients (Barber, 1995). With increasing downward
pressure on the drugs bill, there was the need for health organisations to assess
both the appropriateness and cost effectiveness of treatments in order to
maximise the use of resources.
2.2.2 Appropriate prescribing
Appropriate prescribing is what results (or should result) from the process of
rational prescribing; in other words appropriate prescribing is "the outcome of a
process of decision-making that maximises net individual health gains within
society's available resources" (Buetow et a1. 1997). Inappropriate prescribing not
only has implications in monetary terms, but also in terms of quality
Lunn et al. (1997), in their study of five nursing homes and 13 general practices
in the North West of England, found that elderly residents in nursing homes are
at high risk of inappropriate prescribing. A later study by Strand and Rokstad
(1999) showed that inappropriate prescribing for elderly patients is common in
general practice and the authors suggest that a substantial number of elderly
people may be at risk of suffering adverse drug reactions.
A study by Britten et al. (1995a) which examined the continued inappropriate
prescribing of 25 drugs in 40 patients in general practice found that the influence
of the original prescriber, coupled with the patient's dependence on the drug, in
part explained its continued use. It is interesting to note that the study found that
almost half of the patients were willing to change their medication and shows the
importance of medication review in long-term medication.
Inappropriate prescribing can be attributed to a number of factors including
differences in perspectives of the patient and GP or the result of the complex
interplay in the doctor-patient relationship (Little et al. 2004a). For this reason, it
has been argued that patient involvement in the decision making process is
essential for appropriate prescribing (Barber 1995).
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2.2.2.1 Shared decision making and concordance
The recognition of the need for patient centred consultations has been
documented by Stevenson et al. (2000) in their paper "Doctor-patient
communication about drugs: the evidence for shared decision making". This two-
way communication between patients and health professionals has been termed
"concordance" (Royal Pharmaceutical Society, 1997) and is used to define the
process of successful prescribing and medicines taking, based on a partnership
whereby:
• the patient and health care professional act as partners in making decisions
and agreeing on the treatment
• agreements take into account the experiences, wishes and beliefs of the
patient as to when, how and why the medicines are used
• health care professionals treat each other as partners and work together to
improve patient participation
Concordance is fundamentally different from "compliance" or "adherence"
(which have paternalistic connotations and assume obedience on the part of the
patient) in that it focuses on the consultation process rather than on a specific
patient behaviour. Therefore, although it is possible to have a non-compliant or
non-adherent patient, it is not possible to have a non-concordant patient (Weiss
and Britten, 2003).
Although GPs are likely to learn about concordance as part of their training, there
is evidence that this does not always translate into practice (Stevenson et al.
2000; Jones, 2003). Despite numerous interventions to promote a patient-centred
approach in clinical consultations (Lewin et al. 2004), many GPs still focus on
diseases and disease management rather than on patients, their lives and their
health needs. For concordance to take place, communication between the doctor
and patient is essential.
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2.2.2.2 Communication between doctors and patients
A systematic review of communication between patients and healthcare
professionals about medicine taking and prescribing has been conducted by Cox
et al. (2004). Based on 124 studies, published between 1991 and 2000, this
showed that patients consider talking to doctors about medicines to be very
important and consider it is essential to discuss possible side-effects of their
medicines with them. However, according to one of the studies identified by the
review, (Britten et al. 2000), a number of misunderstandings can arise out of
these discussions. In this qualitative study 14 different categories of
misunderstandings were identified which occurred in GP consultations with
patients. Many of the misunderstandings were "based on inaccurate assumptions
and guesses by both parties" and related to patient/doctor unawareness of
information known to the other party, conflicting information, disagreement
about side-effects, failure of communication about doctors' decisions and
relationship factors. All the misunderstandings were associated with the lack of
patients' participation in the consultation and all were associated with potential or
actual adverse outcomes such as non-adherence to treatment.
These findings were later confirmed by the results of a second study aimed at
developing quantitative measures for use in monitoring communication and
prescribing (Jenkins et al. 2003) which showed that problems in communication
were more likely to lead to poor outcomes in terms of non-adherence. Also, a
Canadian review of 21 studies published between 1983 and 1993 of effective
physician-patient communication, showed that increased communication with
patients was associated with improved patient outcomes (Stewart, 1995).
Communication problems are often linked to unvoiced agendas in the GP
consultation (Barry, 2000) or to different beliefs about medicines (Horne and
Weinman, 1999) and studies have shown that many GPs are largely unaware of
their patients' views concerning medicines (Stevenson et al. 2000). Although it
is a common perception amongst GPs that patients go to the doctor to receive a
36
prescription (Stevenson et al. 1999), many would prefer not to receive one
(Jenkins et al. 2003). Indeed, one study has shown that up to five per cent of
prescriptions issued by doctors are not redeemed by their patients (Beardon et al
1993) and many more that are dispensed are not consumed (Britten et al. 2000).
GPs perceptions of the reactions of patients to changes made in their medications
have also been shown to be inaccurate. A study by Wood et al. (1997) to assess
GPs' and patients' perspectives on three types of prescribing changes to repeat
medication in one fundholding general practice, found that GPs had expected
higher levels of resistance and complaints from patients than had been the case.
In contrast, there were high levels of patient acceptance of changes to medication
provided the proposed change was appropriately communicated.
Thus it would appear that doctor-patient communication should be encouraged to
prevent the unnecessary use of resources and inappropriate prescribing.
2.2.3 Quality of prescribing
Inappropriate prescribing has financial implications in terms of drug wastage
through non-compliance (McGavock, Britten and Weinman, 1996). However, it
also has implications in terms of the quality of prescribing although it is often not
clear what "quality" of prescribing means, how it can be achieved or how it can
be measured.
In a study by Dowell, Snadden and Dunbar (1995) which examined changes in
prescribing patterns and patient satisfaction in one urban, Scottish fundholding
practice, it was uncertain whether the quality of prescribing had improved or
deteriorated due to the "absence of any accepted standards for appropriate
prescribing by general practitioners." Various instruments have been developed
for measuring the appropriateness of prescribing at the individual patient level
and these are discussed below.
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2.2.3.1 Medication Appropriateness Index (MAl)
The Medication Appropriateness Index (MAl) developed by the American
pharmacist, Joseph Hanlon and colleagues (Hanlon et al. 1992) is one such
example. In summary, the MAl may be used to measure the appropriateness of
any medication in any patient according to ten criteria: indication, effectiveness,
dosage, directions, drug-drug interactions, drug-disease interactions, expense,
practicality, duplication and duration (Buetow et al. 1997). The criteria each have
an operational definition, and are worded as questions which can be scored on a
three-point Likert scale. The drug is then deemed appropriate; marginally
appropriate; or inappropriate (or don't know). By combining the scores, a
weighted MAl score can serve as a summary measure of the drug's overall
appropriateness (Schmader et al. 1994).
2.2.3.2 Prescribing Appropriateness Index (PAl)
The National Primary Care Research and Development Centre, University of
Manchester has investigated different aspects of prescribing appropriateness and
quality indicators (Buetow et al. 1996; Buetow et al. 1997; Cantrill, Sibbald and
Buetow, 1998; Campbell, Cantrill and Roberts, 2000). In a systematic literature
review of 62 UK studies published between 1980 and 1995, the researchers
found that although inappropriate prescribing had occurred, the extent of the
problem was difficult to quantify given the variety of indicators used for the
assessments of quality and the uncertainty surrounding the context of the
prescribing decisions (Buetow et al. 1996). Based on the MAl, the researchers
produced the Prescribing Appropriateness Index (PAl) (Buetow et al. 1997)
which uses nine indicators to judge the appropriateness of long-term prescribing
on the basis of what is recorded in the patients' notes and is not specific to any
given condition or particular drug. However it does not take account of patient
perspectives. This aspect is essential for appropriate prescribing since good
prescribing involves interaction between GPs and patients (Barber, 1995; Royal
Pharmaceutical Society et al. 1997; Stevenson et al. 2000; Cox et al. 2004). An
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instrument that includes patients' views is currently being developed (the
Pharmacolgical Appropriateness Rating of Medications, PARM), but this has not
yet been validated for wider use (Britten et al 2003).
The major limitations of both the MAl and the PAl are that they are time
consuming to use and that they require access to patients' medical records, which
has implications in terms of research governance. For these reasons, Prescribing
Analysis and CosT (PACT) data are often used as a proxy measure of prescribing
quality (Naish, Sturdy and Toon, 1995).
2.2.3.3 Prescribing Analysis and CosT (PACT) data
In the UK, the monitoring of prescribing in primary care is carried out through
the Prescription Pricing Authority (PPA), which compiles national statistical data
relating to the volume and types of drugs prescribed in primary care. Population-
based measures of prescribing appropriateness or quality (e.g. use of generic
drugs; levels of antibiotic prescribing) are derived from PACT data, which
contain an analysis of GP prescribing but which do not include diagnostic or
other individualised information. This type of quality assessment places its focus
more on the costs of prescribing and looks for reductions in costs in areas where
savings can be made without detriment to patients. For example, by reducing
wasteful and expensive prescribing practice in the areas highlighted by the Audit
Commission (1994):
• combination products
• modified/sustained release products
• drugs of limited therapeutic value
• drugs that could be bought over the counter (OTC)
• new and expensive drugs
• topical NSAIDs
• expensive hospital-initiated drugs
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Although PACT data are used as a proxy measure of quality of prescribing, few
validated quality indicators exist (Campbell et al. 1998) and according to Avery
et al. (1998) "further research is needed into the development and use of
indicators based on PACT." The major drawback of using PACT data for
assessing the quality of prescribing is the inability to link a prescription to a
diagnosis, particularly relevant when a drug is indicated for more than one
condition (Cantrill, Sibbald and Buetow, 1998).
2.3 VARIATIONS IN PRESCRIBING COSTS
According to the Audit Commission, up to 80% of patients consulting GPs have
similar conditions which could potentially be treated in standard ways (Audit
Commission, 1994). Nevertheless, in their study, the Audit Commission found a
great deal of variation in prescribing costs between the different health authorities
and between individual practices within each authority. A number of studies
have looked at whether certain practice socio-demographic characteristics are
associated with success at controlling prescribing costs. In one study (Morton-
Jones and Pringle, 1993) the researchers found that 81% of the variation in
prescribing costs at family health services authority level (the precursor to health
authorities) could be attributed to 24 demographic, morbidity and practice
factors, suggesting that "variations in prescribing costs essentially reflect
demand." In a more recent study, socio-demographic characteristics were again
shown to have an influence on overall prescribing costs (Rice et al. 2000), and
these factors are taken into consideration in budget allocation. With the exception
of GP training status, which was shown to be influential in one study (Wilson et
al. 1996), other practice characteristics have not consistently been associated with
the control of prescribing costs (Baines et al. 1998).
Although these factors may have accounted for the majority of the variation in
prescribing costs seen at practice or health authority level, studies have shown
that a number of other factors give rise to variations in prescribing costs at the
level of the individual practitioner.
40
2.4 FACTORS WHICH INFLUENCE GP PRESCRIBING
A wide range of factors, including GP views on prescribing costs, have been
shown to influence GP prescribing decisions (Bradley, 1991; Avery et al. 2000a;
Carthy et al. 2000; Jones, Greenfield and Bradley, 2001a). According to Bradley
(1992a), a number of patient specific factors (such as age, gender, social class and
education) and GP specific factors (such as peer influences, concerns about drugs
and self expectations) influence the decision whether or not to prescribe. In one
study which set out to assess whether GPs working in practices with high or low
prescribing costs have different views on prescribing cost issues, the researchers
found that the only differences between the two groups of GPs were in relation to
"substitution with comparable but cheaper drugs" (Avery et al. 2000a). GPs in
higher cost practices were more likely to favour drugs such as modified release
NSAIDs "because they are convenient for patients" (Avery et al. 2000a). In a
recent study by Watkins et al. (2003), certain attitudes and behaviour were found
to be more prevalent in practices with higher prescribing costs e.g. GPs in high
cost practices were more likely to see pharmaceutical company representatives.
2.4.1 The pharmaceutical industry
The pharmaceutical industry has been shown to influence prescribing decisions,
especially in the uptake of new drugs (Peay and Peay, 1988; McGavock et al.
1993; Jones, Greenfield and Bradley, 2001b; Prosser and Walley, 2003;); so too
have hospital consultants (Feely et al.I999). According to Prosser, Almond and
Walley (2003) the decision to initiate a new drug is influenced by "who says
what" and found that the pharmaceutical industry, in particular the company
representative, exerted most influence. It would seem that GPs see the drug
company representative as an important source of information about new drugs
(Jones, Greenfield and Bradley, 2001b).
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2.4.2 Patients' expectations
In the Audit Report (1994) "patients' inappropriate expectations" were cited as
one cause of over prescribing in general practice (Audit Commission, 1994). It
has been shown that GPs' perceptions of patients' expectations (even when they
are not accurate) are indeed a major influence on prescribing decisions (Britten,
and Ukoumunne, 1997; Cockburn and Pit, 1997; Butler et al. 1998). The GP's
concern to maintain their relationship with the patient has been identified as
having a strong influence on prescribing behavoiur (Bradley, 1992b; Cockburn
and Pitt (1997) and it has been shown that GPs sometimes write inappropriate
prescriptions to preserve this relationship (Macfarlane et al. 1997; Butler et al.
1998). The results of a nested observational study within a recent randomised
control trial of the effect of leaflets to empower patients in GP consultations
(Little et al. 2004a), found that "a significant minority of examining, prescribing,
and referral, and almost half of investigations, are still thought by the doctor to be
slightly needed or not needed at all, and perceived patient pressure is a strong
independent predictor of all doctor behaviours."
2.4.3 Collaboration with pharmacists
As early as the mid 1980's the potential for collaboration between GPs and
pharmacists was being recognised. The Nuffield Report (Nuffield Foundation,
1986) stated "closer relations between GPs and community pharmacists would be
in the interests of patients and ..... more efficient use of resources within the
NHS." By the early 1990's, the need for greater collaboration between
pharmacists and GPs to rationalise prescribing was increasingly highlighted
(Royal Pharmaceutical Society, 1992; National Audit Office, 1993; Audit
Commission, 1994; Schneider and Barber, 1996; Bradley, Taylor and
Blenkinsopp, 1997) and before long there was growing interest in the expansion
of the role of the community pharmacist (Morton-Jones and Pringle, 1994;
Britten et al.1995a; Hanlon, 1996; Lunn et al. 1997; Begleyet al. 1997).
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2.4.3.1 The traditional role of the pharmacist
The traditional role of the pharmacist is that of providing pharmaceutical care in
the dispensing of drugs and (in the case of community pharmacists) over-the-
counter preparations used to self-treat minor ailments. The term "pharmaceutical
care" has been defined by Hepler and Strand (1990) as the identification of
potential and actual drug-related problems, the resolution of actual drug-related
problems and the prevention of potential drug-related problems. The
pharmaceutical care that pharmacists give to patients is usually in the form of
product-related information (i.e. relating directly to the drug therapy) although
non-pro duct-related information (e.g. information pertaining to health promotion
activities) is also given. Although pharmacists have extensive knowledge of
medicines, it has only been in the hospital setting that pharmacists have had the
opportunity to fully utilise their skills, having a highly significant role in
medicines management (Tweedie, 2001). However, by the 1990's the under-
utilisation of pharmacist's skills was being recognised and the view of the
pharmacist as the provider of expert advice was one of the central themes of the
"Pharmacy in a New Age" discussion document (Royal Pharmaceutical Society,
1995). The combination of their pharmacological knowledge as well as their
knowledge of drug costs, something which many GPs lacked (Ryan et al. 1990;
Ryan et al. 1992), meant that pharmacists were well placed to help rationalise
prescribing in primary care.
2.4.3.2 The changing role of the pharmacist
In 1994, the Department of Health announced additional funding for projects to
investigate the feasibility of more formal working arrangements between GPs and
pharmacists (Department of Health, 1994) and a number of studies were funded
to assess the training needs of pharmacists to support and influence prescribers in
primary care. One such study was that done by Web and Barton (1997) whereby
six pharmacists were employed to work on a one day per week basis as
prescribing advisers to practices in the Birmingham FHSA. Initial competencies
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of the pharmacists were assessed and a training programme devised to resolve
any deficiencies. It was found that the pharmacists initially lacked the confidence
required to influence prescribers. However, subsequent to the training
programme (which included four days training on communication, negotiating
and influencing skills) the confidence of the pharmacists improved significantly.
However, no formal evaluation of the impact of the pharmacist advice was done.
In total, by the mid 1990's, 17 projects were being funded by the NHS Executive,
all of which were looking at different ways in which community pharmacists
could influence prescribing in areas such as formulary development and repeat
medication reviews. One of these project, known as known as IMPACT
(independent monitoring of prescribing costs and trends) involved the
recruitment of ten pharmacists, to deliver targeted prescribing messages to GPs
on a one-to-one basis (Anon, 1998; Chapman, 1996). However, the results of
many of these projects were never published.
New ways of working were also being investigated, with pharmacists being
employed in general practices or working on a sessional basis in practice-based
outpatient clinics and these are discussed further in section 2.5.4.
2.4.3.3 Barriers to collaboration between pharmacists and GPs
Expanding the role of pharmacists inevitably impacts on the role of the GP and
quantitative surveys addressing GP attitudes towards pharmacists have shown
mixed reactions. A study conducted by Spencer and Edwards (1990) showed that
approximately one third of 744 GPs surveyed thought pharmacists should "stick
to dispensing" and felt that pharmacists were too influenced by commercial
pressures to provide unbiased advice. In contrast, a survey of 266 Scottish GPs by
Bond et al. (1995) found a more positive attitude towards increasing the role of
pharmacists, particularly in areas such as advice on medicines storage within
surgery premises and simplification of drug regimes for the elderly. However,
there was less support for the pharmacist acting independently and having a
direct effect on patient care, such as selection of medicines and dosage according
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to agreed protocols. A post-survey workshop showed this lack of support for the
proposed "new" roles to be attributed to factors such as the professional boundary
infringement, lack of appreciation on the part of the GPs of pharmacists'
knowledge and training, and concerns about the pharmacists' commercial
interests.
Lack of understanding of the pharmacists' extended roles was also shown to lie
behind the perceived attitude of some GPs in a study by Reebye et al. (1999).
This study, which explored community pharmacists' perceptions of their
professional relationships with GPs in Canada and the Netherlands, found that
the major barriers to closer working included the lack of face-to-face contact, the
work environment and issues of territoriality (Reebye et al. 2002). To improve
collaboration between the two groups of professionals the authors suggest that
levels of professional interaction should be increased through structured meetings
or joint initiatives with an emphasis on patient care. In addition, pharmacists
should be more explicit about their extended role so that a mutual understanding
of roles can be achieved thus minimising the issue of territoriality. Other studies
have cited the inability of pharmacists to contact GPs as a perceived barrier to
closer working (Raisch, 1993). Perhaps the structured meetings suggested by
Reebye et al. (2002) could help overcome this obstacle.
2.5 INTERVENTIONS TO INFLUENCE PRESCRIBING BEHAVIOUR
A range of interventions have been developed in an attempt to control the rise in
GP prescribing costs which have been shown to result in varying degrees of
success and some of these are discussed below.
2.5.1 Incentive schemes
In the early 1990's a number of incentive schemes were in place at both national
and local level which aimed to influence GP prescribing behaviour with the end
result of controlling the rise in prescribing costs in primary care. One of the major
initiatives was the fundholding scheme.
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2.5.1.1 Fundholding scheme
The fundholding scheme allocated general practices annual cash-limited budgets,
to cover three aspects of patient care: a range of non-emergency hospital services,
the salaries of non-medical staff and prescribed medicines and appliances
(Keeley, 1997). Savings made on these budgets could be moved between the
different components or used at the practice's discretion to enhance services to
patients. The objective of introducing the initiative was to give practices a direct
incentive to contain the rise in prescribing costs and fundholders who persistently
failed to manage their budgets effectively risked the removal of their fundholding
status. A number of studies showed that relative savings were made by
fundholders in their first year in the scheme (Whynes, Heron and Avery, 1997;
Harris and Scrivener, 1996; Wilson et al. 1997; Rafferty, Wilson-Davis and
McGavock, 1997). These relative savings were made by increasing generic
prescribing (Wilson, Buchan and Walley, 1995; Dowell, Snadden and Dunbar,
1995), and decreasing the average cost per item, rather than by prescribing fewer
items (Harris and Scrivener, 1996). However, the cost-reducing effect did not
appear to extend beyond the first year in the scheme (Stewart-Brown et al. 1995;
Whynes, Heron and Avery, 1997) except by dispensing practices. It was thought
that this was due to the fact that dispensing GPs were better informed about
prescribing costs and so responded more effectively to the initiative (Stewart-
Brown et al. 1995).
2.5.1.2 Indicative prescribing schemes
Those practices that either chose not to enter into fundholding (or were restricted
from doing so due to their list size), were allocated indicative prescribing
amounts with incentives, based on previous spending and adjusted for variables
such as price rises, changes in list size etc. The objective was to encourage GPs
to critically examine their prescribing and to look to ways to make it more
rational. The relative savings that were seen in fundholding practices were to
some extent also seen in non-fundholding practices in their response to these
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incentives (Bateman et al. 1996). However, the lack of studies to investigate the
costs and benefits of such schemes makes it difficult to evaluate the factors which
are crucial for cost control. With the formation of primary care groups (PCGs) in
1999, a new incentive scheme was devised which was more closely linked to the
quality of prescribing. This new incentive scheme was evaluated by Ashworth et
al. (2002) in 2000 by means of a questionnaire survey of prescribing advisers in
145 primary care groups in London and South East England. The researchers
found that the size of incentive payments was not associated with cost control or
quality of prescribing and questioned the use of such schemes to control
prescribing costs.
2.5.2 Prescribing Advisers, guidelines and formulary development
Introduction of the indicative prescribing scheme in the early 1990's included the
provision of medical advisers employed by health authorities to provide impartial
advice on prescribing (Bligh and Walley, 1992) by means of practice visits,
facilitation of educational meetings, production of local bulletins or a
combination of approaches. Although seen by the Audit Commission as essential
for rational prescribing (Audit Commission, 1994), few studies have assessed
their impact on prescribing costs (Newton-Syms et al. 1992).
The objective behind the development of practice formularies was to encourage
rational prescribing by selecting cost effective and acceptable drugs for patients
presenting with the most common conditions seen in general practice. Although
of educational value to those involved in their development (Essex, 1989), it has
been found that they have been associated with relatively small changes in
prescribing costs (Hill-Smith, 1996; Avery et al. 1997). The evidence would
suggest that the same can be said for guidelines (Watson et al. 2001; Wathen and
Dean,2004).
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2.5.3 Educational interventions
With the drugs bill forming such a large proportion of health care expenditure a
wide range of educational interventions have been introduced with the aim of
reducing prescribing costs.
In 1995 Davis and colleagues published a systematic literature review of studies
published between 1975 and 1994 that looked at the effectiveness of education
strategies designed to change physician performance and health care outcomes
(Davis et al. 1995). They identified 99 trials containing 160 intervention
strategies which included:
• dissemination of educational materials
• formal continuing medical education activities
• outreach visits (such as academic detailing)
• audit and feedback (including the use of PACT data)
• development of guidelines, formularies or standards
• a combination of the above
They concluded that commonly used methods of delivering education such as
conferences or prescribing feedback without any discussion with the prescriber
have little impact on improving professional practice. These findings were later
confirmed in 1999 by a large randomised controlled trial from Australia
involving 2 440 GPs in which the investigators found that sending the GPs
prescribing feedback along with some therapeutic recommendations did not alter
their subsequent prescribing rates (O'Connell, Henry and Tomlins, 1999).
It was anticipated that the introduction of Prescribing Analysis and CosT (PACT)
data in the UK in 1988 would enable GPs to look critically at their prescribing
and help them to prescribe more rationally. The data give an analysis of what GPs
have prescribed (and how much their prescribing has cost) in the preceding three
month period and are produced by the Prescription Pricing Authority (PPA)
following the reimbursement of community pharmacists and dispensing GPs for
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dispensing FPI0 prescriptions. The data give information on both individual GPs
and the practices' prescribing costs and at the time of the study, compared these
costs with those of other GPs in the same health authority as well as nationally
(Cantrill, Sibald and Buetow, 1998). However, as has been found with other
"passive" interventions, it met with limited success. Nevertheless, there is some
evidence that GPs find PACT data useful, even if rarely used to examine
prescribing in any great depth (Jones et al. 2002).
The results of the review by Davis at al. (1995) showed that other interventions
such as the dissemination of printed material were also ineffective. A later
review of 79 mainly American studies of 96 separate interventions to change the
prescribing behaviour of GPs drew the same conclusions (Gill et al. 1999). More
successful strategies included systematic practice-based interventions and
outreach visits including academic detailing (Avom and Sournerai, 1983).
According to Thomson O'Brien et al. (2004) an "outreach visit" is used to
describe the use of a trained professional to visit a health provider in their
practice setting with the aim of influencing the provider's performance, In their
systematic review of 18 studies involving more than 1 896 GPs, Thomson
O'Brien et al. (2004) found that the effects of outreach visits (comprising of
meetings and written material) were "small to moderate" but that the evidence
did suggest that, when combined with other interventions (such as reminders or
audit and feedback), they were successful in reducing inappropriate prescribing
behaviour. However, according to the authors, the cost-effectiveness of the visits
was not adequately evaluated and further research is needed to identify the key
factors for success.
In contrast to the findings of Davis et al. (1995), a recent systematic review 85
studies to assess the effects of audit and feedback on the practice of health care
professionals found that this type of intervention can be effective in improving
professional practice (Jamtvedt et al. 2004). However, the effects tend to be small
but as the authors point out "may be worthwhile, if the costs of the intervention
are small relative to the benefits gained."
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2.5.4 Pharmacist-led interventions
By the mid 1990's, the role of the community pharmacist was being expanded to
include working with other health care professionals and the public providing
pharmaceutical care in the form of "prescribing support." Prescribing support has
been defined by the National Prescribing Centre and the NHS Executive (1998)
as:
" ... the use of additional professional input into one or more elements
involved in the prescribing process. It has the overall objectives of
promoting high quality, cost-effective medicine use and of improving
the pharmaceutical care of patients. This should allow NHS resources
to be used more effectively and practices to operate with greater
efficiency allowing GPs more time to spend with individual patients
and also to improve the health of their practices populations."
This expanded role encompassed any role undertaken by the pharmacist beyond
drug formulation and dispensing. From as early as the late 1970's to the mid
1990's a number of models for the provision of prescribing support involving
pharmacists with the aim of rationalising GP prescribing were devised and
evaluated. These included the integration of a pharmacist into the general practice
setting, outreach visits by pharmacists and pharmacist-led medication reviews.
Details of studies thought pertinent to this thesis have been outlined below.
2.5.4.1 Integration into general practice
One model put forward for the provision of prescribing support was that of the
pharmacist being integrated into the general practice to either review a number of
areas relating to prescribing or to focus on one specific area. Examples from the
literature are shown below:
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A study by Macgregor et al. (1996) conducted in a single UK general practice
aimed to evaluate a pharmacist managed primary care anticoagulant clinic.
Results showed that pharmacists have the necessary skills to run such clinics,
achieving good therapeutic control in the surgery and improved patient
knowledge. In addition the authors suggest that the liaison between the GPs and
the pharmacist reduced the risk of toxicity and treatment failure and overall, the
GPs believed the quality of care improved.
Burton, Duffus and Williams (1995) examined the impact of a clinical
pharmacist attached to an urban, non-dispensing general practice on a part-time
basis (three days per week) for four months. The pharmacist examined all the
areas within the practice where medicine and prescribing were involved. It was
found that the presence of the pharmacist was non-threatening to the practice and
that positive benefits were obtained by GPs, staff, patients and the pharmacist.
However, changes in prescribing costs were not examined.
Jameson, VanNoord and Vanderwoud (1995) also demonstrated the benefits of
integrating a clinical pharmacist into the primary care setting. In this study, 27
patients at risk for medication-related problems were randomised to receive a one
hour pharmacist-patient consultation to improve, simplify and explain
complicated drug regimens. Twenty nine patients were randomised to a control
group and received usual care. The results of the intervention showed reductions
in costs, and simplification of drug treatment with no reduction in quality of care.
However, no statistical inference could be made due to the small size of the
study.
2.5.4.2 Outreach visits
As shown by the review by Thomson O'Brien et al. (2004), systematic practice-
based interventions and outreach visits including "academic detailing" are more
effective methods for improving professional practice than other methods such as
audit and feedback and educational materials. For this reason a number of models
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have investigated the effect on prescribing patterns of outreach visits to general
practice by a pharmacist,
The work of Avorn and Sourmerai (1982) in the USA showed the value of face-
to- face meetings between clinical pharmacists and GPs in changing prescribing
habits and improving the quality of prescribing for three drug groups. The results
of this randomised controlled trial showed that physicians who were offered
personal educational visits by pharmacists reduced their prescribing of the target
drugs by 14% as compared with controls resulting in substantial cost savings.
In a randomised controlled trial, Lipton et al. (1992) found that pharmacists'
consultations with geriatric outpatients and their physicians resulted in improved
drug prescribing decisions. Changes in dosage, choice of medication and
appropriateness of drug treatment showed that the pharmacist consultations had a
positive impact on the quality of prescribing.
Quality of prescribing was also shown to improve in a study by Corbett (1995) in
which five pharmacists were employed on a sessional basis in five general
practices in Northamptonshire, UK, to provide advice on 360 prescriptions for
non-steroidal anti-inflammatory drugs. As well as being beneficial to the patients,
the pharmacist intervention resulted in more cost-effective prescribing (through
the increased use of generic substitutions and use of cheaper therapeutic
equivalents), was well received by the GPs, and enhanced the professional role of
the pharmacists.
2.5.4.3 Medication review
Repeat prescribing was one area which was highlighted by the Audit
Commission (1994) as being particularly problematic in terms of costs, with the
majority of prescriptions being issued with no face-to-face contact between the
patient and the GP (Zennansky, 1996).
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In the USA, medication review by pharmacists, which has become known as
"brown bag" review, was developed in 1982 (Larrat, Taubman and Willey, 1990)
and has become an established part of community health care in the USA. The
method involves patients bringing all their medications from home for review by
a pharmacist, either to the pharmacy or some other convenient setting. In the
original study, a brown supermarket bag was provided by the pharmacists, hence
the name for this type of review. Although well established in the USA, by the
mid 1990's only small scale projects were being reported in both the UK (Anon,
1995; Edmondson, 1995) and Denmark (Anon, 1993).
Hanlon et al. (1996) studied a pharmacist intervention involving the review of
208 patients aged 65 years or older with polypharmacy (greater than or equal to 5
medications) from a general medicine clinic. A clinical pharmacist met with the
patients during their scheduled visits to evaluate their drug regimens and made
recommendations to them and their physicians. The results showed that
physicians implemented just over half of the recommended medication changes
resulting in a highly significant reduction in inappropriate prescribing scores (and
potentially adverse drug effects) compared with controls.
Another American study (Cowper et al. 1998), examined the cost-effectiveness of
a pharmacist-led prescribing practice protocol for elderly patients in primary care.
Two-hundred and eight patients aged 65 years or older on at least 5 medications
were randomised, 105 patients to the intervention group and 103 to a control
group. The comparator was usual prescribing practice. Follow up was for the
period of one year and the authors concluded that although MAl scores improved
significantly in the intervention group, there were only minor differences in costs.
However, improved MAl scores are associated with a lower need for care and
hospitalisation. The major limitation of this study was that it was conducted in a
single practice setting, thus limiting it's generalisability.
A Scottish study involving 10 GP practices, evaluated the review of patients'
repeat medication by a pharmacist facilitator (Sykes, Westwood and GiUeghan,
1996). The pharmacist recommended treatment changes after discussion with the
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GPs at a review meeting and it was found that, of the 28% (370) of all items
reviewed, 20% (255) were changed according to the pharmacist's
recommendation. A post-intervention questionnaire survey showed that the
majority of the GPs who responded, would like to see the programme provided
on a regular basis.
2.6 PATIENT VIEWS
Although many of these studies assessed the quality of prescribing in terms of the
appropriateness of the drug(s) in question, little attention had been paid to
patients' views on having their medication changed, especially where the changes
were being made to control prescribing costs.
As early as the late 1970' s both the Department of Health (1977) and the World
Health Organisation (1978) stressed the importance of involving patients in the
evaluation of health services. It was recognised that patients' acceptance of advice
may be influenced by their satisfaction with health services (Kincey, Bradshaw
and Ley, 1975) and that by assessing patients' views it may be possible to
ascertain information that could lead to improvements. The 1990 contract for
general practitioners (Department of Health, 1989) stipulated that Family Health
Services Authorities were required to undertake patient opinion surveys and this
was further encouraged by the Patients' Charter for Primary Care (1992) whereby
patients were seen as "users" or "consumers" of healthcare. The importance of
patients' involvement in health care is now widely recognised by the medical
profession (Richards, 1999; Royal Pharmaceutical society, 1997) and the need to
measure patient outcomes as a result of interventions is increasingly required
(Bero et at. 1999). One form of outcome that can be used to measure the impact
of changes in prescribing patterns is patient satisfaction.
2.6.1 Patient satisfaction
Although it would seem that measuring satisfaction is a relatively simple process,
the difficulty lies in the definition of satisfaction and what it means to different
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people. Satisfaction is related to a number of factors such as past experiences,
expectations, lifestyle and values (Locker and Dunt, 1978) and can take on a
variety of meanings depending on the situation and the individual involved. For
example what a GP constitutes as good quality medicine (such as refusing to
prescribe an antibiotic for a sore throat) may not seem so to the patient (who was
hoping for a prescription) with the end result of low patient satisfaction with the
consultation. Therefore the way in which satisfaction is measured, where it is
measured and when it is measured all need to be taken into consideration in the
interpretation of the results (Keeble and Keeble, 1989).
A wide range of surveys of patient satisfaction have taken place over the years
(Hall and Doman, 1988a; Hall and Doman, 1988b; Baker and Streatfield, 1995;
Poulton, 1996; Largey and O'Neill, 1996) and some of these have focused on
prescribing in general practice (Lervy and Clayton, 1986; Dowell, Snadden and
Dunbar, 1995).
In 1995 John Dowell and colleagues studied changes in prescribing patterns and
patient satisfaction in one urban, Scottish fundholding practice upon its entry into
the third wave of the scheme (Dowell, Snadden and Dunbar, 1995). During its
first two months in the scheme, the practice transferred 1187 patients to a newly
developed formulary and employed a communication strategy to inform patients
about changes to their drug regimes. In consequence, the practice's generic
prescribing rate rose from 37% to 58%, average costs per treatment day were
reduced by 9.4% and prescribing volumes fell by 10.4 %. To ascertain reactions
to the changes made, a questionnaire was sent to a stratified random sample of
280 patients whose medication had been changed. Of the 167 patients who
returned the questionnaires, 44% of patients were slightly "unhappy" or "very
unhappy" with the changes made to their treatment. Interviews suggested that the
main reason for unhappiness was with the communication they received rather
than the change itself.
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2.6.2 Factors that may be associated with patient satisfaction
Studies which have looked at patient sociodemographic characteristics to
investigate whether they are associated with patient satisfaction (Hall and
Doman, 1990; Lewis, 1994) have found that satisfaction is associated with
characteristics such as the age and gender of the respondent. Older patients and
female patients tend to report higher levels of satisfaction (Largey and O'Neill,
1996). In addition, levels of educational attainment and social class have been
shown to effect patient satisfaction with health care services (Largey and O'Neill,
1996).
Baker and Streatfield (1995) set out to examine the characteristics of general
practices that influence patient satisfaction. Using a surgery satisfaction
questionnaire, shown to have validity and reliability (Baker, 1990), 220 patients
in 89 general practices were surveyed with a mean response rate of 82%. Results
showed that patients preferred smaller practices, non-training practices and
practices that had personal list systems. The association between levels of
satisfaction and continuity of care has also been demonstrated in other studies
(Hjortdahl and Laerum, 1992; Freeman and Richards, 1993; Freeman and
Hjortdahl 1997).
Increased communication with patients has been shown to be associated with
improved patient outcomes, including levels of satisfaction (Stewart, 1995). In a
recent study, Little et al. (2004b) found that satisfaction, particularly in short
consultations, was increased by encouraging patients to raise issues and to
discuss symptoms and other health related issues in the consultation.
One of the reasons for assessing patient satisfaction is that it has been linked to
adherence to medication. A study by Home, Hankins and Jenkins (2001) showed
that "levels of satisfaction with medicines information were associated with
higher levels of reported adherence and lower levels of satisfaction were
associated with stronger concerns about the potential adverse effects of
medicines. "
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2.7 IMPLICATIONS FOR RESEARCH
It can be seen that by the mid 1990's the potential for collaboration between GPs
and pharmacists to rationalise prescribing had been recognised. In a review of 14
studies published between 1977 and 1996 to examine the effect of expanding the
role of outpatient pharmacists on health services utilisation, costs and patient
outcomes, Bero et al. (1999) found that pharmacist services targeted at health
professionals resulted in favourable outcomes (such as decreased prescribing and
drug costs) compared to health professionals who did not receive the intervention.
However, since many of the studies reviewed (including that by Jameson,
VanNoord and Vanderwoud (1995» were conducted at single sites outside the
UK, it was questionable whether the findings were generalisable to the UK
setting.
In their conclusion, the authors of the review (Bero et al. 1999) highlighted the
fact that "studies that measure the costs as well as the effects of pharmacist
interventions are needed." In addition the authors commented on the fact that
"none of the studies assessing decreased prescribing by physicians evaluated the
impact of the changes in prescribing patterns on patient outcomes." The studies
presented in this thesis set out to investigate both these gaps in the literature.
2.8 DEVELOPMENTS SINCE THE TIME OF THE STUDY
Since completing this study, many changes have occurred, in both policy and
practice. The abolition of regional health authorities and schemes such as
fundholding coupled with the development of Primary Care Groups (PCGs) in
1999 and more recently Primary Care Trusts (peTs) in 2002, (Department of
Health, 2001) have changed the way health care is delivered enormously. InJuly
2000, the NHS Plan set out its vision of health services shaped around the needs
and aspirations of patients (Department of Health, 2000a). The under utilisation
of the skills and expertise of pharmacists has been recognised, opening up new
opportunities for pharmacists designed around the needs of patients and
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integrated with other services (Department of Health, 2000b). Initiatives such as
one-stop primary care centres (Department of Health, 1999) and repeat
dispensing (Bond et al. 2000; Iverson et al. 2001) have been instigated to
improve convenience for patients and reduce waste. Pharmacists now have a key
role to play within PCTs as pharmaceutical advisers (Braybrook and Walker,
1996; Mason, 1996) and have expanded into health care services such as
medicines use review (Nathan et al. 1999; Petty, Zermansky and Raynor, 2001)
(for example as required in the Older People National Service Framework),
medicines management, supply of medicines under minor ailment schemes
(Whittington et al. 2001) and patient group directions (such as emergency
hormonal contraception and smoking cession). One key aspect of their role is
routine analysis of PACT data which affords them an excellent overview of
prescribing patterns within a PCT (Jones and Kendall, 2004). According to the
Audit Commission Report (2003) the number of pharmacists providing
prescribing support to GPs has increased from 150 in 1998 to an estimated figure
in excess of 600 in April 2002.
In addition to the expansion of the range of medicines which pharmacies can
supply without a prescription (Bond and Bradley, 1996; Blenkinsopp and
Bradley, 1996; Thomas and Noyce, 1996), the legal framework has been put in
place to allow pharmacists to act as supplementary prescribers, (Department of
Health, 2003) whereby pharmacists are able, after an initial assessment and
diagnosis of a patient's condition by an independent prescriber (GP), to prescribe
for that patient in accordance with a clinical management plan. This form of
prescribing is particularly suitable for pharmacists working with patients with
chronic conditions, for example, asthma, diabetes, heart disease and mental
illness. However, the expansion of the pharmacist's role in this way may be
perceived as a threat to the status quo from the GPs' perspective (Reebye et al.
2002; Reebye et al. 1999; Lambert, 1996; Spencer and Edwards 1992). Role
boundaries with nurse (and other) supplementary prescribers may not be easily
negotiated, as they move into general practice and begin to prescribe for patients
with long-term conditions. Primary care nurses view chronic disease
management as one of their core activities. A study by Gilbert (1997) which
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examined the perceptions of pharmacists, GPs and nurses on the role of the
pharmacist as a member of the primary health care team in South Africa found
that GPs and nurses strongly protect their own domains when it comes to the
allocation of potential tasks. This has implications with regard to the effective
implementation of this extended role for pharmacists.
It is intended that the role of the pharmacist will eventually be expanded to
include independent prescribing (Department of Health, 2003). Pharmacist
prescribing for mild self-limiting medical conditions has been permitted in
Florida, in the USA for some years and a qualitative study revealed that the two
major perceived barriers to pharmacist prescribing were time costs and liability
exposure (Szeinbach et al. 1998). However, the greatest concern was over
liability exposure. As pointed out by Boatwright (1998), pharmacists need to be
aware of the legal and ethical issues surrounding the adoption of these new roles
and concludes that "the pharmacy profession needs to prepare for expanded
prescribing authority in order to avoid negative reactions from patients,
physicians and possibly the legal community."
In the UK a further barrier to the adoption of new pharmaceutical care models is
the lack of access to patients' medical records (Tully, Seston and Cantrill, 2000).
It is interesting to note that in a pilot study in one urban general practice in
Grampian, UK (Iverson et al. 2001), fewer than half of the respondents to a
questionnaire survey to ascertain attitudes of the general public to the expanding
role of community pharmacists were in favour of pharmacists accessing medical
records. However, as the authors acknowledge, the low response rate (55%) and
the location of the study practice limit the generalisability of the findings.
The evidence base for the benefits of pharmacist intervention in primary care is
growing (Geoghegan et al. 1998; Bradley, Round and Ramsden, 2000; Malone et
al. 2000; Nazareth et al. 2002; Freemantle et al. 2002; Fish, Watson and Bond,
2002; Beney, Bero and Bond, 2004). In one UK-based randomised controlled
study (Zermansky et al. 2002), in which the pharmacist intervention involved a
review of 608 patients receiving one or more drugs on repeat prescription, the
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results showed a significant increase in the mean number of medication changes
per patient compared to the usual-care group. In addition, the number of
medications prescribed and the mean medication cost per patient was less in the
intervention group than in the control group. However, the generalisability of
these findings are limited by the fact that the study took place in just 4 general
practices and the pharmacist involved in the study was an academic research
pharmacist. A larger project involving more practices and pharmacists would be
needed to substantiate these findings.
A recent systematic review of practiced-based pharmaceutical services showed
that educational outreach resulted in the desired outcomes in seven out of the
eight trials identified (Fish, Watson and Bond, 2002). One UK randomised
controlled study evaluated educational outreach visits to general practices by
trained pharmacists to influence GP prescribing in line with four evidence-based
clinical guidelines (Freemantle et al. 2002). The results showed that, overall, the
intervention was associated with a significant improvement in prescribing
practice, although it would appear that the larger the practice, the harder it was to
influence prescribing behaviour. Barriers to the implementation of the guidelines
were identified as being "organisational difficulties, the GPs' scepticism of the
evidence presented to them and the doctors' lack of interest in changing their
prescribing behaviour" (Nazareth et al. 2002).
Another recent systematic review, based on information from 324 papers (Royal
Pharmaceutical Society, 2003), found that collaboration with other health
professionals and patients is a prominent issue in relation to the extension of
pharmacists' roles within primary care service delivery (Tully, Seston and
Cantril, 2000; Dowell et al. 1998). In circumstances where this type of
collaboration has taken place, the review found evidence to suggest that the
pharmacists have been well received and their contributions valued (petty,
Zermansky and Raynor, 2001; Spencer and Edwards, 1992; Williams, Bond and
Menzies, 2000; Bond and Bradley, 1996). A number of barriers to the provision
of extended services have been identified, such as time constraints, renumeration
systems and issues relating to appropriate staff-mix (Petty, Zermansky and
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Raynor, 2001; Szeinbach, Allen and Barnes, 1998). However, the most
significant challenge will be the provision of appropriate training and
professional development support (Tully, Seston and Cantrill, 2000; Smith,
Salkind and Jolly, 1990; Fish et al. 2001). In a qualitative study by Rushton
(2001), 81% of pharmacists surveyed considered that they required further
training and development to undertake new and extended roles.
Pharmacists have an important role to play in the process of concordance and this
has been highlighted in a number of studies identified in the review by Cox et al.
(2004). The review identified two UK based pharmacist interventions comprising
of new or modified pharmacy services (Blenkinsopp et al. 2000; Raynor et al.
2000) which resulted in improvements in a number of patients' health outcomes,
including adherence, satisfaction with services and reductions in the number and
cost of their medications. The first study (Blenkinsopp et al. 2000) assessed the
impact of a patient-centred pharmaceutical intervention involving 25 community
pharmacists targeted at 117 hypertensive patients. Patients in the intervention
group reported significantly increased adherence and greater satisfaction. The
second study (Raynor et al. 2000) involved community pharmacist visits to 143
patients aged over 65 years who lived alone and were regularly prescribed 4 or
more drugs. Results showed a significant increase in adherence and the majority
of patients felt that the intervention had made their medicines easier to manage.
These are important findings and lend weight to the argument that pharmacist
intervention can lead to improved patient outcomes.
Although there has been much emphasis on prescribing costs in this programme
of work, it is important to recognise that the most important role for practice-
based pharmacists is likely to be in promoting high quality patient-centred care
(Ryan-Woolley et al. 2001; Tadros et al. 2003). It is recognised that there is scope
for improving prescribing in primary care (Audit Commission, 2003) and there is
great potential for the involvement of pharmacists in the reduction of
inappropriate prescribing (Mackie et al. 1999; Zermansky et al. 2001) and
medication-related problems in general practice (Yuan, Hay and McCombs,
2003).
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Ten key roles for the future of pharmacy have been identified (Department of
Health, 2003):
• to provide convenient access to prescription and other medicines
• to advise patients and other health professionals on the safe and effective use
of medicines
• to be a point of first contact with healthcare services for people in the
community
• to provide medicines management services, especially for people with
enduring illness
• to promote patient safety by preventing, detecting and reporting adverse drug
reactions and medication errors
• to contribute to seamless and safe medicines management throughout the
patient journey
• to support patients as partners in medicine taking
• to prescribe medicines and to monitor clinical outcomes
• to be a public health resource and provide health promotion, health
improvement and harm reduction services
• to promote value for money in the use of medicines and to reduce wastage
It could be argued that all of the above roles could be best filled by pharmacists
working within a general practice setting.
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CHAPTER3
CHANGES IN PRESCRIBING COSTS OF INTERVENTION AND
CONTROL PRACTICES
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3.1 INTRODUCTION
At the time of this study, a number of reports had suggested benefits from
practice-based pharmacists (Bradley, 1996; Burton, Duffus and Williams, 1995;
Corbett, 1995; Jameson, VanNoord and Vanderwoud, 1995; Jenkins, 1996;
Macgregor, 1996; Macgregor et al. 1996; Macgregor and Hamley, 1996; Mason,
1996; Moorhouse, 1996; Pilling, 1997; Stephenson, 1996) but it was recognised
that there had been little in the way of detailed evaluation making it difficult to
determine whether any changes in prescribing were primarily due to the
pharmacist intervention rather than any other factors.
3.2 OBJECTIVE
The objective of this aspect of the study was to determine whether intervention
practices made savings on their prescribing costs, relative to controls and if so,
whether these savings covered the costs of the intervention. To do this, PACTline
data were used to assess the differences in prescribing costs between the
intervention and control practices for the year of the intervention (September
1996 to August 1997) and the 12 months prior to the intervention (September
1995 to August 1996).
3.3METHODS
3.3.1 Study Design
An observational study was conducted using PACT data to determine whether
intervention practices made savings in their prescribing costs relative to matched
controls. Analysis of PACT data has been widely used by researchers to
investigate variations and differences in prescribing costs (Morton-Jones and
Pringle, 1993; Wilson et al. 1996; Harris and Scrivener, 1996). While a
randomised controlled trial (RCT) might have given a more reliable answer to the
question of whether pharmacists working in general practices can help to control
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prescribing costs, this was not possible using the approach taken by Doncaster
Health Authority.
3.3.2 Selection of practices
3.3.2.11ntervention practices
All 50 practices in the Doncaster Health Authority were offered the services of
dedicated pharmacists. Eight practices volunteered to join the scheme and
received intensive input from five WTE pharmacists for a twelve-month period
(September 1996 to August 1997).
3.3.2.2 <7ontroLS
Before the intervention took place, the practices were individually matched with
controls on the basis of several characteristics that might have an influence on
changes in prescribing costs. These were fundholding, dispensing status, list size,
limiting long-term illness (Majeed et al. 1995) and NIC (net ingredient cost) per
ASTRO-PU (age, sex, temporary resident-originated prescribing unit) for the
quarter January to March 1996 (Roberts and Harris, 1993). The matching was
done by David Meechan from Doncaster Health Authority. Further details are
given in section 3.4.1.
3.3.3 Use of PACT line Data
3.3.3.1 Data collection and manipulation
Changes for overall prescribing costs and prescribing costs within chapters and
subchapters of the British National Formulary (BNF) (Joint Formulary
Committee, 1996) were assessed using PACT standard reports (pACTline) for
each of the intervention and control practices (Majeed, Evans and Head, 1997).
These data contain details of general practitioner (GP) prescribing that has taken
place during the previous quarter and, at the time of data collection, was
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transferred electronically to health authorities from the Prescription Pricing
Authority (PPA). The PPA, which is a Special Health Authority within the NHS,
is responsible for processing all NHS prescriptions that are dispensed by any
community pharmacy or dispensing doctor in England. The data contained
information at practice level for each month on:
• prescribing costs (net ingredient cost (NIC) which is the basic price of a drug
as listed in the Drug Tarift)
• numbers of items prescribed (an item is equivalent to a single product order
on a prescription form and does not take quantity prescribed into
consideration)
• generic prescribing (that is prescribing of drugs using non-proprietary names)
• practice populations (including numbers over 65 years and temporary
residents) from which prescribing units (PU) could be calculated.
(prescribing units give a weighting of three to patients over the age of sixty
five, recognising the increased need for medication in elderly patients).
Data were available for overall prescribing and prescribing within chapters and
subchapters (sections) of the BNF (Joint Formulary Committee, 1996). The BNF,
which is published twice a year by the British Medical Association (BMA) and
the Royal Pharmaceutical Society of Great Britain (RPSGB), consists of
classified notes on clinical conditions, drugs and preparations and is divided into
15 chapters, each of which is related to a particular system of the body or to an
aspect of medical care. Each chapter is then divided into sections which are
structured as a form of hierarchy e.g. chapter 2 covers the drugs affecting the
cardiovascular system, section 2.2 diuretics and section 2.2.2 loop diuretics.
Monthly PACTline data for the period September 1995 to August 1997 were
obtained for the 16 practices under investigation. For the purposes of the
evaluation, the monthly data were combined for the 12 months of the study
(September 1996 to August 1997) and the 12 months prior to the study
(September 1995 to August 1996) to give yearly data for both the intervention
practices and their respective controls.
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3.3.3.2 Use of ASTRO-PUs
Although the PU was to be used initially in the study, it was decided that the age,
sex and temporary resident originated prescribing unit (ASTRO-PU) would be a
more appropriate denominator for measuring changes in overall prescribing costs
(Roberts and Harris, 1993). This is because it takes more account of the cost
implications of differences in the age-sex distribution of practice populations by
weighting patients according to age and sex and also numbers of temporary
residents. Therefore, ASTRO-PU figures (which were available on a quarterly
basis from Doncaster Health) were assigned to the relevant monthly PACTline
data for each practice. This made it possible to calculate NIC/ASTRO-PU and
items per ASTRO-PU for each practice for each of the two years. Also, by
combining the ASTRO-PU figures, it was possible to calculate NIC/ASTRO-PU
and items!ASTRO-PU for the two groups of practices.
3.3.3.3 British National Formulary chapters examined
Most drug costs come from chapters 1 to 6 and 10 of the British National
Formulary (SNF) and so it was decided that the analysis would focus on these
BNF chapters:
• Chapter 1: gastro-intestinal system
• Chapter 2: cardiovascular system
• Chapter 3: respiratory system
• Chapter 4: central nervous system
• Chapter 5: infections
• Chapter 6: endocrine system
• Chapter 10: musculoskeletal and joint diseases
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3.3.3.4 Excluded chapters
The following chapters were not included in the analysis:
• Chapter 7: obstetrics, gynaecology and urinary tract disorders
• Chapter 8: malignant disease and immunosupression
• Chapter 9: nutrition and blood
• Chapter 11: eye
• Chapter 12: ear, nose and oropharynx
• Chapter 13: skin
• Chapter 14: immunological products and vaccines
• Chapter 15: anaesthesia
3.3.3.5 Use of STAR-PUs
STAR-PUs (specific therapeutic area related prescribing units) are considered to
be appropriate denominators for measuring changes in prescribing costs within
BNF therapeutic chapters (Lloyd, Harris and Roberts, 1995). For each of these
chapters, STAR-PUs assign weightings to patients according to their age and sex,
to take account of demographic differences in the use of different types of drugs.
STAR-PU figures for each practice were obtained for chapters 1 to 6 and 10 of
the BNF for quarters ending March 1996 and March 1997. These figures were
assigned to the relevant BNF chapter level PACTline data so that it was possible
to calculate costs (NIC) per STAR-PU for each of the intervention and control
practices.
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3.3.3.6 Prescribing-related outcome measures
Primary and secondary prescribing-related outcome measures were used to assess
changes.
1. Primary outcome measures:
• change in total NIC between the years September 1995 to August 1996
and September 1996 to August 1997
• change in total NIC per ASTRO-PU
• change in number of items between the two years
• change in number of items per ASTRO-PU
• change in total NIC per item
• change in percentage of prescriptions written generically between the two
years
2. Secondary outcome measures:
• changes in NIC per STAR-PU for chapters 1 to 6 and 10 of the BNF
• changes in items per STAR-PU for chapters 1 to 6 and 10 of the BNF
• change in percentage of prescriptions written generically between the two
years for chapters 1 to 6 and 10 of the BNF
3.3.4 Analysis
3.3.4.1 Data manipulation
Data manipulation was carried out using Microsoft Excel (versions 95 and 97).
Monthly data were combined (or averaged in the case of ASTRO-PUs) to give
yearly data for each practice for the year of the intervention (September 1996 to
August 1997) and the previous year (September 1995 to August 1996). This
made it possible to calculate NIC per ASTRO-PU and items per ASTRO-PU for
each of the practices for each of the two years. Inaddition, the data on costs and
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items were added together to give overall figures for the eight intervention
practices and eight control practices for each of the two years. By combining the
ASTRO-PU figures, it was possible to calculate NIC per ASTRO-PU and items
per ASTRO-PU for the two groups of practices. A similar approach to data
processing was taken with data obtained from chapters 1 to 6 and 10 of the BNF
(using STAR-PUs rather than ASTRO-PUs).
3.3.4.2 Choice of statistical test
The data were imported into the software programme Statistics Package for
Social Scientists (SPSS-PC version 8) and tests of normality were carried out on
changes in the different variables between the two years to determine the nature
of the data. The results of these tests showing the Normal Q-Q (Quantile-
Quantile) plots, detrended normal Q-Q plots and values of the Kolmogorov-
Smimov statistic with the Lillifors correction applied, are shown in Appendix 2.
It can be seen that there was deviation from the straight line for all the plots and,
in addition, the significance level was found to be small in more than one
instance. The data could therefore not be taken as having a normal distribution
and so a non-parametric statistical test (Wilcoxon matched-pairs signed-ranks
test) was chosen to investigate differences between the practices. The Wilcoxon
Test is the most appropriate test for a matched case-control study, as it allows for
the pairing to be taken into account in the analysis (Campbell and Machin, 1999).
It is used for paired (two related) samples where the differences observed can be
meaningfully ranked in both magnitude and sign. (Seigel and Castellan, 1988).
The main disadvantage of using this type of test is that it is less powerful than the
equivalent parametric test (the paired t-test).
3.3.4.3 Statistical analysis
Statistical analysis of changes In prescribing variables for intervention and
control practices was carried out using SPSS. The primary analysis was
conducted on changes in overall prescribing variables using a significance level
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of p<O.05. Secondary analysis was performed on changes in prescribing at BNF
chapter level.
3.3.4.4 Calculation of savings
One of the main objectives of the study was to calculate any savings made by
intervention practices compared with controls. Relative savings were calculated
by applying the percentage increase in NIC per ASTRO-PU of control practices
to intervention practices for the year September 1995 to August 1996 to give a
projected NIC per ASTRO-PU for the year of the intervention. This figure was
then multiplied by the mean number of ASTRO-PUs for intervention practices
for the period September 1996 to August 1997 to give projected total costs. The
actual costs of the intervention practices were then subtracted from the projected
costs to give an estimate of the relative savings made.
3.3.4.5 Assessing whether control practices were unusual in their increases in
prescribing costs
In order to compare changes in prescribing costs for intervention and control
practices with other practices, data were obtained for the Trent region as a whole
and for the 10 most similar health authorities in England (selected by the
Prescribing Support Unit, Leeds, on the basis of sociodemographic
characteristics).
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3.4RESULTS
3.4.1 The study population
Table 3.1 shows how the intervention and control practices were matched in
terms of dispensing and fundholding status.
Table 3.1. Dispensing and fund holding status of cases and controls
Group Dispensing Non- Fundholding Non-
Disl!ensing Fundholding
Intervention (n=8) 1 7 4 4
Controls (n=8) 1 7 4 4
Totals 2 14 8 8
As mentioned earlier, practices were also matched with controls on the basis of
initial NIC per ASTRO-PU, list size, locality and estimated percentage of the
population with limiting long term illness. Details are given below.
The median NIC per ASTRO-PU for January to March 1996 (minimum to
maximum) was £6.39 (£5.23 to £10.69) for intervention practices and £6.44
(£5.44 to 8.13) for controls. For the same time period, the median list sizes
(minimum to maximum) for the intervention and control practices were 8 285 (1
370 to 11 674) and 8 394 (2 065 to 13261) respectively. The interquartile ranges
for the list sizes were 2984 to 10874 and 4909 to 9 814 respectively. Postcodes
of individual patients in each practice were applied to Census data, to estimate
the percentage of patients with limiting long-term illness in each of the two
groups (Majeed et al. 1995). The median estimated percentage of population with
limiting long term illness (minimum to maximum) were 15.6 (13.0 to 17.2) for
intervention practices and 15.4 (9.1 to 17.6) for controls. Using the Mann-
Whitney U test, (Campbell and Machin, 1993) there were no statistically
significant differences between intervention and control practices in any of the
above variables at the start of the study.
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Differences between the groups of practices in terms of actual changes in list size
or ASTRO-PUs over the study period were investigated using Wilcoxon
Matched-Pairs Signed Ranks Test and, as can be seen in Table 3.2, there were no
statistically significant differences.
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3.4.2 PACTline analysis of the study practices
3.4.2.1 Overall prescribing variables/or intervention practices and controls
Figure 3.1 shows combined monthly prescribing costs per ASTRO-PU for the
intervention practices and the controls. It can be seen that having started off
slightly more expensive than control practices, the intervention practices were
making relative savings soon after the start of the project in September 1996.
Statistical analysis of PACTline data for overall prescribing variables is shown in
Table 3.4. It can be seen that the change in NIC per ASTRO-PU for intervention
practices was significantly lower than the change in NIC per ASTRO-PU for
controls (p=O.02S). The intervention practices achieved a significantly higher
growth in generic prescribing (p=O.02S), despite their median baseline proportion
of generics being higher than that of controls. While there were small changes in
the number of items prescribed per ASTRO-PU in both intervention and control
practices there were no significant differences between the two groups. However,
the rise in NIC per item for intervention practices was significantly lower than for
control practices (p=O.017).
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Table 3.4 shows combined data for the intervention and control practices
between September 1995 to August 1996 and September 1996 to August 1997. It
can be seen that intervention practices increased their NIC per ASTRO-PU by
3.4% compared with a 9.2% increase for controls. Had the cost growth of the
intervention group been as great as that of the control group, their total
prescribing expenditure would have been around £347 000 higher (Appendix 3).
Given that the cost of the scheme was £163 000, it was estimated that the project
made a net saving of £184000.
For the same time period, the percentage increase in NIC per ASTRO-PU for the
control practices was similar to that of practices in the 10 most similar health
authorities in England (8.5%) (Roberts, D. personal communication) and the
Trent region as a whole (8.4 %) (Wilson, 1. personal communication).
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3.4.2.2 Overall prescribing variables for individual intervention practices and
controls
Changes in prescribing variables for individual intervention practices and
controls over the two years can be found in Appendix 4. Figures 3.2 to 3.5
illustrate the percentage change in these variables. It can be seen that with one
exception, all the intervention practices managed to control prescribing costs
relative to their matched controls. Although the inverse was true in relation to the
number of items prescribed, it can be seen that in general, the intervention
practices were better able to control costs per item and increase generic
prescribing, compared to controls.
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3.4.2.3 Changes at BNF chapter level
The results of the analysis of changes in PACTline data at BNF chapter level are
shown in Table 3.5. Statistically significant differences between intervention
practices and controls were found in chapters 1 (p=0.035) and 5 (p=0.036).
The results of the analysis of changes in PACTline data at BNF chapter level for
combined data for the intervention and control practices are shown in Tables 3.6
and 3.7. It can be seen that there were some consistent trends among the data. In
summary:
• intervention practices showed greater savings than controls in BNF chapters 1,
5 and 10. It can be seen that:
- intervention practices reduced their costs for gastro-intestinal drugs (per
STAR-PU) while controls increased their costs by 6.7%
- intervention practices reduced their costs for drugs used for treating
infections by almost 15% (per STAR-PU) while controls decreased costs
by approximately 3%
- intervention practices reduced their costs for drugs used for treating
musculoskeletal and joint diseases (per STAR-PU) while controls
increased their costs by 3.2%
• intervention practices showed relatively smaller increases in costs than
controls in BNF chapters 2, 3 and 4
• in each of the BNF chapters studied, the intervention practices increased their
generic prescribing rates by a greater amount than the controls
Chapter 2.12 of the BNF, which consists of lipid-lowering drugs, was specifically
looked at, as this is a group of drugs where increases in items and costs would be
expected if practices were taking account of evidence-based medicine
(Scandinavian Survival Study Group, 1994; Oliver, 1995; Shepherd et al. 1995).
Although it is recognised that the use of PACT data to assess quality of
prescribing in this way has many limitations (Naish, Sturdy and Toon, 1995;
McGavock, 2001) the fact that the intervention practices increased their costs for
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these drugs by almost 90% suggests no lack of enthusiasm for increasing the
prescribing of this important class of drugs. Findings relating to the quality of
prescribing for intervention practices are presented in Chapter 4.
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3.5 SUMMARY OF MAIN FINDINGS
3.5.1 Results of PACTline analysis of overall prescribing variables
The change in NIC per ASTRO-PU between September 1995 to August 1996
and September 1996 to August 1997 for intervention practices was significantly
lower than the change for controls (p=0.025). While there were small changes in
the number of items prescribed per ASTRO-PU in both intervention and control
practices, there were no significant differences between the two groups.
However, there was a significant difference between the groups in terms of
percentage change in the percentage of items prescribed generically (p=0.025)
and NIC per item (p=0.017).
Compared with their matched controls, the intervention practices made relative
savings of more than twice the amount that the project cost in terms of the
employment and training of the practice based pharmacists. The relative
differences between the two groups of practices did not appear to be the result of
control practices increasing their costs at an extraordinary rate. For the same time
period, the percentage increase in net ingredient costs for the control practices
(9.2%) was similar to that of practices in the Trent region as a whole (8.4%)
(Wilson, J. personal communication) and the ten most similar health authorities
in England (8.5%) (Roberts, D. personal communication).
Individual practice level analysis showed that, with one exception, all the
intervention practices managed to control prescribing costs relative to their
matched controls. Although the majority of intervention practices increased the
number of items prescribed per ASTRO-PU, in general they were better able to
control costs per item and increase generic prescribing compared to controls.
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3.5.2 Results of PACT line analysis at BNF chapter level
The results of the analysis of changes in PACTline data at BNF chapter level
found statistically significant differences between intervention practices and
controls in chapters 1 (p=0.035) and 5 (p=0.036). Overall:
• intervention practices showed greater savings than controls in BNF chapters 1,
5 and 10
• intervention practices showed relatively smaller increases m costs than
controls in BNF chapters 2, 3 and 4
• in each of the BNF chapters studied, the intervention practices increased their
generic prescribing rates by a greater amount than the controls
Analysis of section 2.12 of the BNF, which consists of lipid-lowering drugs,
showed that intervention practices increased their costs for these drugs by almost
90%.
A detailed account of how exactly practices changed their prescribing costs is
given in Chapter 4.
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CHAPTER4
CHANGES IN PRESCRIBING PATTERNS OF INTERVENTION AND
CONTROL PRACTICES
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4.1 INTRODUCTION
The main aim of the study was to evaluate a pharmacist-led intervention to
determine whether this helped general practices to control their prescribing costs.
Chapter 3 has shown that overall, intervention practices did indeed control their
prescribing costs relative to matched controls but it does not give a great deal of
insight into how this was achieved.
There were 3 key hypotheses:
1. Intervention practices that were successful in making savings were likely to
have introduced specificmeasures aimed at tackling prescribing costs
2. These measures were likely to have focused on areas of prescribing where
changes could be predicted to produce significant savings e.g. generic
substitution or use of less expensive drugs
3. Intervention practices would have chosen to make savings m areas of
prescribing where cost reduction is unlikely to cause detrimental effects to
patients
The first two hypotheses were tested by analysing changes in prescribing patterns
in order to identify the types of strategy used. The third hypothesis was tested by
investigating the different ways in which it has been suggested that GPs could
make savings (without detriment to patients). Many of these suggested methods
for cost control were outlined in the Audit Commission Report: "A Prescription
for Improvement: Towards more Rational Prescribing in General Practice"
(1994) and are shown below:
• increased prescribing of the "top 20" generic drugs
• substitution of comparable but cheaper drugs
• appropriate use of expensive preparations
• prescription of fewer drugs of limited therapeutic value
• less use of drugs often over prescribed
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Although previous studies have suggested that general practices can control their
prescribing costs by reducing the volume of prescribing (Bradlow and Coulter,
1993, Dowell, Snadden and Dunbar, 1995; Maxwell et al. 1993; Wilson, Buchan
and Walley, 1995), and the cost per unit volume (Bradlow and Coulter, 1993,
Dowell, Snadden and Dunbar, 1995; Maxwell et al. 1993), and by increasing
their rates of generic prescribing (Bradlow and Coulter, 1993, Dowell, Snadden
and Dunbar, 1995; Maxwell et al. 1993; Wilson, Buchan and Walley, 1995;
Stewart-Brown et al. 1995) few studies have looked in detail at the range of cost
control strategies suggested by the Audit Commission (1994) (Baines, Tolley and
Whynes, 1997; Baines, Whynes and Tolley, 1997). A key issue for this part of the
study was to identify which of these suggested methods were actually used by the
intervention practices.
4.2 OBJECTIVES
The objectives of this aspect of the study were to determine exactly how the
practices either controlled or increased their prescribing costs in terms of changes
m:
1. Volume of prescribing
2. Cost per unit of prescribing volume
3. Generic prescribing
4. Areas of prescribing where the Audit Commission suggested that savings
might be made (without detriment to patients) :
• combination products
• modified/sustained release products
• drugs of limited therapeutic value
• drugs that could be bought over the counter (OTC)
• new and expensive drugs
• topical NSAIDs
• expensive hospital initiated drugs
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5. BNF chapters
6. BNF therapeutic groups
7. Specific drugs and preparations
A supplementary objective was to assess whether quality of prescribing was
maintained by practices that made relative savings on their prescribing costs. Due
to time and financial constraints, it was not possible to visit the individual
practices to do detailed analyses of prescribing quality. It was therefore decided
to use PACT data to provide proxy measures of prescribing quality.
4.3METHODS
4.3.1 Analysis of Level3 PACT data
An observational study was carried out using Level 3 PACT data to do detailed
analyses of changes in prescribing (Majeed, Evans and Head, 1997). These data
provide information on practices' prescribing patterns right down to the level of
individual drugs and preparations. From Level 3 PACT data it was possible to
calculate defined daily doses, which, according to Bogle and Harris (1994) are a
more accurate measure of prescribing volume than items.
Changes in prescribing patterns were based on combined data for each of the two
groups. The combined data were produced by the Optimise software using a
function that allows for the combination of different data files.
4.3.1.1 Use of Optimise software
Enigma Medical Systems (EMS) developed Optimise software in order to help
analyse changes in Level 3 PACT data. The software was designed to help
general practitioners and health authorities to:
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• identify potential savings that could be made on prescribing costs
• look at prescribing indicators of their choice
• compare changes in prescribing costs (and other prescribing patterns)
between two years
The software worked in the following way. Paper-based Level 3 PACT data were
entered onto computer. The following information was recorded on a database:
• name of preparation
• strength of preparation in milligrams (or mg/SmL for liquids)
• number of "units" prescribed (a unit is a single tablet or SmL of a liquid)
From this information the number of defined daily doses (DDDs) could be
calculated (World Health Organisation, 1978):
Number of defined daily doses = strength of drug x number of units
defined daily dose for the drug
The system of DDDs, developed and maintained by the World Health
Organisation (WHO), gives each drug a value that represents the assumed
average maintenance dose per day for a drug used for its main indication in adults
and is a unit of measurement, not a recommended dose.
The Optimise software did not automatically record the prescribing costs
assigned by the PPA. Instead, a computerised "drug file" was used to assign costs
to the drugs recorded on the database. This drug file was based on the Drug Tariff
(Department of Health, 1997) for any chosen month. Using this system, it was
possible to look at potential savings on prescribing costs using the most recent
drug costs according to the Drug Tariff.
4.3.1.2 Use of the Drug Tariff
"Produced monthly by the Pharmaceutical Directorate of the PPA on behalf of
the Secretary of State, the Drug Tariff outlines the rules to be followed when
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dispensing, the fees and allowances for dispensing and what will be reimbursed
for supplying drugs and appliances against an NHS prescription form" (National
Prescribing Centre, 2004). For the purposes of the study, it was necessary to be
sure that the costs assigned to the data were as close as possible to those that had
been used by the Prescription Pricing Authority (PPA) and so the September
1997 Drug Tariff was used. This meant that when comparing a time before the
intervention with one after the intervention, the costs of the drugs were artificially
inflated, particularly for the first year of the study. The advantage of this method
was that it was possible to assess changes in prescribing behaviour without
having to account for inflation in drug costs. The disadvantage was that the
calculated changes in drug costs did not tally exactly with real changes in costs.
4.3.1.3. Data validation
Initially there were concerns about errors that might occur from inputting paper-
based PACT data onto computer. However, double-entry was done on at least
20% of the data and the data entry was found to be at least 99% accurate. Also,
there were other checks on the accuracy of data recording. Firstly, all data entered
were visually checked for accuracy by an experienced supervisor. Secondly, the
Optimise system was designed to alert the data entry clerk should they input an
unusual quantity for a drug. Thirdly, the data were closely scrutinised as part of
the analysis and any potential inaccuracies were highlighted. In these cases, it was
possible to refer back to the initial paper-based PACT data to check the computer
records. Comparison with data obtained from PACT catalogues was also carried
out to ensure accuracy of the data.
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4.3.1.4 Chapters examined
Most drug costs come from chapters 1 to 6 and 10 of the British National
Formulary (BNF). Given the costs of data entry, detailed analysis was focused on
these BNF chapters:
• Chapter 1: gastro-intestinal system
• Chapter 2: cardiovascular system
• Chapter 3: respiratory system
• Chapter 4: central nervous system
• Chapter 5: infections
• Chapter 6: endocrine system
• Chapter 10: musculoskeletal and joint diseases
Chapter 8 of the BNF (malignant disease and immunosupression) was also
examined, as it was possible that some practices might have had important
changes in their prescribing costs attributable to these potentially expensive,
hospital initiated drugs. Therefore, when considering changes in "total costs"
based on the Optimise analysis, this included chapters 1 to 6, 8 and 10 of the
BNF.
4.3.1.5 Chapters excluded
For the reasons given in the section 4.3.1.4, the following chapters were not
included in the analysis:
• Chapter 7: obstetrics, gynaecology andurinary tract disorders
• Chapter 9: nutrition and blood
• Chapter 11: eye
• Chapter 12: ear, nose and oropharynx
• Chapter 13: skin
• Chapter 14: immunological products and vaccines
• Chapter 15: anaesthesia
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4.3.1.6 Transfer of data
Doncaster Health Authority were requested to order level 3 PACT catalogues
from the PPA for the financial years:
• September 1995 to August 1996
• September 1996 to August 1997
When the catalogues arrived at the Health Authority, they were delivered by
secure transport to Enigma Medical Systems for entry onto computer and were
kept securely until all data validation had been completed. The Level 3 PACT
catalogues were then destroyed.
Optimise software was used to assign costs to the prescribing data and to conduct
further analyses as outlined below. Processed data were sent on floppy disks or
by email with identification of each practice only by its PPA code.
4.3.2 Types of analysis done using Optimise software
This section describes the types of analysis done using the Optimise software.
4.3.2.1 Analysis of changes in overall prescribing variables
Optimise analysis was used to investigate changes in the following variables for
both intervention and control practices:
• total costs
• total units(= tablets or 5mL quantities of liquid)
• total cost per unit
• generic and cost Optimise (explanation given in section 4.3.4)
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4.3.2.2 Changes in costs at BNF chapter level
The results of this analysis were used to validate the data obtained from Enigma
Medical Systems with data obtained from the PPA (PACTline data).
4.3.2.3 Changes in costs at BNF subchapter level
From changes in cost at BNF subchapter level it was possible to identify those
sections where there appeared to be important differences between the 2 groups.
For these sections, a detailed analysis was done to look at exactly how
prescribing patterns had changed. Defined daily doses for the drugs and
preparations used were calculated (World Heath Organisation, 1978), and
changes in the following variables were analysed:
• prescribing volume
• cost per defined daily dose
• generic prescribing rates
4.3.2.4 Audit Commission type categories
The Optimise software was also used to analyse changes in types of drug
category where the Audit Commission suggested that general practices might be
able to control prescribing costs (Audit Commission, 1994). The categories are
listed below and a more detailed explanation is given further in section 4.3.6:
• combination products
• modified/sustained release products
• drugs of limited therapeutic value
• drugs that couldbe bought over the counter (OTC)
• new and expensive drugs
• topical NSAIDs
• expensive hospital-initiated drugs
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4.3.3 Denominator used for the analyses
The results of analyses presented in Chapter 3 used the denominator of ASTRO-
PU for changes in overall costs and STAR-PU for changes in chapters and
subchapters of the BNF. However. the objective of this Chapter is to present
results that make clear comparisons between different therapeutic groups and
"indicators" to determine where exactly changes in cost came from. Therefore.
most of the data are presented in terms of costs (or defined daily doses) per 1000
patients. Given that the focus was on changes within the two groups of practices
between two years. it is doubtful whether accounting for demographic changes
(in terms of age and sex) would have made an appreciable difference to the
results.
4.3.4 Generic Optimise and Cost Optimise
One of the strengths of the Optimise software is its ability to calculate potential
savings that could have been made if:
• brand-named drugs were substituted with generic drugs where it would make
a difference to costs (this is termed "Generic Optimise")
• brand-named drugs were substituted with generic drugs (where generics were
cheaper) and brand-named drugs were used in place of generics (or another
brand) where this brand-named drug was cheaper (this is termed "Cost
Optimise")
Changes in potential savings through generic substitution were examined for the
two groups of practices between the two years. Where the intervention or control
practices reduced the potential savings they could have made. this implies that
they stopped using some of the more expensive preparations. It is likely that in
most cases this was because they made lower-cost substitutions, and this has been
demonstrated in some cases. However, in other cases the practices may have
made substitutions with more expensive drugs that were still within patent
(where a lower cost alternative may not have been available).
101
It was desirable to be able to separate the potential savings that could be made
through generic substitution and those that could be made through using brand-
named drugs that were cheaper than generics (or other equivalent brands). It was
possible to obtain the latter figure by subtracting the Generic Optimise figure
from the Cost Optimise figure. This has been called "Lower-cost brand
Optimise". In this context, it is worth pointing out that generic preparations are
not always cheaper than brands. For example, when the tariff generic, co-
amilofruse became available, several of the brand-named versions of the drug
were cheaper than the price set for the generic in the Drug Tariff. In other cases,
there may be differences in costs for chemically equivalent brand-named drugs
(where a generic is not available). In order to identify brand-named preparations
that are cheaper than either a generic or an equivalent brand, it is necessary to
have detailed knowledge of prices (and changes in prices) in the Drug Tariff.
4.3.5 Specific generic changes
Using the Optimise software, it was possible to identify the drugs where the
greatest changes in costs occurred between 1995/6 and 1996/7 for both
intervention practices and controls. Analysis was then done to identify the
switches between brand-named drugs and generics that might have had the
greatest impact on costs.
4.3.6 Selection of drugs for Audit Commission type categories
In developing prescribing indicators, the Audit Commission took selected drugs
within different categories. For example, "drugs of limited therapeutic value",
"modified release preparations" and "combination products" contained a
selection of the drugs and preparations that contributed most to cost in these
areas. It is understandable that the Audit Commission did not use a
comprehensive list of drugs within each category as this would have been very
time consuming and it would have made data extraction from the pp A database
more complicated. However, Avery et al (2000) produced a set of categories
which were similar, but more comprehensive than those used by the Audit
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Commission by carefully going through the BNF (Joint Formulary Committee,
1996) and selecting out all relevant drugs from chapters 1 to 6, 8 and 10. The
choice of drugs was validated by showing the categories to a group of academic
GPs and pharmacists. The latter were paid to check carefully all entries and to
highlight any possible omissions. The categories were mutually exclusive so that
there was no "double-counting" of drugs. For example, "drugs of limited
therapeutic value" that could be bought aTC, were put within the aTC category.
Enigma Medical Systems then wrote software to identify these different
categories of drug, and the software was checked to ensure that all relevant drugs
had been included in the different categories. Although the software was
designed for use as part of an NHS Prescribing Research Initiative project (Avery
et al. 2000b), permission to use the software to analyse the Doncaster data was
sought from the Principle Investigator and granted.
A detailed explanation of the different categories is given below.
Combination Products
Preparations containing two or more drugs, excluding:
• those in which clinically important components cannot be prescribed
separately:
dopa-decarboxylase inhibitors with dopaminergic drugs used in
parkinsonism
- clavulanic acid in co-amoxiclav
- sulphamethoxazole inco-trimoxazole
• those in which components are in a dose that could not be prescribed
separately but where aTC equivalents are available e.g. co-codamol,
migraleve. (These preparations are included in the "aTC" section)
• Lisinopril and Quinapril preparations (where the combination product was as
cheap as the ACE inhibitor prescribed alone)
103
Modified/Sustained Release Preparations
All modified release (MR) preparations listed in the BNF with the exception of:
• Adalat MR preparations (because MR preparations are indicated for the
treatment of hypertension)
• Diltiazem and Felodipine preparations (because no "short-acting" equivalent
was available)
• Products where the BNF gave a justification for the use of a modified release
preparation:
- theophylline preparations (because the BNF notes that "the use of rapid-
release oral theophylline preparations has declined because of the high
incidence of side-effects associated with absorption")
- lithium preparations (because the BNF notes "once daily administration is
preferred when plasma concentrations (have been) stabilised")
- modified release morphine salts (because the BNF recognises the
advantages of these preparations - page 12 BNF).
- carbamazepine preparations (because the BNF notes "use of modified
release tablets (Tegretol Retard) also significantly lessens the incidence of
dose-related side-effects")
dopaminergic drugs used In parkinsonism (because the BNF notes
"modified release preparations may help with "end-of-dose" deterioration
or nocturnal immobility and rigidity")
Drugs of Limited Therapeutic Value
Drugs for which the BNF makes comments suggesting that they are of limited
clinical value. The following drugs and preparations are excluded:
• those for which similar preparations could be bought over the counter (these
appear in the OTe section)
• topical NSAIDs (these appear in their own section)
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Over the Counter Products
Drugs and preparations for which an equivalent could be bought over the counter
excluding:
• enemas
• nitrates
• topical NSAIDs (these appear in their own section)
Topical NSAIDs
All topical NSAIDs listed in section 10.3.2 of the BNF.
New and Expensive Drugs
Increasing use of relatively new and expensive products may have an important
influence on the control of prescribing costs. This section lists:
• Therapeutic groups that showed important increases (more than 20% per
year) in prescribing costs across the Trent region between financial years
1994/5 and 1995/6:
- proton pump inhibitors (PPls) (BNF 1.3.5)
- lipid-lowering drugs (LLDs) (BNF 2.12)
- Selective serotonin re-uptake inhibitors (SSRIs) (BNF 4.3.3)
- Oestrogens and hormone replacement therapy (HRT) (BNF 6.4.1.1)
• A selection of drugs (not included in the above therapeutic groups) that
showed important increases in prescribing costs across the Trent region
between financial years 1994/5 and 1995/6:
- long acting beta-2 stimulants (salmeterol and eformoterol preparations)
- fluticasone preparations
- sumatriptan preparations
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Expensive Hospital Initiated Drugs (1)
Drugs that would almost certainly be initiated in secondary care used for
malignant disease and immunosuppression (BNF chapter 8).
Expensive Hospital Initiated Drugs (2)
Drugs that would almost certainly be initiated in secondary care that would be
likely to cost over £30 per week at adult dose (according to prices listed in the
BNF, March 1996).
4.3.7 Quality of prescribing
It is recognised that the use of PACT data to assess quality of prescribing has
many limitations (McGavock, 2001). The main problem is that the data cannot be
related to individual prescribing decisions (Cantrill, Sibbald and Buetow, 1998).
Thus, while certain prescribing patterns might suggest either good or poor
prescribing, it is not possible to make a firm judgement on the basis of PACT
data. Analysing changes in costs is not a particularly good way to assess quality
of prescribing, especially where there are variations in cost per unit volume.
However, due to the time and financial constraints imposed by the project it was
not possible to visit each of the eight individual practices to carry out detailed
analyses of prescribing quality. For this reason, analysis of Level 3 PACT data
was used as a proxy measure of prescribing quality to address the following
questions:
1. Did intervention practices increase their prescribing in areas where this might
be necessary to give patients the drugs that they need?
• inhaled corticosteroids
• lipid-lowering drugs
• hormone replacement therapy
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2. Did intervention practices control or decrease their prescribing in areas where
it has been suggested that GPs may "overprescribe"?
• drugs oflimited therapeutic value
• antimicrobial agents
• NSAIDs
3. Did intervention practices control prescribing costs in areas where it has been
suggested that savings might be made without detriment to patient care?
• selected generic substitutions
• reductions in use of selected combination products
• reductions in use of selected modified release products
The ways in which information was obtained to give a proxy assessment of
prescribing quality are outlined in the relevant sections of the methods and
results. In the discussion (Chapter 6), this information is drawn together to give a
view on whether practices that controlled costs managed to maintain quality.
4.3.8 Analysis
All calculations of variables were done using Microsoft Excel (versions 95 and
97). As mentioned in section 4.3.1, changes in prescribing patterns were based on
combined data for each of the two groups.
Due to the variation in the magnitude of the figures presented in the tables, results
have been presented to a minimum of one significant figure. The concept of one
significant figure was chosen on the basis that percentage changes of any smaller
magnitude were not likely to be important. It is hoped that this allows for easy
reading of the figures while at the same time permitting small changes in
variables to be presented. For the purposes of this chapter, Year 1 refers to the
year October 1995 to September 1996 and Year 2 refers to October 1996 to
September 1997.
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Chapter 3 demonstrated that there were statistically significant differences in
costs between intervention practices and controls in terms of overall prescribing
costs and prescribing costs in chapters I and 5 of the BNF. Since the aim of this
Chapter was to explore in detail the types of changes taking place, no statistical
analyses were carried out.
4.4RESULTS
A considerable amount of information is presented in the results section therefore
a brief summary has been given below on the content of each subsection:
• 4.4.1:refers to the denominator used in the analyses
• 4.4.2:validation of Optimise data against PACTline data
• 4.4.3: information on overall prescribing variables (and how they changed
between 1995/6 and 199617) based on Optimise analysis of Level 3 PACT
data for combined BNF chapters I to 6, 8 and 10:
- costs (£) per 1000 patients
- units (tablets or 5mL quantities of liquid) per 1000 patients
- Generic Optimise: missed opportunity for making generic savings per
1000 patients
- "Lower-cost brand Optimise": missed opportunity for making savings by
using brand-named drugs that were cheaper than either the generic
preparation or an equivalent brand (per 1000 patients)
• 4.4.4: information on prescribing variables based on Audit Commission type
categories (and how they changed between 1995/6 and 199617) based on
Optimise analysis of Level 3 PACT data for combined BNF chapters I to 6, 8
and 10:
- combination products
- modified/sustained release products
- drugs of limited therapeutic value
- drugs that could be bought over the counter (OTe)
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- new and expensive drugs
- topical NSAIDs
- expensive hospital initiated drugs
• 4.4.5: information on prescribing costs in BNF chapters 1 to 6, 8 and 10 (and
how they changed between 1995/6 and 199617) based on Optimise analysis of
Level3 PACT data
• 4.4.6: information on how exactly the two groups of practices changed their
prescribing patterns within selected therapeutic groups between 1995/6 and
199617 (based on Optimise analysis of Level 3 PACT data). The therapeutic
groups were chosen on the basis of important differences having been found
between the two groups (demonstrated in section 4.4.6)
• 4.4.7: information on how practices changed their prescribing patterns for
drugs where they had reduced costs for certain brand-named preparations
• 4.4.8: information on quality of prescribing
Details of the study population can be found in section 3.4.1.
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4.4.1 Denominator used for analyses
Table 4.1 shows the total numbers of patients in each group for the two years of
the study. Analyses were based on combined data for each of the two groups
using "per 1000 patients" as the denominator.
Table 4.1. Total patient numbers for intervention and control practices for
1995/6 and 199617
Group Total number of patients
Sept to Aug 1995/6 Sept to Aug 199617
Year 1 Year2
------------------------~~~------59777 59695
63676 62891
Intervention practices
Control practices
4.4.2 Validation of Optimise data against PACTline data
Doncaster Health Authority was requested to order level 3 PACT catalogues
from the ppA for the financial years:
• September 1995 to August 1996
• September 1996 to August 1997
The PPA was unable to provide catalogues for the exact dates requested.
However, catalogues were provided for the following dates:
• October 1995 to September 1996
• October 1996 to September 1997
Costs assigned using Optimise were compared with costs assigned by the pp A
(PACTline data). Differences of less than five per cent were found within each of
the BNF chapters and, overall, only very minor differences were found (less than
one per cent), despite the discrepancy in dates and different methods of assigning
costs (Tables 4.2 to 4.3).
110
-...
~
.-
.-
I
\.0
00
\.0
r-
o
.-
.-
\.0
C'I
C'I
o
C'I
.-
.-
.-
.-
r-
oo
o
0'1
00
r-
0'1
o
0'1
00
00
.-
~
o
I
C'I
\.0
o
\.0
o
00
0'1
C'I
('f')
0'1
o
00
.-
o
8
00
lJ"\
o
M
00
('f')
00
00
I
.-
.-
00
~
('f')
.-
o
.-
\.0
o
I
~
.-
-C'I
I
00
0'1
o
111
.-4
a..
~
\0
o
'"r l
N
o
.....
o
0"1
o
0"1
r-
r"l
.....
N
o
I
N
N
~
N
I
.....
0"1
.....
00
$
N
.....
N
o
.....
.....
00
0"1
0"1
\0
'".....
r"l
I
~
'"00
00
00
r"l
.....
.....
.....
.....
0"1
00
0"1
o
.....
N
'"r"l
N
00
0"1
\0
o
r"l
0"1
\0
\0
r"l
00
\0
0"1
\0
.....
r"l
00
.....
\0
r"l
.....
I
.....
\0
00
~
r"l
N
o
o
r"l
.....
o
.....
.-4
=
'"00
00
r"l
\0
r"l
0"1
.....
00
'"
I
112
4.4.3 Changes in overall prescribing variables
Table 4.4 shows the changes in overall prescribing variables for combined data
for intervention practices and controls for Chapters 1 to 6, 8 and 10 of the BNF. It
can be seen that the percentage increase in total costs per 1000 patients for the
control practices was almost twice that for the intervention practices. Although
the percentage increase in the number of units (a unit = one tablet or 5mL of a
liquid) per 1000 patients was similar in both groups, the percentage change in
total cost per unit for the control practices was almost three times that of the
intervention practices. This is despite the fact that both groups of practices had
similar baseline figures.
As mentioned in section 4.3.4, one of the strengths of the Optimise software was
its ability to calculate potential savings that the practices might have made in
each year if they had prescribed generic preparations instead of the brand-named
preparations that they did prescribe (Generic Optimise). From Table 4.4 it can be
seen that intervention practices had the potential to make savings of £1 271 per
1000 patients by switching to generic preparations. They succeeded in making
savings of £507 per 1000 patients (40%), implying that either they made generic
switches or that they stopped prescribing some of these drugs altogether. By
contrast, the control practices, which started with greater potential for making
generic savings, actually increased their potential savings by three per cent.
Cost Optimise is the potential savings that practices might have made in each
year if brand-named drugs were substituted with generic drugs (where generics
were cheaper) and brand-named drugs were used in place of generics (or another
brand) where this brand-named drug was cheaper. It can be seen that having
started from a similar baseline, intervention practices succeeded in making
savings of £775 per 1000 patients (30.41%) compared to £47 per 1000 patients
for control practices.
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As mentioned previously, it was also desirable to calculate potential savings that
could be made if practices prescribed brand-named drugs that were either cheaper
than a generic (or an equivalent brand). This was termed "Lower-cost brand
Optimise" and it can be seen that intervention practices reduced their potential
savings by almost threefold compared to controls (21.0% and 7.3% respectively).
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4.4.4 Optimise analysis of Audit Commission type categories
In this subsection, results of analysis of changes in cost for "Audit Commission
type categories" are presented. These categories have been explained in detail in
section 4.3.6. However, it is worth restating that the categories are mutually
exclusive. Abbreviations for the categories have been used and a key has been
provided to explain these abbreviations. Results are for combined data.
Table 4.5 shows the changes in costs for intervention practices and controls for
the categories studied. The categories are set out in order of increasing magnitude
of total costs per 1000 patients for intervention practices in Year 1. It can be seen
that intervention practices appeared to reduce costs for:
• modified/sustained release preparations
• drugs of limited therapeutic value
• topical NSAIDs
Intervention practices appeared to restrict the rise in costs compared with controls
for:
• drugs that can be bought over-the-counter
• new and expensive drugs
Relative to controls, intervention practices increased costs for:
• combination products
• expensive hospital initiated drugs (1) (chapter 8 of the BNF)
• expensive hospital initiated drugs (2) (costing >£30 per week)
From the results it can also be seen that "new and expensive" drugs accounted for
the majority of overall costs. Both intervention and control practices increased
their costs for this category and it was the category where there were the greatest
differences between the two groups of practices in terms of changes in costs.
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4.4.4.1 Optimise analysis of new and expensive drugs
Table 4.6 gives a breakdown of the contribution of different types of new and
expensive drugs to the overall increase in costs for this drug category.
Intervention practices managed to control the increase in costs in certain areas
more effectively than the control practices:
• Selected new and expensive drugs (other)
• Proton Pump Inhibitors
• SSRIs
Intervention practices did not restrict their percentage increase in costs more than
control practices in the following areas:
• Lipid-lowering drugs
• Oestrogens and HRT
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4.4.5 Changes in costs at BNF chapter level
This section presents data on changes in costs per 1000 patients for BNF
subsections for combined data for intervention practices and controls. The
following tables give a breakdown of costs per 1000 patients for:
• October 1995 to September 1996 (Year 1)
• October 1996 to September 1997 (Year 2)
• the change between the two years
• the percentage change between the two years
This information is presented for:
• overall prescribing costs for BNF chapters 1to 6, 8 and 10 combined
• prescribing costs for each of the BNF chapters 1 to 6, 8 and 10
• prescribing costs for BNF therapeutic groups within each of the BNF chapters
studied
The data are presented in a way that means that it is possible to determine the
contribution that costs in different therapeutic groups make to:
• costs in their respective BNF chapters
• overall costs in BNF chapters 1 to 6, 8 and 10
Specific therapeutic groups in which there were the greatest differences in cost
changes between intervention and control practices have been highlighted in bold
type. Where there were less important differences between the two groups, the
results have been given at BNF subchapter level e.g. antacids.
At the end of section 4.4.6, therapeutic groups where there were the greatest
differences in changes in costs per 1000 patients have been listed. From this list it
was possible to see which were the most important therapeutic groups in terms of
cost control.
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4.4.5.1 Changes in overall prescribing costs/or BNF chapters 1to 6,8 and 10
Changes in overall prescribing costs per 1000 patients for BNF chapters 1 to 6, 8
and 10 are given in Table 4.7. It can be seen that intervention practices managed
to reduce costs for drugs used for infections and musculoskeletal diseases
(chapters 5 and 10 respectively). For chapters 1 to 3 they managed to control
costs (compared with controls), although there were greater increases for chapters
4,6 and 8.
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4.4.5.2 Chapter 1:gastro-intestinal system
Table 4.8 shows the costs per 1000 patients for gastro-intestinal drugs for
October 1995 to September 1996, October 1996 to September 1997 and the
change between the two years. It can be seen that intervention practices managed
to reduce overall costs for ulcer-healing drugs by controlling increases in costs of
proton pump inhibitors whilst at the same time making large reductions in costs
for H2-receptor antagonists. By comparison, control practices had much larger
increases in costs for proton pump inhibitors but were not as successful m
reducing costs for Hrreceptor antagonists.
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4.4.5.3 Chapter 2: cardiovascular drugs
Tables 4.9 to 4.10 show the costs per 1000 patients for cardiovascular drugs.
Although intervention practices almost doubled their costs for lipid-lowering
drugs, they managed to reduce their costs for antihypertensive therapy. It is worth
noting that intervention practices were more successful at controlling increases in
costs for cerebral vasodilators than controls.
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4.4.5.4 Chapter 3: respiratory system
Table 4.11 shows the costs per 1000 patients for respiratory drugs for September
1995 to October 1996, September 1996 to October 1997 and the change between
the two years. It can be seen that intervention practices managed to reduce costs
for adrenoceptor stimulants and in addition made only slight increases in costs for
both bronchodilators and corticosteroids in contrast to control practices.
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4.4.5.5 Chapter 4: central nervous system (CNS)
Table 4.12 shows the costs per 1000 patients for eNS drugs for 1995/6, 1996/7
and the change between the two years. It can be seen that the clear majority of the
increased costs for both intervention and control practices came from
antidepressant drugs and analgesics. "Other antidepressant drugs" (mainly SSRIs)
was the most important of these drug groups.
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4.4.5.6 Chapter 5: infections
Table 4.13 shows the costs per 1000 patients for drugs used to treat infections for
September 1995 to October 1996, September 1996 to October 1997 and the change
between the two years. It can be seen that the clear majority of the changes in costs
came from the highlighted drug groups. Intervention practices managed to reduce
costs for all of the highlighted drugs. Control practices managed to reduce costs for
the majority of the highlighted drugs but to a lesser extent than the intervention
practices.
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4.4.5.7 Chapter 6: endocrine system
Table 4.14 shows the costs per 1000 patients for endocrine drugs for September
1995 to October 1996, September 1996 to October 1997 and the change between the
two years. It can be seen that drugs used for diabetes had an important impact on
increased costs for this BNF chapter for both intervention and control practices. It is
worth noting that intervention practices increased costs for subchapter 6.5 which are
mainly hospital-initiated drugs, whereas control practices reduced costs for this
subchapter. This was probably attributed to a prescription of expensive drugs in one
or more patients in the intervention practices.
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4.4.5.8 Chapter 8:malignant disease and immunosuppression
Table 4.15 shows the costs per 1000 patients for drugs used for malignant disease
and immunosuppression for September 1995 to October 1996, September 1996
to October 1997 and the change between the two years. It can be seen that the
greatest increases in costs were for BNF section 8.3. Given that these drug groups
relate to mainly hospital-initiated drugs, it was decided not to look at which
particular drugs were responsible for the changes in costs.
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4.4.5.9 Chapter 10: musculoskeletal andjoint diseases
Table 4.16 shows the costs per 1000 patients for drugs used for musculoskeletal
and joint diseases for September 1995 to October 1996, September 1996 to
October 1997 and the change between the two years. It can be seen that NSAIDs
were the most important drug group in terms of overall costs (and changes in
costs). Intervention practices showed decreased costs, while control practices
showed increased costs.
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Table 4.17 summarises data from Tables 4.8 to 4.16. It shows the contribution of
20 therapeutic groups to the differences observed in changes in cost per 1000
patients for intervention practices and controls. The list was constructed on the
basis of the largest differences seen between the two groups of practices. The
therapeutic groups are listed in order of the magnitude of difference in change in
costs between the intervention and control practices. It can be seen that just over
80% (£3 177) of the differences seen between the groups came from changes in
costs from the "top 10" therapeutic groups. Almost 30% (£1 174) of the changes
in costs came from ulcer-healing drugs (proton pump inhibitors and H2-receptor
antagonists) alone. This equates to almost 70% and 26% respectively in terms of
differences in costs for all drugs in chapters 1 to 6, 8 and 10 of the BNF.
The way in which the two groups of practices changed their prescribing patterns
for these 10 therapeutic groups is explored in detail in section 4.4.6.
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Table 4.17. Differences in changes in costs (£) per tOOOpatients for selected
therapeutic groups for intervention and control practices
BNF Therapeutic groups Change in costs (£) per 1000 patients
Section between 1995/6 and 199617
Intervention Control A minusB
Practices Practices
(A) (B)
1.3.5 Proton pump inhibitors (PPIs) 613 1436 -823
3.1.1 Adrenoceptor stimulants -139 328 -467
10.1.1 Non-Steroidal Anti-Inflammatory Drugs -245 146 -391
(NSAIDs)
1.3.1 Hrreceptor antagonists -865 -514 -351
2.5.5 Angiotensin-converting enzyme -201 101 -302
inhibitors
2.6.1 Nitrates 97 324 -227
5.1.2 Cephalosporins, cephamycins and -276 -81 -195
betalactams
5.1.1 Penicillins -243 -89 -154
2.5.4 Alpha-adrenoceptor blocking drugs 49 188 -139
5.1.5 Macrolides -10 118 -128
Subtotal for "top 10" -1220 1957 -3177
2.6.3 Peripheral vasodilators and related drugs 46 173 -127
6.4.2 Male sex hormones and antagonists -87 24 -111
5.1.3 Tetracyclines -153 -55 -98
6.1.1 Insulin 136 223 -87
4.8.1 Control of epilepsy 272 352 -80
2.6.2 Calcium-channel blockers 171 240 -69
4.3.3 Compound antidepressant preparations 46 104 -58
8.2.1 Cytotoxic immunosuppressants 43 100 -57
10.3.2 Rubefacients and other topical -3 51 -54
anti rheumatics
6.7.1 BromocriEtine and metef!~oline -15 23 -38
Difference in costs (£) for the above drug -764 3192 -3956
grou~s combined
Total difference in costs (£) for all drugs in 4788 9333 -4545
cha~ters 1 to 6, 8 and 100fBNF
Percentage oftotal difference in costs (%) from -16.0 34.2 87.0
above drug grou~s
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4.4.6 Analysis of therapeutic groups where there were the greatest
differences in costs between the two groups of practices
As shown in Table 4.17 ten therapeutic groups were responsible for just over
80% of the difference between the two groups in their changes in costs between
1995/6 and 199617. This section examines in detail how prescribing patterns
changed within these therapeutic groups.
The two factors that determine changes in costs are:
• changes in volume of prescribing
• changes in cost per unit of volume
The contribution of these factors to the changes in costs for the ten therapeutic
groups was explored. Tables have been presented in the order that the therapeutic
groups appear in the BNF. Changes in volume of prescribing have been presented
in tenus of defined daily doses (ODDs) per 1000 patients. One of the limitations
of using DDDs for this analysis is that it may not be a particularly good measure
where appreciable numbers of prescriptions may be given to children in lower
doses than the DOD e.g. penicillin antimicrobial agents. This needs to be
remembered when interpreting the results. In addition, for a small number of
drugs, the concept of a ODD is inappropriate e.g skin preparations such as
creams and ointments where the unit of issue is a tube. In these instances, an
estimated DOD has used. Tables showing changes in cost per unit of volume
have only been included in those cases where there was a change in costs per
ODD between the two years for either intervention practices or controls.
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Table 4.18. shows where the relevant tables of results can be found for each of
the therapeutic groups.
Table 4.18. Index of tables of results of analysis of "top 10" therapeutic
groups
BNF Therapeutic Group Table Page
Section
1.3.1 H2-receptor antagonists 4.19 to 4.20 144-145
1.3.5 Proton pump inhibitors (PPIs) 4.21 146
2.5.4 Alpha-adrenoceptor blocking drugs 4.22 to 4.23 148-149
2.5.5 Angiotensin-converting enzyme 4.24 to 4.25 150-151
inhibitors (ACEIs)
2.6.1 Nitrates 4.26 to 4.27 152-153
3.1.1 Adrenoceptor stimulants 4.28 to 4.29 156-157
5.1.1 Penicillins 4.30 to 4.31 159-160
5.1.2 Cephalosporins, cephamycins and 4.32 to 4.33 161-162
betalactams
5.1.5 Macrolides 4.34 to 4.35 163-164
10.1.1 Non-steroidal anti-inflammatory 4.36 to 4.37 166-167
drugs (NSAIDs)
Summary of key findings 4.51 to 4.52 182-183
4.4.6.1 Changes in prescribing/or gastrointestinal drugs
Tables 4.19 and 4.20 show DDDs per 1000 patients and cost per DDD for
1995/6, 199617 and the change between the two years for Hj-receptor antagonists.
It can be seen that intervention practices reduced their prescribing volume for H2-
receptor antagonists to a much greater extent than controls. Also, they reduced
the cost per DDD to a greater extent, despite having started at a lower base figure.
Intervention practices reduced DDDs per 1000 patients for ranitidine, cimetidene,
famotidine and algitec, while increasing the volume of nizatidine prescribed.
Similar changes were seen for control practices but to a lesser extent.
Table 4.21 shows DDDs per 1000 patients for 1995/6, 199617 and the change
between the two years for proton pump inhibitors. It can be seen that intervention
practices increased the number of proton pump inhibitor DDDs per 1000 patients
by 653 (12%). However, this increase was offset by a reduction of 903 in the
143
number of Hr-receptor antagonist DDDs per 1000 patients (13%). In contrast
there were substantial rises in proton pump inhibitor DDDs per 1000 patients for
control practices (26%), despite these practices having a smaller reduction for H2-
receptor antagonists (7%).
From Table 4.21 it can be seen that both intervention and control practices
substantially increased their use of lansoprazole. Intervention practices, unlike
control practices, reduced their overall use of omeprazole preparations. This was
achieved by reducing their use of 20mg omeprazole (treatment dose) by 1 352
DDDs per 1000 patients (35%). Overall, there were no changes in costs for
intervention or control practices.
It would therefore seem that the main differences in costs for gastro-intestinal
drugs arose from differences in prescribing volume and greater use of
maintenance doses of omeprazole in intervention practices.
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4.4.6.2 Changes in prescribing/or cardiovascular drugs
Changes in prescribing for cardiovascular drugs are presented in Tables 4.22 to
4.27. Details are presented of changes in DDDs per 1000 patients and costs per
DOD for different types of drug (and for nitrates, different types of preparation).
Although both groups of practices increased prescribing volume and cost per
DOD for alpha-adrenoceptor blocking drugs, intervention practices increased
prescribing volume to a lesser extent.
Tables 4.24 and 4.25 show changes in prescribing volume and cost per volume
for angiotensin converting enzyme inhibitors (ACEls). It can be seen that both
groups of practices increased prescribing volume, although the percentage
increase in DDDs per 1000 patients for intervention practices was twice that for
controls. This was offset by a reduction in cost of six pence per ODD.
From Tables 4.26 and 4.27 it can be seen that both intervention and control
practices showed an increase in prescribing volume, but decrease in cost per unit
volume, for different types of nitrates. Both groups of practices showed
reductions in relatively expensive preparations such as glyceryl trinitrate (GTN)
patches and sustained release GTN tablets. However, control practices showed a
marked rise in the use of modified release isosorbide mononitrate (ISMN), which
appeared to be at the expense of the standard isosorbide mononitrate tablets and
isosorbide dinitrate (ISDN) preparations. Intervention practices almost doubled
their use of GTN spray but reduced the cost per DDD by almost half. Overall, it
would seem that intervention practices managed to control the rise in costs of
nitrate preparations by reducing the cost per DDD.
It would therefore seem that the main differences in costs for cardiovascular
drugs arose from differences in cost per unit volume.
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4.4.6.3 Changes in prescribing/or respiratory drugs
Changes in prescribing for respiratory drugs are presented in Table 4.28. Details
are presented of DDDs per 1000 patients for 1995/6, 1996/7 and the change
between the two years for:
• beta-2 adrenoceptor stimulants
• different types of salbutamol preparations
The reason for looking at different types of preparation was because it is
recognised that certain drug delivery systems are much more expensive than
others.
Beta-2 adrenoceptor stimulants
Table 4.28 shows changes in DDDs per 1000 patients for different beta-2
adrenoceptor stimulants. Salbutamol preparations accounted for the vast majority
of prescribing in this therapeutic group, followed by salmeterol and terbutaline.
It can be seen that intervention practices reduced prescribing volume for
salbutamol and terbutaline and only slightly increased prescribing volume for
salmeterol preparations. However, there was a marked increase in the use of
Eformoterol. Control practices also managed to reduce prescribing volume for
salbutamol and terbutaline (but to a lesser extent) and, despite increasing their
use of salmeterol to a greater extent than intervention practices, managed to
reduce their overall volume of prescribing by almost three per cent. In contrast to
control practices, intervention practices managed to reduce costs per DDD for
salbutamol and salmeterol preparations and overall, reduced their costs per DDD
for beta-2 adrenoceptor stimulants by 1 pence.
Different types of salbutamol preparations
Table 4.29 shows changes in prescribing volume salbutamol preparations. It can
be seen that intervention practices managed to reduce prescribing volume for the
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more expensive breath-actuated and dry powder inhalers to a greater extent than
controls and this was reflected in a slight decrease in cost per DDD.
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4.4.6.4 Changes in prescribingfor drugs usedfor infections
Penicillins
Tables 4.30 and 4.31 show DDDs per 1000 patients and cost per DDD for
1995/6, 199617 and the change between the two years for penicillins. It can be
seen that both intervention and control practices decreased prescribing volume
for penicillins, although intervention practices decreased prescribing volume to a
slightly lesser extent. However, intervention practices showed a marked
reduction in cost per DDD (16%).
Cephalosporins, cephamycins and other beta-Iactam antibiotics
Tables 4.32 and 4.33 show DDDs per 1000 patients and cost per DDD for
1995/6, 199617 and the change between the two years for cephalosporins and
related antimicrobial agents. It can be seen that although intervention practices
increased prescribing volume in contrast to control practices, which reduced
prescribing volume, there was a substantial reduction in cost per DDD for the
intervention practices (14%).
Macrolides
Tables 4.34 and 4.35 show changes in DDDs per 1000 patients and cost per DDD
for macrolide antimicrobial agents. It can be seen that intervention practices
managed to reduce prescribing volume relative to control practices, and control
the rise in costs per DDD for macrolides to a slightly greater extent.
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4.4.6.5 Changes in prescribing/or musculoskeletal drugs
Oral NSAIDs
Tables 4.36 and 4.37 show changes in DDDs per 1000 patients and cost per DDD
for oral NSAIDs. Less commonly used drugs have been grouped together into an
"others" category. It can be seen that while intervention practices slightly
increased their prescribing volume, control practices showed a very slight
reduction. However, intervention practices managed to control or reduce costs
per DDD for all of the most commonly used NSAIDs to a greater extent than
control practices.
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4.4.7 Changes in potential generic savings
As explained earlier, using Optimise software it is possible to calculate the
potential savings that could be made through generic substitution of brand-named
products. Section 4.4.3 showed that intervention practices reduced their potential
for making generic savings between 1995/6 and 199617 by almost 40%, while
control practices slightly increased their potential (by almost three per cent). The
ways in which a practice could reduce its potential generic savings between two
years are as follows:
• substitution of brand-named drugs with generics where these are:
- available and
- cheaper that the brand-named product
• prescribing less of the brand-named drug (where a cheaper generic was
available)
Therefore, in order to work out how practices changed their potential for making
generic saving, it was important to explore the changes in detail.
This section presents:
• changes in potential generic savings for intervention and control practices
(Tables 4.38 to 4.39):
- listing top 20 changes in potential generic savings between 1995/6 and
199617
- showing totals for these "top 20" changes in potential generic savings
- showing totals for other changes in potential generic savings
- showing "grand totals" for changes in potential generic savings
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• changes in prescribing volume for drugs where there was a decrease in costs
for specific brand-named preparations (Tables 4.40 to 4.49):
- changes in volume for specific brand-named preparations from the list of
"top 20" changes in intervention practices
- changes in volume for other brand-named preparations of the same drug
(equivalent formulation and dose)
- changes in volume for generic preparations of the same drug (equivalent
formulation and dose)
From this information it was possible to identify how the practices managed to
change their potentials for making generic savings and the key findings for
intervention practices are summarised in Table 4.53.
4.4.7.1 Changes in potential generic savings
Table 4.38 shows a list of the brand-named drugs where there was the greatest
change in potential for making generic savings between 1995/6 and 199617 for
intervention practices. It can be seen that the "top 10" changes were particularly
marked and were responsible for 84% of the total change in potential generic
savings.
It should be noted that the potential for making generic savings was slightly
greater in 199617 than 1995/6 for brand-named preparations outside the ''top 20",
This was a result of either an increase in volume for these brands, or an increase
in cost per unit volume of the brands (without a substantial reduction in overall
volume).
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Table 4.38. Changes in potential generic savings* for intervention practices
between 1995/6 and 199617 (with details of "top 20" savings)
Brand-named preparations Potential generic saving
I!er 1000 I!atients {£}
1995/6 199617 Change
Becloforte inhaler 2S0mcg (200 metered doses) 142 47 -96
Becotide 100 inhaler (1OOmcg)200 metered dose 125 51 -74
Ventolin inhaler (200 metered doses) 82 23 -59
Voltarol tablets SOmg 78 22 -55
Adalat tablets (lOmg) 31 0 -31
Nitrolingual spray 400mcg (200 metered dose) 29 4 -25
Colofac tablets (13Smg) 40 15 -24
Voltarol tablets (2Smg) 26 3 -23
Triludan tablets (60mg) 28 10 -18
Tagamet tablets (400mg) 23 6 -18
Subtotal for "top 10" 604 181 -423
Zyloric 300 tablets (300mg) 26 9 -16
Moduretic tablets 27 11 -16
Frumil tablets 31 18 -14
Stemetil tablets (Smg) 22 9 -13
Ponstan Forte tablets (SOOmg) 27 15 -13
Amoxil SF paediatric suspension (l2S/Sml) 14 2 -13
Tenormin (LS) tablets (SOmg) 24 14 -10
Prothiaden tablets (7Smg) 19 9 -10
Amoxil capsules 2S0mg 15 4 -10
Minocin SOtablets (SOmg) 16 6 -10
Totals for "to~ 20" 826 277 -548
Totals for other potential generic savings 445 487 42
{= 175 ~re~arationsl
Grand total for ~otential generic savings 1271 764 -506
* a potential generic saving is the arnountof money that could have been saved if a brand-narned
preparationhad been prescribedgenerically.A reduction in potentialgeneric savingssuggeststhat
a practice has either made generic switches,or that it has stoppedprescribinga drug. An increase
in potential generic savings suggests that a practice has increased costs for a brand-narned
preparation.Reasonsfor this increasemaybe:
a) increasedcost per tablet
b) increasedvolumeof prescribingof the brand-narnedpreparation.
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Table 4.39 shows a list of the brand-named drugs where there was the greatest
change in potential for making generics savings between 1995/6 and 199617 for
control practices. With the exception of Becloforte, there was considerable
overlap between the list of "top 20" changes for intervention and control
practices, although the magnitude of the changes was less for controls.
Once again it should be noted that the potential for making generic savings was
slightly greater in 1996/7 than 1995/6 for brand-named preparations outside the
"top 20" for the reasons explained at the beginning of section 4.4.7.1.
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Table 4.39. Changes in potential generic savings* for control practices
between 1995/6 and 1996/7 (with details of "top 20" savings)
Potential generic saving
per 1000 patients (£)
Brand-named preparations
1995/6 1996/7 Change
Becotide 100 inhaler (100mcg) 200 metered dose
Adalat tab (1Omg)
Ventolin inhaler (200 metered doses)
Nordox capsules (100mg) compliance pack
Frumil tablets
Nitrolingual spray (400mcg) 200 metered dose
Tagamet tablets (400mg)
Triludan tablets (60mg)
Amoxil capsules (250mg)
Amoxil capsules (500mg)
Subtotals for "top 10"
Floxapen capsules (250mg)
Amoxil SF paediatric suspension (125/5ml)
Erythroped granules for suspension (250mg/5ml)
Colofac tablets (135mg)
Voltarol tablets 50mg
Volraman tablets (50mg)
Minocin 50 tablets (50mg)
Moduretic tablets
Hypovase tablets (5mg)
Epilim 200 tablets E/C (200mg)
71 44 -27
27 0 -27
64 39 -26
22 2 -20
48 29 -19
23 4 -18
47 32 -15
24 11 -14
78 67 -11
54 44 -10
458 272 -187
25 15 -10
37 28 -9
43 36 -8
41 34 -7
82 75 -7
10 3 -7
12 6 -6
35 29 -6
4 -2 -6
11 5 -5
Totals for "top 20" 759 499 -260
Totals for other potential generic savings
(= 189 preparations)
723 1022 299
Grand total for potential generic savings 1482 1521 39
* a potential generic saving is the arnount of money that could have been saved if a brand-narned
preparation had been prescribed generically. A reduction in potential generic savings suggests that
a practice has either made generic switches, or that it has stopped prescribing a drug. An increase
in potential generic savings suggests that a practice has increased costs for a brand-narned
preparation. Reasons for this increase may be:
a) increased cost per tablet
b) increased volume ofprescribing of the brand-narned preparation.
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4.4.7.2 Changes in prescribing volume for specific brand-named preparations
Tables 4.40 to 4.49 show changes in prescribing volume for the "top 10" drugs
where there were reductions in costs of a brand-named preparation between
1995/6 and 199617 for intervention practices (Table 4.38). As explained above, it
was possible to see whether practices changed prescribing volume for these
preparations. Also, it was possible to see whether there were changes in brand-
named or generic drugs of the same dose and formulation,
Table 4.40 shows that intervention practices switched from Becloforte inhalers to
a mixture of alternative brand-named inhalers (mainly Beclazone) and generic
inhalers. Control practices switched mainly from generic inhalers to Becloforte
and alternative brand-named inhalers. Table 4.41 shows a similar picture for
beclomethasone 100mcg inhalers in the intervention practices, although control
practices did manage to control their use of Becotide 100, switching mainly to
other brand-named inhalers.
Table 4.40. Change in volume of beclomethasone 250mcg inhalers (200
metered doses)
Preparation type Inhalers (!er 1000 (!atients
1995/6 199617 Change % Cbange
Intervention (!ractices
Becloforte inhaler 28 9 -19
-67.8
Other brand-named inhalers 1 4 3 295.6
Generic inhalers 14 21 7 48.9
TOTAL 43 34 -9
-21.0
Control (!ractices
Becloforte inhaler 17 21 3 18.1
Other brand-named inhalers 10 14 4 39.3
Generic inhalers 23 16 -7 -30.6
TOTAL 50 51 1 2.1
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Table 4.41. Change in volume of beclomethasone 100mcg inhalers (200
metered doses)
Preparation type Inhalers I!er 1000 I!atients
1995/6 199617 Change %Change
Intervention I!ractices
Becotide inhaler 60 24 -36 -59.9
Other brand-named inhalers 6 10 4 65.8
Generic inhalers 44 57 13 29.4
TOTAL 110 91 -19 -17.3
Controll!ractices
Becotide inhaler 34 21 -13 -38.3
Other brand-named inhalers 11 17 6 53.9
Generic inhalers 40 40 -0.5 -1.2
TOTAL 85 78 -7 -8.8
Table 4.42 shows that for intervention practices, reductions in the prescribing of
Ventolin were mainly substituted by increases in alternative brand-named
inhalers, namely Salamol Easi-breathe. Control practices mainly switched from
Vento lin to generic inhalers.
Table 4.42. Change in volume of salbutamol100mcg inhalers (200 metered
doses)
Preparation type Inhalers I!er 1000 I!atients
1995/6 199617 Change % Change
Intervention I!ractices
Vento lin inhalers 142 46 -96 -67.7
Other brand-named inhalers 4 63 59 1474.1
Generic inhalers 236 242 6 2.4
TOTAL 382 351 -31 -8.1
Controll!ractices
Ventolin inhalers 111 77 -34 -30.6
Other brand-named inhalers 75 75 OJ 0.4
Generic inhalers 193 219 26 13.5
TOTAL 379 371 -8 -2.1
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Tables 4.43 and 4.44 show that generic substitution was the major factor in
reducing potential generic savings for Volterol 50mg and Volterol 25mg tablets
in the intervention practices.
Table 4.43. Change in volume of diclofenac 50mg tablets
Preparation type Tablets eer 1000 eatients
1995/6 1996/7 Change % Change
Intervention eractices
Voltarol 50mg tab 631 226 -405 -64.2
Other brand-named preparations 1.5 2.3 0.8 53.3
Generic preparations 2193 4342 2149 98.0
TOTAL 2826 4570 1745 61.7
Control eractices
Voltarol 50mg tab 664 757 93 14.0
Other brand-named preparations 99 39 -60 -60.9
Generic preparations 1 599 2194 595 37.2
TOTAL 2362 2990 628 26.5
Table 4.44. Change in volume of diclofenac 25mg tablets
Preparation type Tablets eer 1000 eatients
1995/6 1996/7 Change % Change
Intervention eractices
Voltarol 25mg tab 436 70 -366 -83.9
Other brand-named preparations 0.0 0.0 0.00 t
Generic preparations 886 1259 373 42.1
TOTAL 1322 1329 7 0.5
Control eractices
Voltarol 25mg tab 173 147 -26 -15.2
Other brand-named preparations 1.3 0.00 -1.3 -100.0
Generic preparations 988 1 193 205 20.8
TOTAL 1162 1340 178 15.3
t denotes undefined
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Table 4.45 shows that there was an overall reduction in prescribing volume of
nifedipine IOmg tablets for both groups of practices. Intervention practices
appeared to switch from generic nifedipine to "other brand-named preparations",
specifically Tensipine.
Table 4.45. Change in volume of nifedipine 10mg tablets
Preparation type Tablets eer 1000 eatients
1995/6 199617 Change % Change
Intervention eractices
Adalat IOmg tab 997 618 -379 -38.0
Other brand-named preparations 0.9 364 363 40366.7
Generic preparations 1102 605 -497 -45.1
TOTAL 2100 1587 -513 -24.5
Control eractices
Adalat 10mg tab 880 743 -137 -15.5
Other brand-named preparations 0.0 1.3 1.3 00
Generic preparations 1 536 1 157 -379 -24.7
TOTAL 2416 1901 -515 -21.3
OC) denotes infinity
Table 4.46 shows that there was no' real reduction in prescribing volume for GTN
spray in intervention practices, and that switches were being made from
Nitrolingual spray to a mixture of other brand-named products and generics.
Table 4.46. Change in volume of glyceryl trinitrate 400mcg spray (200
metered doses)
Preparation type Aerosol seral:s I!er 1000 I!atients
1995/6 199617 Change % Change
Intervention I!ractices
Nitrolingual spray 43 20 -23 -54.4
Other brand-named preparations 10 24 14 145.5
Generic preparations 34 43 9 24.4
TOTAL 87 87 0.0 0.0
Control eractices
Nitrolingual spray 39 38 -1 -1.3
Other brand-named preparations 19 20 1 3.6
Generic preparations 21 23 2 11.0
TOTAL 79 81 2 2.7
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Table 4.47 shows that both intervention and control practices reduced their use of
Colofac 135mg tablets by switching to generic preparations.
Table 4.47. Change in volume of mebeverine hydrochloride 135mg tablets
Preparation type Tablets I!er 1000 I!atients
1995/6 199617 Change % Change
Intervention I!ractices
Colofac 135mg 1672 690 -982 -58.7
Other brand-named preparations 0.0 0.0 0.0 t
Generic preparations 1387 2463 1076 77.6
TOTAL 3059 3153 94 3.1
Controll!ractices
Colofac 135mg 1 714 1499 -215 -12.6
Other brand-named preparations 0.0 0.0 0.0 t
Generic preparations 1049 1 531 482 46.0
TOTAL 2763 3030 267 9.7
t denotes undefined
Table 4.48 shows that both intervention and control practices reduced their
prescribing volume for Terfenadine 60mg by substantially reducing prescribing
of Triludan 60mg tablets as well as reducing other brand-named and generic
preparations.
Table 4.48. Change in volume of Terfenadine 60mg tablets
Preparation type Tablets I!er 1000 I!atients
1995/6 199617 Change % Change
Intervention I!ractices
Triludan 60mg tablets 863 285 -578 -67.0
Other brand-named preparations 1 0.0 -1 -100.0
Generic preparations 821 741 -80 -9.7
TOTAL 1685 1026 -659 -39.1
Controll!ractices
Triludan 60mg tablets 758 3 14 -444 -58.5
Other brand-named preparations 11 0.0 -11 -100.0
Generic preparations 1259 776 -483 -38.3
TOTAL 2028 1090 -938 -46.2
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Table 4.49 shows that the major factor in reducing potential generic savings for
Tagamet was an overall reduction in prescribing volume.
Table 4.49. Change in volume of cimetidine 400mg tablets
Preparation type Tablets 2er 10002atients
1995/6 199617 Change 0/0 Change
Intervention 2ractices
Tagamet 400mg tablets 90 22 -68 -75.3
Other brand-named preparations 0.0 0.0 0.0 t
Generic preparations 2366 2 122 -244 -10.3
TOTAL 2456 2144 -312 -12.7
Control 2ractices
Tagamet 400mg tablets 183 125 -58 -31.3
Other brand-named preparations 2 1 -1 -44.4
Generic preparations 2381 2172 -209 -8.8
TOTAL 2566 2298 -268 -10.4
t denotes undefined
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4.4.8 Quality of prescribing
As mentioned in section 4.3.7, analysis of Level 3 PACT data was used as a
proxy measure for prescribing quality. From Table 4.50 it can be seen that
intervention practices increased their prescribing costs per 1000 patients for lipid-
lowering drugs, inhaled corticosteroids and hormone replacement therapy, which
implies that they did not try to cut back on the prescribing of these drugs. They
decreased their prescribing costs for drugs of limited therapeutic value,
antimicrobial agents and NSAIDs, areas where it has been suggested that GPs
may "over-prescribe" (Audit Commission, 1994). They also managed to reduce
prescribing costs for selected modified release products and potential generic
savings, and control the rise in costs for selected combination products, which
implies that the practices were reducing prescribing costs in areas where it has
been suggested that savings might be made without detriment to patient care
(Audit Commission, 1994).
Table 4.50. Analysis of changes in prescribing costs for Intervention
practices as a proxy measure for prescribing quality.
Therapeutic Group Total cost (£) per 1000 patients
Year I Year2 Change % change Table*
Has prescribing increased for:
Lipid-lowering drugs 908 1 787 880 96.9 4.10
Inhaled corticosteroids 7490 7500 9.1 0.1 4.11
Hormone replacement 2437 2609 172 7.1 4.6
therapy
Has prescribing been controlled or decreased for:
Drugs of limited 510 436 -74
-14.5 4.5
therapeutic value
Antimicrobial agents 4665 4063
-602
-12.9 4.13
NSAIDs 4527 4281 -245
-5.4 4.16
Has prescribing been controlled or decreased for:
Potential generic 1271 764 -507
-39.9 4.4
savings
Combination products 3818 3845 27 0.7 4.5
Modified release 4944 4701
-243
-4.9 4.5
products
*This column gives the table in which further details can be found, including comparisons with
controls
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4.5 SUMMARY OF MAIN FINDINGS
4.5.1 Changes in overall prescribing variables
The percentage increase in total costs per 1000 patients for the control practices
was almost twice that for the intervention practices. Although the percentage
increase in the number of units (a unit = one tablet or 5mL of a liquid) per 1000
patients was similar in both groups, the percentage change in total cost per unit
for the control practices was almost three times that of the intervention practices.
This is despite the fact that both groups of practices had similar baseline figures.
Intervention practices had the potential to make savings of almost £1 271 per
1000 patients by switching to generic preparations. They succeeded in making
savings of just over £507 per 1000 patients (almost 40%), implying that either
they made generic switches or that they stopped prescribing some brand-named
drugs altogether. By contrast, the control practices, which started with greater
potential for making generic savings, actually increased their potential for making
savings by almost three per cent.
4.5.2 Audit Commission type categories
Intervention practices appeared to make savings relative to controls for
modified/sustained release preparations, drugs of limited therapeutic value and
topical NSAIDs. Relative savings were not apparent for drugs that could be
bought over the counter or combination products.
"New and expensive" drugs accounted for the majority of overall costs. Both
intervention and control practices increased their costs for this category and it
was the category where there were the greatest differences between the two
groups of practices in terms of changes in costs. Intervention practices managed
to control the increase in costs in certain areas more effectively than the control
practices for selected new and expensive drugs, proton pump inhibitors and
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SSRIs. Intervention practices did not restrict their increase in costs more than
control practices for lipid-lowering drugs or oestrogens and HRT.
4.5.3 Changes in costs at BNF chapter level
Intervention practices managed to reduce costs per 1000 patients for drugs used
to treat infections and musculoskeletal diseases (chapters 5 and 10 respectively).
For chapters 1 to 3 they managed to control costs (compared with controls),
although there were greater increases for chapters 4, 6 and 8.
It was found that ten therapeutic groups were responsible for just over 80% of the
difference between the two groups in terms of their changes in costs between
1995/6 and 199617. Almost 30% (£1174) of the changes in costs came from
ulcer-healing drugs (proton pump inhibitors and H2-receptor antagonists) alone.
This was equivalent to almost 70% and 26% respectively in terms of differences
in costs for all drugs in chapters 1 to 6, 8 and lOaf the BNF.
4.5.4 Analysis of therapeutic groups where there were the greatest
differences in costs between the two groups of practices
A summary of how intervention and control practices changed their prescribing
patterns in the "top 10" specific therapeutic groups is shown in Tables 4.51 to
4.52.
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4.5.5 Changes in potential generic savings
Table 4.53 gives an overview of how intervention practices reduced their
potential for making generic savings from certain brand-named drugs between
1995/6 and 199617. It can be seen that generic substitution was the most
important factor for Volterol 50mg, Colofac and Volterol 25mg. It was also an
important factor for Becloforte and Becotide 100, but to a lesser extent.
Reduction in overall prescribing volume (for the brand-named drug and all
equivalent preparations) was the most important factor for Adalat 10mg, Triludan
60mg and Tagamet 400mg.
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4.5.6 Quality of prescribing
In order to give an impression of whether quality of prescribing had been
maintained or improved in the intervention practices, the following questions
were explored using the results of the analysis of Level 3 PACT data. A
summary of the answers is given below:
1. Did intervention practices increase their prescribing in areas where this might
be necessary to give patients the drugs that they need?
• inhaled corticosteroids: Yes
• lipid-lowering drugs: Yes
• hormone replacement therapy: Yes
2. Did intervention practices control or decrease their prescribing in areas where
it has been suggested that GPs may "over-prescribe"?
• drugs of limited therapeutic value: Yes
• antimicrobial agents: Yes
• NSAIDs: Yes
3. Did intervention practices control or decrease prescribing costs in areas where
it has been suggested that savings might be made without detriment to patient
care?
• selected generic substitutions: Yes
• reductions in use of selected combination products: Yes
• reductions in use of selected modified release products: Yes
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CHAPTERS
PATIENT SATISFACTION WITH MEDICATION CHANGE
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5.1 INTRODUCTION
As shown in Chapters 3 and 4, the employment of dedicated pharmacists to
support GP activity within the intervention practices helped to control the rise in
prescribing costs over the study period. To achieve this outcome, a number of
medication changes were made, particularly the switching of brand-named drugs
to generics. It was felt to be important to assess patient satisfaction with
medication change in the intervention practices, given that most of the changes
were made for reasons of cost-control whereby patients might not expect to
receive direct benefits.
5.1.1 Rationale for the study
The results of the study conducted by Dowell, Snadden and Dunbar (1995)
showed that 44% of patients undergoing prescribing change in a practice that had
reduced its prescribing costs were "slightly unhappy" or "very unhappy". These
results are important, as levels of patient satisfaction have been linked to
adherence to medication (Home, Hankins and Jenkins, 2001). Given the results of
this study, and the increase in pharmacist intervention in general practice (Bond et
al. 1995; Mason, 1996; Speak, 1996; Corbett, 1995; Wells, 1997; Bradley, 1996;
Macgregor et al. 1996; Burton, Duffas and Williams, 1995), my own study set out
to assess patient satisfaction with medication change where a pharmacist was
employed to support GPs' prescribing activity.
5.2 OBJECTIVES
The objectives of the study were to:
• explore patients' satisfaction with changes in their medication
• identify levels of satisfaction in relation to the way in which the change was
carried out
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5.3. METHODS
5.3.1 Study design
A postal questionnaire survey was developed to assess the views of patients who
had undergone a change in their medication in practices where a pharmacist was
employed to support GPs' prescribing activity. Issues relating to levels of
satisfaction with how the change was communicated were explored and the
questionnaire was similar to the one used by Dowell, Snadden and Dunbar
(1995). Although interviews or focus groups with patients might have yielded
"richer" data, the use of a questionnaire for gauging levels of satisfaction is
widely acknowledged (Hall and Doman, 1988a; Hall and Doman, 1988b; Baker
and Streatfield, 1995; Poulton, 1996; Largey and O'Neill, 1996) and enabled a
wider sample of patients to be reached within the time and financial constraints of
the study (Bowling, 1997).
5.3.2 Study population
5.3.2.1 Selection of study practices
Due to the success of the Doncaster Prescriber Support Project, the five
pharmacists continued to be employed in the 8 intervention practices for a second
year and the scheme was rolled out to a further 11 practices, receiving input from
an additional six pharmacists between September 1997 and August 1998.
This study was conducted in the second year of the Doncaster Prescriber Support
Project and all 11 pharmacists working with 19 practices were asked to take part.
Three pharmacists declined the invitation due to workload commitments. The
remaining eight pharmacists (working with 13 practices) were therefore recruited
to help administer the questionnaire. The median list size (interquartile range) for
these practices was 7 390 (3 848 to 8 925). The median (interquartile range)
Townsend scores (Townsend, Phillimore and Beattie, 1988) were 2.88 (1.93 to
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4.41). The practices included 52 GPs (median four), of whom two were single
handers. Six of the practices were fund holding and one was dispensing.
Permission to conduct the survey was requested and granted from the lead GP
from each practice (Appendix 5.1)
5.3.2.2 Identification of subjects
Each pharmacist was requested to print off anonymised lists of patients who
underwent a change in medication, during the period 1 October 1997 to 31
January 1998, where the aim was to rationalise prescribing. These changes
included generic substitution or substitution with a cheaper brand, changing to
lower cost inhaler devices or brands, therapeutic substitution and
reduction/discontinuation of dose. To reduce the possibility of selection bias, the
lists were sent to a third party at Doncaster Health Authority where a systematic
sampling technique (with random start point) was used to choose a sample of up
to 25 patients per practice (Bowling, 1997). This number was decided upon after
consultation with the pharmacists regarding the number and types of changes
taking place. For each practice, the third party was asked to count up the number
of patients who underwent a change in medication in the specified time period
(I October 1997 to 31 January 1998) and divide by 25 i.e. the number of
questionnaires to be sent, to give the sampling fraction. This was then used to
select the sample. For example, if the number of patients who underwent a change
in medication was 100, in order to select a sample of 25 patients a one in four
sampling fraction would be used. The sampling would then start at a random
point between one and four.
The pharmacists were then notified which patients were to receive the
questionnaires. Two of the practices could not identify 25 patients who had
undergone a change in medication in the above time period. In these cases, all the
patients who had undergone a medication change were sent a questionnaire. For
one practice, this was 22 patients and for the other 19 patients. From the 13
practices a total of 316 patients were identified for the survey.
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5.3.2.3 Exclusion criteria
It was important that the potential respondents could read and write English, as
no provision had been made for alternative languages. To avoid any confusion, it
was also important that patients had only undergone one change in medication in
the time period specified. Therefore, the pharmacists were asked to exclude
patients known to be non-English speaking and those who had undergone more
than one change of medication in the study period. For practical reasons
(including consenting issues), the pharmacists were also asked to exclude patients
with severe mental illness, cognitive impairment and those aged under 18 years
old.
5.3.3 Questionnaire design
In developing the questionnaire, the previous survey conducted by Dowell,
Snadden and Dunbar (1995) and the comments of pharmacists and GPs involved
in the Doncaster Prescriber Support project were taken into account. In addition,
five patients were interviewed to assess their views on medication change and to
pilot an early version of the questionnaire.
5.3.3.1 Patient interviews
In order to explore the issues surrounding patient medication change, semi-
structured face-to-face interviews were conducted between June 1997 and July
1997 with five patients from two of the study practices. According to Britten
(1995), semi-structured interviews are "conducted on the basis of a loose
structure consisting of open-ended questions that define the area to be explored,
at least initially, and from which the interviewer or interviewee may diverge in
order to pursue an idea in more detail." In the same paper, Britten (1995) goes on
to comment on the importance of the setting of the interview, recommending that
it is preferable to interview people at home. For this reason, all the interviews
were conducted in interviewees' homes at their convenience. To reduce
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interviewer bias, all interviews were carried out by the researcher and it was
made explicit that the researcher was not medically trained or connected in any
way to the interviewees' general practice (Bowling, 1997). It was intended that
the interviews would last approximately one hour and the mean duration was one
hour and nine minutes, ranging from 45 minutes to one hour and 35 minutes. To
ensure accuracy of the data, all interviews were audio-taped with full permission
of the interviewees and later transcribed verbatim by the researcher.
Selection of patients
A purposive sampling technique was used whereby practice pharmacists were
requested to select up to 20 patients (ten patients from each of the two practices)
who had recently (within the last three months) undergone a change in their
medication and forward a letter on behalf of the researcher requesting an
interview (Appendix 5.2). This method of sampling is not designed to be
representative, "rather to identify specific groups of people who either possess the
characteristics or live in circumstances relevant to the social phenomenen being
studied" (Mays and Pope, 1995). It was requested that the sample be as diverse as
possible in terms of the age and sex of the patients and the types of changes in
medication. Of the 20 patients invited for interview, five agreed to take part. The
age, sex and type of change in medication for the interviewees are shown in
Table 5.1 below.
Table 5.1. Characteristics of interviewees
Patient Age Sex Type of medication change
Number
1 61 Male Adalat Retard to Tensipine
2 38 Female Nifedipine to Tensipine
3 40 Male Zantac to Lansoprazole
4 60 Male Atrovent nebuliser solution
to Ipratropium Steri-Nebs
5 65 Male Adalat Retard to Tensipine
193
Interview schedule
An interview schedule was developed to facilitate the interviews. The schedule,
shown in Appendix 5.3, consisted mainly of open-ended questions concentrating
on the key areas to be explored namely:
• background information
- demographic data
- knowledge of condition
- past/current medication
• change in medication
- patients' perceptions of why the change was offered
- reasons for accepting/refusing medication change
• patients' perceptions of how change was handled
- how the change was handled
- opportunity to discuss concerns
- adequate information
• how things could be improved
The questions were ordered in the above way so as to put interviewees at ease
(Britten, 1995) and to let them become accustomed to the tape recorder.
Assurances were given that the data would be treated confidentially and that no-
one from their GP practice would receive any feedback from the interview.
Data analysis
Each tape was transcribed verbatim and a content analysis (a procedure for the
categorisation of verbal or behavioural data, for purposes of classification,
summarisation and tabulation) was done to identify the emergent themes
(Bowling, 1997). A summary of the key is shown below.
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Figure 5.1. Summary of key findings from the patient interviews
1. There was a lack of understanding/confusion over the need for medication
change
2. Several patients were suspicions of cost-cutting which they perceived
could be to the detriment of patient care
3. Concern was often expressed over (real or potential) side effects of the
new medication
4. The need for improved communication regarding the change in medication
was often expressed
5. So too was the need for increased opportunity/time to discuss concerns
over changes to medication and raise questions
6. There was a strong desire to be involved in the decision making process
From these findings, three main hypotheses were formulated. The first hypothesis
was that satisfaction with the manner in which the respondent found out about
the change in treatment would be positively correlated with:
• information being conveyed in a personal manner
• information being provided on why the change had been suggested
• the respondent perceiving themselves as having a choice with respect to the
suggested change
• the respondent having an opportunity to ask questions about the proposed
change in treatment
The second hypothesis, based on evidence from the literature (Hjortdahl and
Laerum, 1992; Freeman and Richards, 1993; Baker and Streatfield, 1995; Largey
and O'Neill, 1996; Freeman and Hjortdahl 1997) was that satisfaction might be
related to a number of patient characteristics such as:
• age
• sex
• how long they had been with the same practice
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• how often they saw the same GP when visiting the practice
• whether they paid for their prescriptions
The third hypothesis was that satisfaction with a new treatment might also be
related to some or all of the above factors.
5.3.3.2 Objectives of the questionnaire
In order to test the hypotheses, a questionnaire was designed which aimed to:
1. Determine patients' levels of satisfaction with:
• medication change and
• how they found out about the medication change
2. Determine whether patients' levels of satisfaction were associated with:
• the different ways in which they found out about the change
• whether they felt that they had a choice about the change in medication
• whether they were able to ask questions
• any problems encountered with the new medication
• their characteristics:
age
- sex
- how long they had been with the same practice
- how often they saw the same GP when visiting the practice
- whether they paid for their prescriptions
3. Determine whether patients' levels of satisfaction were significantly associated
with the ways in which they found out about the medication change (when
controlling for the other factors).
4. Obtain patients' comments on their medication changes.
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5.3.3.3 Development of questions relating to satisfaction
Two questions were used to assess satisfaction:
• Question 5: "In general, how satisfied are you with the way you found out
about the change in your treatment?"
• Question 10:"In general, how satisfied are you with your new treatment?"
Respondents were asked to give their views on a 5-point ordinal Likert scale
(Likert, 1932) with possible responses across the range:
• "very satisfied"
• "satisfied"
• "neither satisfied nor dissatisfied"
• "dissatisfied"
• "very dissatisfied"
Responses were coded in descending order of satisfaction:
• 5= "very dissatisfied"
• 1= "very satisfied"
Likert scales are used extensively for this type of questioning in health services
research due to their ease of administration, analysis and interpretation (Bowling,
1997). They have been employed in a number of patient satisfaction surveys in
general practice (Baker, 1990; Grogan et al. 1995; McKinley et al. 1997).
According to Bowling (1997), one of the potential limitations with using this type
of scale is that "many respondents will opt for the middle response category and
prefer to avoid a decision at either end of the response scales." However, as can
be seen from the results, this did not appear to be the case.
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5.3.3.4 Development of remaining questions
Other questions were developed, based on the current literature at the time (Hall
and Doman, 1990; Lewis, 1994; Stewart, 1995; Largey and O'Neill, 1996),
covering topics believed to be associated with levels of satisfaction, namely:
• the type of medication change
• how patients found out about the medication change
• whether patients went through with the medication change
• patients' characteristics, including whether they paid for their prescriptions
• how long patients had been with their current GP surgery and the extent to
which they saw the same GP when visiting the surgery
5.3.3.5 Questionnaire format
The format of the questionnaire was carefully considered in line with well
recognised general principles which have been summarised by McColl et al.
(2001). It was short, commercially printed on pale yellow paper, was easy to
complete with clear unambiguous questions and was of direct relevance to the
practice patients. Although it contained predominantly closed questions,
respondents were invited to make general comments about their change in
medication at the end of the questionnaire. Answers to closed questions were pre-
coded for ease of data analysis. The front page of the questionnaire conveyed the
fact that the survey was being conducted from the University of Nottingham and
that responses to the questionnaire were non-identifiable to the researcher.
Although the use of a reference number on the front of the questionnaire meant
that responses were identifiable to the pharmacists, reassurances were given that
practice staff would not have access to responses and that they would be treated
with the utmost confidentiality. A recent systematic review by Edwards et al.
(2004) highlighted some of these factors in improving the response rate to
questionnaires.
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The questionnaire followed a logical sequence (McColl et al. 200 1) in that
general questions pertaining to changes in medication preceded specific questions
and demographic questions were placed at the end. The questionnaire was
designed to take no more than ten minutes to complete. The final version of the
questionnaire is shown in Appendix 5.4.
5.3.3.6 Piloting the questionnaire
The questionnaire was piloted on the five patients who agreed to take part in the
face-to face interviews. All five patients replied to the questionnaire and a brief
telephone discussion took place with each respondent within one week of
receiving the questionnaire to ask for feedback on the questions, the design of the
questionnaire and the covering letter. This process, known as cognitive pretesting
(McColl et al. 200 1), involved taking the respondents through the steps of
completing the questionnaire (from opening the envelope and reading the
instructions) and asking them questions about every aspect of the process, what
they were thinking while answering the questions, and their opinion of the format
and layout of both the questionnaire and covering letter. Notes were made during
the telephone conversations which were to be used to make modifications. In
summary, all five patients found the questionnaire easy to read, unambiguous,
and quick to complete and only minor changes to the wording of the instructions
and the layout of the questionnaire were made.
5.3.4 Survey administration
In order to increase potential response rate, the practice pharmacists distributed
the questionnaires along with a pre-prepared letter on headed notepaper from the
relevant general practice (Edwards et al. 2004) (Appendix 5.5). Questionnaires,
instructions (Appendix 5.6), envelopes, labels, and FREEPOST reply envelopes
addressed to the researcher were sent to each of the pharmacists.
The questionnaires were non-identifiable to the researcher and this fact was
emphasised in the letter to patients and on the first page of the questionnaire. To
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allow for the identification of non-responders, a five digit reference number was
written on the front each questionnaire. The first two digits referred to each
practice (1-13), the middle two digits referred to the patient number (1-25) and the
last digit referred to the type of medication change. The last digit was filled in by
the pharmacists using the classification codes sent to them as shown in Table 5.2
below.
Table 5.2. Classification for type of change in patient medication
Code Type of change
1 Generic substitution (including branded generics but not inhalers)
2 Changing to lower cost inhaler devices or brands
3 Substitution of premium price preparations (combination products and
modified release products)
4 Discontinuation of drugs (e.g. those of limited therapeutic value or over-
the-counter)
5 Other
The pharmacists wrote brief details of patients' medication changes in a box on
the first page of each questionnaire. This acted as a reminder to the patient, and it
also served to provide information on the types of change that had taken place. On
the basis of this information, it was possible to check the codes that the
pharmacists had used and a number of new codes were developed to cover other
types of medication change (see Table 5.3). The pharmacists then addressed the
envelopes, ensuring a copy of the questionnaire, covering letter and FREEPOST
reply envelope were enclosed, and distributed them to patients. Each pharmacist
was sent a Patient Record Booklet to assist with follow up of non-responders
(Appendix 5.7).
The survey was sent out in March 1998, giving sufficient time for patients to have
undergone any changes in their medication that had been suggested in October
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1997 to January 1998, whilst minimising the potential for recall bias (Bowling,
1997). To maintain patient confidentiality, the replies were sent directly to the
Division of General Practice at the University of Nottingham. After one month,
the pharmacists were notified of the reference number of non-responders and
reminder questionnaires were issued.
5.3.5 Data entry and analysis
All data, with the exception of free text responses, were numerically coded and
entered onto a Microsoft Access database by the researcher using the patient
reference number as an identifier. Accuracy of data inputting was validated by
checking every fifth entry on the database against the associated questionnaire.
No inconsistencies were found. Descriptive statistics on the responses were
obtained using SPSS (version 8) and responses to open-ended questions were
typed into a word processing package (Microsoft Word 95) and a content analysis
done to identify emergent themes (Bowling, 1997). Incomplete questionnaires
were included in this part of the analysis and therefore the total numbers of
patients responding to each question have been indicated in the results section.
Advice on how best to further analyse the data was sought from Dr Ciaran
O'Neill, Reader in Health Economics and Policy, University of Ulster. His
suggestion was that the data be imported into LIMDEP (version 7) to perform an
ordered logistic regression analysis to determine the factors that were associated
with different levels of patient satisfaction. It would then be possible to examine
the relationship between satisfaction, ranked in an ordinal manner (very satisfied,
reasonably satisfied etc) and a range of variables thought to be related to this
within the context of a multivariate analysis.
Ordered logistic regression is an appropriate statistical technique for analysing
ordinal data of this type (Largey and O'Neill, 1996). It identifies the independent
effects of different factors on satisfaction. The technique produces odds ratios
associated with each independent variable and associated p-values. If the odds
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ratio for a given characteristic is less than one, it can be interpreted in this context
as indicating that a person with that characteristic is more likely to be satisfied
than a person without it. If it is greater than one, in this context it can be
interpreted as indicating that a person with this characteristic is less likely to be
satisfied than a person without this. The p-value associated with the independent
variable indicates the probability at which the variable in question is significant.
The logistic regression analysis was carried out by Dr Ciaran O'Neill, but the
results were interpreted by the researcher. Patients who did not answer all of the
questions were excluded from this analysis. Variables used in the multivariate
analysis are shown in Appendix 5.8
For the multivariate analysis, data have been presented at the following levels:
• p<O.1 (significant at the 90% level of confidence)
• p<0.05 (significant at the 95% level of confidence)
• p<O.01 (significant at the 99% level of confidence)
5.4RESULTS
5.4.1 Descriptive analysis
5.4.1.1 Questionnaire response rate
A total of 314 questionnaires (from a potential number of 316) were issued by the
pharmacists. Two questionnaires were not issued because one patient had died
and another had been admitted to hospital. After the first questionnaire round,
181 patients (58%) responded. After sending out the reminder questionnaires an
additional 38 patients (12%) responded giving an overall response rate of 70%
(219/314).
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5.4.1.2 Demographic characteristics of respondents and non-respondents
Respondents
The mean age of respondents was 64 years (standard deviation: 11.8) and 51 %
were female.
Non-respondents
As pointed out by Baker (1990) "Future studies should seek to ... obtain some
comparative information for responders and non-responders." For this reason,
age, gender and type of medication change of non-respondents was obtained from
the pharmacists. The mean age of non-respondents was 63 years (standard
deviation: 15.1) and 53% were female.
Using the Independent t-test function in SPSS (version 8) (Purl, 1996), it was
found that the difference between the age of respondents and non-respondents
was 1.56 years. The 95% confidence interval for this difference was -1.937 to
5.066. Since this interval contains zero, the difference was not statistically
significant at the two-tailed 5% level. Using the Chi-square test function in SPSS
(Purl, 1996 ), it was found that there was no significant difference between the
observed and expected frequency of males and females in terms of responding to
the questionnaire (i=0.123, degrees of freedom = 1, P = 0.725).
5.4.1.3 Types of changes in medication
On the basis of the types of medication changes recorded on the questionnaires, a
number of new classification codes were developed as shown in Table 5.3. The
corresponding number of respondents and non-respondents with each
classification code has also been shown.
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Table 5.3. Re-classification for type of change in patient medication
Code Type of change Respondents Non-respondents
(%) (%)
1 Generic substitution or 90 (41.1) 43 (45.3)
substitution with a cheaper
brand (not including inhalers)
2 Changing to lower cost inhaler 5 (2.3) 4 (4.2)
devices or brands (including
generic substitutions)
3 Substitution of premium price 0 (0.0) 2 (2.1)
preparations (combination
products and modified release
products)
4 Discontinuation of drugs (e.g. 8 (3.7) 0 (0.0)
those of limited therapeutic
value or over-the-counter)
5 Reduction of dose 17 (7.8) 12 (12.6)
6 Therapeutic substitution 39 (17.8) 16 (16.8)
7 Unspecified change in 21 (9.6) 7 (7.4)
medication as a result of
medication review
8 Unspecified change in 18 (8.2) 3 (3.2)
medication as a result of
attending coronary care clinic
9 Unspecified change in 17 (7.8) 5 (5.3)
medication as a result of
attending acid suppression
clinic
99 Other 4 (1.8) 3 (3.2)
TOTAL 219 (100.0) 95 (100)
It can be seen that the types of changes in medication were similar for both
respondents and non-respondents.
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5.4.1.4 Responses to questionnaire
Patients first found out about their change in treatment by a variety of methods
and these are summarised in Table 5.4.
Table 5.4. Ways in which patients first found out about their change in
medication
Method of communication Responses a (%)
Received a letter from the practice
GP discussed change face-to-face
Practice pharmacist discussed change face-to-face
Told about change when picking up repeat
62
51
46
33
(27.4)
(22.6)
(20.3)
(14.6)
prescription
Not told 11 (4.9)
Received a phone call from the practice 9 (4.0)
Unable to remember 3 (1.3)
Other 11 (4.9)
TOTAL 226 (100.0)
• 212 respondents gave a total of226 responses (7 respondents did not answer this question)
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Table 5.5 shows responses to questions relating to patients' perceptions of the
process of medication change. It can be seen that nearly 39% (80/206) of patients
stated that they were not told why the change was taking place. Sixty-one per cent
(127/207) did not perceive that they had a choice with respect to the change and
38% (78/204) felt they were not given the opportunity to ask questions.
Table 5.5. Responses to questions relating to patients' perceptions of the
process of medication change
Questions Res20nses {%l
Yes No Can't Total
remember
Were you told why your Doctor 108 80 18 2068
wanted to change your treatment? (52.4) (38.8) (8.8) (100)
Were you given any choice about 66 127 14 207b
whether or not your treatment was (31.9) (61.3) (6.8) (lOO)
changed?
Were you given the chance to ask 112 78 14 204c
any questions about the change in (54.9) (38.2) (6.9) (100)
your treatment?
a 13 respondents did not answer this question
b 12 respondents did not answer this question
c 15 respondents did not answer this question
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Table 5.6 shows respondents' levels of satisfaction with how they found out
about the changes in their medication and with the medication changes
themselves. Almost 65% (131/203) of patients were reasonably or very satisfied
with the way in which they found out about their medication change and an even
greater proportion, 72% (144/199), were reasonably or very satisfied with the
new treatment itself.
Table 5.6. Patients' levels of satisfaction with how they found out about the
changes in their medication and with the medication changes themselves
Responses (%)
Satisfaction with finding
out about the change a
63 (31.0)
68
35
Very satisfied
Reasonably satisfied
Neither satisfied or
dissatisfied
Dissatisfied
Very dissatisfied
Not applicable
TOTAL 203
• 16 respondents did not answer this question
b 20 respondents did not answer this question
Satisfaction with
new treatment b
75 (37.7)
25
12
o
(33.5) 69 (34.7)
(17.3) 25 (12.6)
(12.3) 20 (10.0)
(5.9) 7 (3.5)
(0.0) 3 (1.5)
(100.0) 199 (100.0)
In terms of reported adherence to the medication change, 94% (188/201) of
responders said that they had gone along with the change. However, 22%
(44/200) experienced problems with the "new" treatment, and of these, 70%
(30/43) spoke to their GP about the problems. At the time of the survey, 87%
(174/200) of patients reported that they remained on their changed medication.
Descriptive analyses of the results were then undertaken to inform the next stage
of the analysis.
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5.4.2 Multivariate analysis of attitudinal data
As mentioned previously, a number of studies have demonstrated the link
between patient characteristics, such as age and sex, and levels of satisfaction
with health care services. The main purpose of using the multivariate analyses
was to control for these potential confounding factors when assessing the
importance of different methods of informing patients about medication change.
However, using these techniques, it was possible to assess the importance of any
of the variables considered.
The distribution of responses to a number of questions made it impracticable to
examine the relationship between satisfaction and each possible response. For
example:
• in relation to Question 16, none of the respondents had been with their GP for
less than 6 months and very few for anything less than five years. Therefore,
the impact on satisfaction of being with one's GP for more than 5 years was
tested against being with them for less than this period
• in relation to Question 17, the categories "never" and "occasionally" were
combined
• the age distribution of the sample was reduced to just two categories in the
analysis: those 65 years and older, and those under this age
When interpreting the ordered logistic regression analysis it should be recognised
that an odds ratio (OR) less than one indicates that the variable was associated
with higher satisfaction. The reason for this was because "very satisfied"
responses were coded as "1" and ''very dissatisfied" responses were coded as "5".
5.4.2.1 Satisfaction withfinding out about the change in treatment
Results of the logistic regression analysis (Tables 5.7 to 5.8) showed that
satisfaction with the way in which the patients found out about their change in
medication was associated with:
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• being told of the change by:
- the practice pharmacist (odds ratio (OR)=0.24)
- the GP (OR=O.32)
- a letter from the practice (OR=O.25)
• the patient feeling that:
- they had a choice about whether their medication was changed (OR=O.17)
- they had been told why the change in treatment was taking place
(OR=O.36)
• the degree to which patients saw the same GP when visiting the surgery
- respondent always saw the same GP (OR=O.17)
- respondent often saw the same GP (OR=O.23)
- respondent sometimes saw the same GP (OR=O.22)
• female gender (OR=0.43)
Satisfaction with the way in which the patient found out about their proposed
change in medication was not associated with:
• age (OR=O.58)
• whether the respondent paid for their prescriptions (OR=O.83)
• informing the patient of the change by telephone (OR=0.34)
• length of time the patient had been with the same surgery
respondent coming to surgery more than five years (OR=2.75)
5.4.2.2 Satisfaction with the new treatment
From Tables 5.7 to 5.8 it can be seen that satisfaction with the new treatment was
associated with:
• the patient feeling that:
- they had a choice about whether their medication was changed (OR=0.26)
- they had been told why the change in treatment was taking place
(OR=0.48)
• female gender (OR=O.42)
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Satisfaction was not associated with:
• Being told of the change by:
- the practice pharmacist (OR=1.52)
- letter (OR=0.69)
- the GP (OR=l.OI)
• The degree to which patients saw the same GP when visiting the surgery
- respondent a/ways saw the same GP (OR=1.14)
- respondent often saw the same GP (OR=0.98)
- respondent sometimes saw the same GP (OR=0.73)
• Length of time the patient had been with the same surgery
respondent coming to surgery more than five years (OR=1.07)
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5.4.3 Analysis of free-text comments
The questionnaire contained two open-ended questions; Question 11 "If you did
not go through with the change in your treatment please explain why" and
Question 13 "If there is anything else you would like to add, please write in the
space below." A total of 12 patients gave a response to Question 11 and a total of
84 patients gave a response to question 13. Content analysis (Mays and Pope,
1995) was used to draw out the main themes and it should be noted that a single
response may have fitted into more than one theme. This process of multiple
coding of single items is, according to Bowling (1997), "permissible, as well as
often being necessary for analytic coding ...... analytic coding requires multiple
coding which can be cross-referenced for conceptual and theoretical
development. "
5.4.3.1 Analysis of responses to Question 11 "If you did not go through with
the change in your treatment please explain why"
Four themes were identified from the responses to this question and these are
listed below. The number of responses within each theme is given in brackets.
Quotations have then been used to illustrate each of the themes.
1. Side effects from the new drug (7)
2. Perception that the tablets were less effective (4)
3. Lack of explanation/understanding about why the change was made (2)
4. Packaging of new drug not acceptable (1)
One of the main reasons cited for not going through with the change III
medication was concern over side-effects from the new drug:
"As a diabetic indapamide caused me to pass far more water which
was at times embarrassing when shopping etc. Also disturbed
nights" [Patient 08241,female, aged 83years]
213
"I didn't feel as well on the second tablet as I did on the previous one
so my GP put me back onto my original tablets. " [Patient 09075,
female, aged 68 years J
"I have temporarily stopped because of side effects which mayor
may not be due to the tablets. " [Patient 09095, male, aged 70years]
"They caused me dizzy spells" [Patient 11222, female, aged 76
years]
There was also a perception that the new tablets were less effective:
"The new tablets did not do the job they were intended to do"
[Patient 09235, female, aged 77years J
"The new treatment was not successful." [Patient 09255, male aged
61 years]
"My symptoms of burning in my throat got worse so I went to my GP
who has put me back on Losee for another 6 months." [Patient
03115,female, aged61 yearsJ
"Trouble came back within a few days, causing me to vomit after
every meal. " [Patient 10095,femaie, aged 59J
In two cases, a lack of explanation/understanding about why the change was
being made was cited as the reason for refusing to go through with the
medication change:
"The only time I used these tablets was when my stomach was bad
and it wasn't that often, so really I don't know why they stopped them
in the first place, and why they didn't let me know." [Patient 07074,
female, aged 64 years J
"Though unhappy I have not been given a full explanation for the
reason of change only that it would make no difference in a medical
way. It did very much so for several weeks - hence I am back on
Tenormin. " [Patient 02181, male, aged 67 yearsJ
One patient found the packaging of the new drug unacceptable:
"Tablet supplied loose and liable to disintegrate. Metformin is not
supplied in aluminium foil packet which is easier to carry and is
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safer. I want to stick to Glucophage and so 1had to pay 50p to
pharmacist for 84 tablets which is against the principle that a
diabetic gets afree prescription. To supply Metformin as loose tablet
is a step in retrograde hygienically and financially both to patient
and NHS. " [Patient 06041, male, aged 73 years]
From this analysis, it can be seen that the reason given for not going through with
the change in treatment can be attributed to a number of factors, namely concern
about side effects of the new treatment, the belief that the new treatment would
not be (or was not as) effective as their existing treatment, and lack of adequate
explanation as to why the change was taking place.
5.4.3.2 Analysis of responses to Question 13 "If there is anything else you
would like to add,please write in the space below"
As previously mentioned, 84 patients gave a response to this question. In some
instances, patients claimed not to have had a change in medication. In these
cases, the information given by the pharmacists was verified and it was found
that the patients had indeed undergone a change in medication. However, these
changes were usually quite minor e.g. a switch from a brand-named preparation
to a generic preparation or a move from daily medication to "use when required".
A total of 16 themes were identified from the responses to this question and these
are shown below. The number of responses within each theme is given in
brackets and once again, quotations have been used to illustrate the key themes.
1. Very satisfied with/have complete confidence in their doctor (15)
2. Dissatisfied due to lack of choice/explanation (9)
3. Resistant to changes being implemented by the pharmacist rather than the
doctor (2)
4. Suspicious of cost-cutting which could compromise patient care (6)
5. Dissatisfied with method of communication (5)
6. Reassured by pharmacist (4)
7. Unaffected by change due to perception that only the name of the drug had
changed(6)
8. Unaware change in medication had taken place (6)
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9. Under consultant care (7)
10. Satisfied with change/experienced a real benefit (4)
11. Dissatisfied with change (5)
12. Reverted to their previous regime (4)
13. Experiencinglhave experienced side-effects (6)
14. Confusion (real or potential) arising from change in packaging (3)
15. Reduction in dose not as effective (3)
16. General comments of no relevance (6)
Approximately 15 of the 84 respondents (18%) had full confidence in their GP to
make any changes in treatment on their behalf:
"I have no problems with our doctors Dr [name] and Dr [name).
They have always been very helpful. " [Patient 04211, male, aged 64
years]
"I always say the doctor is right to change your treatment if he
thinks it's going to be better for you. " [Patient 09045, female, aged
77years]
"My doctor changed my treatment who I have every confidence in. "
[Patient 06171,female, aged 64 years]
However, several respondents felt strongly that patients should be consulted and
involved in any proposed changes:
" ...one gets the feeling that most patients are kept very much in the
dark about the true purpose of change. Surely, one should have a
wider aspect of patient's intelligence and much fuller explanations
given before changes take place and indeed possible side effects of
theses changes. I raise the question, is it all about cost rather than
effect?" [Patient 02181, male, aged 67 years]
Respondents also felt that they should have a say in whether to accept the
proposed treatment:
"I suggest that when they change anybody's tablets in the near future
that they should tell whoever it concerns that if they don't agree with
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them in any way they should return them to the surgery right away. "
[Patient 07245, female, aged 90 years]
If not consulted, patients could be confused about changes:
"Since the first change about 3 months ago, my surgery has made
another change without any consultation or notification whatsoever.
I think patients should always be consulted because it can lead to
confusion. " [Patientl0185, male, aged 56years]
There were two examples of resistance to change where it was initiated by the
pharmacist, rather than a doctor:
" ...I do not think a practice pharmacist should interfere with
hospital treatment.... The only person who should consider changing
your treatment is a doctor. " [Patient 01155, female, aged 66yearsJ
" ...It seems the pharmacist is above law and the rule of
government ... " [Patient 06041, male, aged 73 years]
Patients were not so much concerned about change per se, but rather the manner
in which it was conveyed to them:
H ... as far as I can recall, I was never consulted by any doctor re:
change of programme. Thefirst indication I had was a letter from the
pharmacist (of which I didn't know we had one) re new treatmentfor
ulcer. " [Patient 01075, male, aged 79J
For some, the change was not communicated at all:
HI found out about the change in my treatment after receiving this
form tofill in. " [Patient 02161, male, aged 50J
Patients who did not receive a full explanation regarding the change in
medication viewed it as a cost-cutting exercise that could compromise patient
care:
HI consider that this practice is for health care on the cheap. I am
not convinced that generic labelled goods are as good You only get
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what you pay for and cheaper drugs cannot be the same. " {Patient
13055, male, 57 years]
"The pharmacist was put back when I told him the only reason for
the change was money! And I was right. Luckily Lansoprazole works
for me, but no doubt if another cheaper drug comes out, I will be
expected to try that. Patient care should not have a price tag on it. "
{Patient 11165, male, aged 36 years]
"I assumed the change was for economic reasons, as I find the
reduction in dosage 20mg to 15mg means the dosage is only effective
for approximately 15 hours out of the 24 hour interval." {Patient
03125, male, aged 65 years]
In one case, a patient thought the change was a result of the offer of an incentive
from a pharmaceutical company:
HI would have liked an explanation of why the name of my tablets
had changed. I have heard that some chemical companies give
incentives if Doctors prescribe their products. I was a little
concerned of the change of the name of my tablets. " {Patient 04111,
male, aged 51 years]
There was a perception held by some patients (or their experiences indicated) that
where a change resulted in lower dosage, this was not as effective:
"I am not satisfied with the new low dosage as it is not effective. "
{Patient 15065, male, aged 37 years]
"When I was on 30mg Zoton it was perfect. I had no discomfort
whatsoever by taking one a day. But when I had to change to 15mgs
I still suffered with heartburn at some time of the day or night. It
doesn't seem strong enough in my case to stop the discomfort."
{Patient 03055,female, aged 68 years]
The change in medication made no difference to SIX respondents as they
perceived that only the name of the drug had changed (when a branded
preparation was changed to a generic preparation):
"Zyloric and Allopurinol are the same thing. No change in treatment
only change in tablet name (Zyloric trade name}." {Patient 02251,
male, aged 59 years]
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"I did not question this change since I already knew that Pons tan
Forte and Mefenamic Acid were the same thing" [Patient 06081,
female, aged 46 yearsJ
However, in some circumstances, switching to generic preparations resulted in
confusion due to the change in packaging of drugs e.g. from strips or blister
packs to loose tablets, highlighting the fact that this needs to be considered when
making changes to medications:
"My Trandate tablets were in day to day strips so that I always knew
whether I had taken them i.e. morning and night. The Labetalol
tablets are loose and sometimes I cannot remember whether I have
taken one or not and this is very inconvenient." [Patient 08061,
female, aged 56yearsJ
" ....Zyloric helped with date/days on blister pack Sometimes I've
forgotten the tablets." [Patient 02111, male, aged 50 yearsJ
A number of patients were pleased with their change in medication and/or
experienced a real benefit:
"The best change I ever did. " [Patient 01105,female, aged 67J
"Lansoprazole capsules instead of Zantac: less tablets, more
beneficial. " [Patient 13155, male, aged 69 yearsJ
However, a number reverted to their previous regime:
"I wasn't happy about the change so I changed back to Losee"
[Patient 03155, male, aged 82 years]
Although some patients seemed largely unaware and uninformed about the role
of the practice pharmacist:
" ...Maybe the cost of employing a Practice Pharmacist would be
better spent on less cost-cutting of patients' treatment." [Patient
13055, male, aged 57yearsJ
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Others had either been contacted or had made contact with the practice
pharmacist regarding their change in medication:
"I have now gone back to my original tablets after discussion with
the pharmacist. " {Patient 09235. female. aged 77years}
"The pharmacist gave me to understand this change is only a brand
name change." {Patient 02031.female. aged 66 years}
"The pharmacist assures me that cholestyramine is the medical term
for Questram ... " {Patient 08041.female. aged 77years}
To summarise, the results of the free-text comments lend weight to the findings
of the survey i.e. the way in which the change in medication was communicated
was of importance to respondents. So too was the opportunity to discuss the
change and have some degree of choice in whether the change was implemented
or not.
5.5 SUMMARY OF MAIN FINDINGS
The patients first found out about their change in treatment by a variety of
methods. Fifty-two percent (108/206) of patients were told why the change was
taking place, 32% (66/207) perceived that they had a choice with respect to the
change and 55% (112/204) were given the opportunity to ask questions. Almost
65% (131/203) of patients were reasonably or very satisfied with the way in
which they found out about their medication change, and 72% (144/199) were
reasonably or very satisfied with the new treatment itself.
Results of the logistic regression analysis showed that satisfaction with the way in
which the patients found out about their change in medication was associated
with:
• being told of the change by the practice pharmacist, the GP or by a letter from
the practice; and
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• the patient feeling that:
- they had a choice about whether their medication was changed
- thy had been told why the change in treatment was taking place
- the degree to which patients saw the same GP when visiting the surgery
- the patient being female
Satisfaction with the new treatment was associated with:
• the patient feeling that:
- they had a choice about whether their medication was changed
- they had been told why the change in treatment was taking place
• the patient being female
Analysis of free-text comments showed that, of the small number of patients who
did not go through with their change in medication, the reasons cited included
concerns over effectiveness, side-effects and lack of adequate explanation as to
why the change was taking place. There was a strong message that the way in
which the change was communicated was crucial to the level of satisfaction with
the new treatment, with patients wanting more involvement in the decision-
making process.
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CHAPTER6
DISCUSSION
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6.1 INTRODUCTION
The main aim of this study was to evaluate a pharmacist-led intervention to
determine whether this helped general practices to control their prescribing costs.
In order to achieve this aim, a series of research questions was devised:
1. Do intervention practices make savings in prescribing costs compared with
matched controls?
2. Do any savings cover the costs of the intervention?
3. What changes do intervention practices make in their prescribing patterns
compared with matched controls?
4. Is the quality of prescribing maintained on the basis of any changes m
prescribing patterns?
5. What are the views of patients on changes made to their medication?
The research questions were addressed in three discrete studies. This final thesis
chapter now draws together and discusses the key fmdings from each of these
studies in light of recent literature and policy developments.
6.2 METHODOLOGICAL CONSIDERATIONS
Before embarking on a discussion of the results, it is worth commenting on the
methods used in the evaluation (to consider the validity and reliability of the
findings) and the practices and pharmacists that were involved in the intervention
(to consider the generalisability of the results).
6.2.1 Study design
6.2.1.1 Assessing changes in prescribing costs and patterns of prescribing
Observational studies are widely used in the investigation of changes in
prescribing costs (Geoghegan et al. 1998; Bradley, Round and Ramsden, 2000;
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Walker and Mathers, 2002). However, the design lends itself to a number of
potential biases including:
• secular trend - the outcome may be increasing or decreasing with time; for
example, the observations might be increasing before the intervention and
could be wrongly attributed to the intervention
• cyclical or seasonal effects - there may be cyclical patterns in the outcome of
interest that occur over time. For example, prescribing of certain drugs may
vary with the occurrence of seasonal illnesses
• duration of the intervention - the intervention may have an effect for a
limited time only, for example a period of four months; data collected yearly
would not identify this effect
• random fluctuations - these are short fluctuations with no discernible pattern
that can bias intervention effect estimates
To overcome these potential biases, it could be argued that use of an interrupted
time series (ITS) analysis may have been a more appropriate method for the
analysis of PACTline data than the one used (Shadish, Cook and Campbell,
2002). In ITS design, data are collected at multiple instances over time before and
after an intervention (interruption) to detect whether the intervention has an effect
significantly greater than the underlying secular trend (Ramsay et al 2004). One
of the main advantages of ITS designs is that it allows for the statistical
investigation of potential biases in the estimate of the effect of the intervention.
However, all of the potential biases outlined above were recognised and
addressed in the design of the study. A control group was used to assess changes
in prescribing costs which were reasonably well matched on baseline
characteristics. Therefore there was some degree of certainty that the changes
observed in the intervention practices were not the result of chance alone or due
to natural changes in prescribing patterns. The two year period of data collection
allowed for cyclical or seasonal effects and by obtaining changes in prescribing
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costs for the Trent Region as a whole and for the ten most similar health
authorities in England, it was possible to show that the control practices were not
increasing their prescribing costs at an extraordinary rate.
A randomised controlled trial (RCT) would have given a more reliable answer to
the question of whether pharmacists working in general practices can help to
control prescribing costs and this method has been employed by a number of
recent pharmacist-led intervention based studies (Zermansky et al. 2001;
Freemantle et al. 2002). However, this was not possible using the approach taken
by Doncaster Health Authority who chose to offer the intervention to all practices
in Doncaster. As pointed out by Black (1996), although RCTs are viewed as the
"gold standard" for measuring the effectiveness of interventions, they are
sometimes impossible to do and "well designed observational methods offer an
alternative to doing nothing."
6.2.1.2 Patient satisfaction with medication changes
The use of questionnaire surveys to elicit levels of patient satisfaction in general
practice is common (Baker and Streatfield, 1995; Dowell, Snadden and Dunbar,
1995) and, given the objectives, was an appropriate methodology for this study.
The advantages of postal questionnaire surveys are their low cost and the ability
to access a wider sample of patients compared with other methods such as face-
to-face interviews (Bowling, 1997). However, the main disadvantage tends to be
poor response rate (Edwards et al. 2004). Low response rates have been
acknowledged as potential sources of bias upon survey results, making
generalisations from the research findings to the wider population difficult
(Edwards et al. 2004). This is due to the fact that non-respondents are likely to
differ from respondents with respect to important characteristics. For this reason,
all the major guidelines to increase response rate were followed (McColl et al.
2001) resulting in an acceptable number of returns (70%). Although non-
response bias can affect results, the age and sex distribution of non-respondents
was found to be similar to that of respondents (no significant differences). In
addition, there were few differences between respondents and non-respondents in
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terms of the types of medication changes being made. A second potential source
of bias for surveys of this type is the desire for respondents to give a socially
acceptable answer. Although it was emphasised that responses to the
questionnaire were confidential and anonymised to the researcher, the use of a
reference number (for non-response identification) may have led some patients to
believe that their responses would be fed back to their general practice and may
have influenced their answers. A third type of potential bias is recall bias
(Bowling, 1997) which relates to the respondents' selective memory of events,
experiences or behaviour. To reduce the likelihood of recall bias, the
questionnaires were issued relatively soon after the change in medication.
One of the strengths of the study was that it allowed various factors to be
accounted for when assessing patients' levels of satisfaction with medication
change. In assessing the importance of different ways of telling patients about
medication change it was possible to control for potential confounding factors
such as age and gender (Largey and O'Neill, 1996) continuity of care by the same
GP (Freeman and Richards, 1993; Freeman and Hjortdahl 1997), and whether the
patient paid for their prescriptions. However, social class or patients' levels of
educational attainment were not explored. These may have been important
confounders as other studies have shown education and income to affect client
satisfaction with services (Largey and O'Neill, 1996). Other confounders not
taken account of were potential differences in satisfaction associated with the
different pharmacists, practices and individual GPs involved in changing
patients' medications. Also, the different types of changes in medication were not
taken into account. The reason for not including these variables in the
multivariate analysis is that there were too many distinct categories to produce
meaningful results.
Although the design of the questionnaire was very similar to the one used by
Dowell, Snadden and Dunbar (1995), it could have been strengthened by further
piloting and testing. Validity and reliability of the questionnaire were not
adequately assessed and this is discussed further in section 6.2.3.5.
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6.2.2 Study setting
6.2.2.1 Assessing changes in prescribing costs and patterns of prescribing
While the study showed that intervention practices managed to contain their
prescribing costs relative to controls, it is important to consider the
generalisability of the results to other practices. It is possible that the changes
observed were strongly influenced by the characteristics of the volunteer
practices, the pharmacists themselves and the input from Doncaster Health
Authority.
The practices involved in the project came from a health authority with relatively
high prescribing costs. It could therefore be argued that the relative savings made
by the intervention practices were not the result of the intervention per se, but due
to a phenomenon known as "regression to the mean" (Campbell and Stanley,
1963). This can occur when "respondents are selected (or select themselves)
because they had scores that were higher or lower than average" (Shadish, Cook
and Campbell, 2002). When such extreme scorers are selected, there is a
tendency for them to score less extremely when retested on the original measure
and this can easily be mistaken for a treatment effect. Use of a control group and
comparison with other practices for the same time period would indicate that it is
unlikely that the findings of the study were as a result of regression to the mean,
rather than as a result of the intervention. However, it is possible that the scale of
the relative "savings" made by the intervention practices would not be replicated
in other practices with lower baseline figures.
This was a voluntary project that included interested GPs only. Although
intervention and control practices were carefully matched, they differed on the
important issue of whether they took up the offer of pharmacist support. It is
doubtful whether the results would be replicated in practices that did not want
help from a practice-based pharmacist.
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It should be recognised that this was a managed project that required considerable
input from a committed health authority team. It is possible that the information,
training and support that the pharmacists received had a major impact on the
success of the project. The pharmacists certainly perceived these things to be
important (Davis S. personal communication). However, it is not possible to
identify with certainty which aspects of the information, training and support
were most important. It is possible that the lack of any of one of these elements
might have adversely affected the success of this initiative, making it difficult to
replicate in other parts of the country.
There is also the possibility that the pharmacists working in the intervention
practices were particularly gifted and that other projects might have had
difficulties in attracting people of such high calibre. It should be noted that the
pharmacists employed in the project had at least five years' experience and were
all considered appropriate to be employed at senior/principallevel.
By charting the changes in costs for the study period, it was possible to see that
the pharmacist intervention had an almost immediate effect on prescribing costs.
According to Wagner (2002), it is usual for the effect of interventions to take
time to become manifest. However, the pharmacists involved knew that the
project was being evaluated and may have perceived that their jobs were unlikely
to continue unless they had achieved some degree of success at controlling costs
or improving the quality of prescribing in the study period.
These factors may have increased the motivation of both practices and
pharmacists, In other circumstances one might not find such marked changes in
prescribing as a result of pharmacist intervention.
6.2.2.2 Patient satisfaction survey
The patient satisfaction survey took place in the second year of the Doncaster
project when an additional six pharmacists were employed to work (on a
sessional basis) in a further 11 practices. The 13 practices chosen for the survey
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were therefore unusual in that they all had the support of a dedicated pharmacist
and this factor may well have limited the generalisability of the results.
Nevertheless, the survey provided a good opportunity to gauge patients' views on
medication change where pharmacists had been involved, and in contrast to the
Dowell study took place in more than one practice. The major limitation of the
study however, was the fact that no control group was used to measure levels of
patient satisfaction undergoing medication changes in practices where no
pharmacists were employed. It is therefore difficult to say with any certainty
whether the presence of the pharmacists had any bearing on the levels of patient
satisfaction with changes in their medication in the study practices.
6.2.3 Validity and reliability of results
The concept of reliability relates to the reproducibility of a study, and validity,
relates to the 'truth' (Mays and Pope 1995). Hammersley (1990) interprets
validity as "the extent to which an account accurately represents the social
phenomenon to which it refers" and reliability as "the degree of consistency with
which instances are assigned to the same category by the same observer on
different occasion." The validity and reliability of the results are discussed below.
6.1.3.1 Use of PACT data
Although the use of PACT data to assess changes in prescribing costs is common
(Wilson et al. 1996; Harris and Scrivener, 1996; Leach and Wakeman, 1999;
Bradley, Round and Ramsden, 2000; Avery et al. 2000b; Walker and Mathers,
2002), the validity of the results are dependent upon the validity of the PACT
data from which they are derived. It is important to note that PACT data only
relates to those drugs dispensed, not those prescribed. The way in which the
PACT data were manipulated and analysed deserves comment. All data
manipulation was carried out in Microsoft Excel. The figures were then "rounded
off' to a minimum of one significant figure on the basis that percentage changes
of any smaller magnitude were not likely to be important.
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In analysing the Level 3 PACT data, the September 1997 Drug File was used for
both the year of the intervention and the previous year. Although this made it
possible to assess changes in prescribing behaviour without having to account for
inflation in drug costs, a limitation was that the calculated changes in drug costs
did not tally exactly with real changes in costs. Therefore accuracy of the data
was compromised.
In order to check for accuracy and precision of the data used in the analysis, data
obtained from the PPA were compared with data obtained from Enigma Medical
Systems and it was found that there was less than five per cent variation between
the two which was considered acceptable.
6.2.3.2 Choice of denominator
The use of the item is not a reliable measure of prescribing volume as it does not
take the quantity of the drug prescribed into consideration (Bogle and Harris,
1994). For this reason DDDs were used to measure changes in prescribing
volume (World Health Organisation, 1978). One of the limitations of using this
system is that, for a small number of drugs, the concept of a DDD is
inappropriate e.g skin preparations such as creams and ointments where the unit
of issue is a tube. Since patients use different quantities depending on the area to
be covered, it is not possible to produce a meaningful DDD. Therefore an
estimated DDD was used for these drugs which may have affected the accuracy
of the data.
A second limitation of the system is the fact that it is based on an adult dose. This
presents a problem with drugs used to treat infections where a large number of
paediatric doses are given e.g. penicillin antimicrobial agents. Although the net
effect was to reduce the overall number of DDDs in this class of drug, the same
was true for both intervention and control practices. Since the study was
concerned with changes in volume of prescribing, it could be argued that the
results are indeed valid.
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More recently, a new method for measuring volume has been developed by the
Prescribing support unit, the Average Daily Quantity (ADQ). Where as the DDD
is defined by international prescribing habits, the ADQ is based upon the
prescribing behaviour in England and represents the assumed average
maintenance dose per day for a drug used for its main indication in adults. The
ADQ, which was not available for use at the time of the study, is now used to
more accurately compare the prescribing activity of primary care practitioners in
the UK (National Prescribing Centre, 2004).
6.2.3.3 Quality of prescribing
Using PACT data is not a good way to measure quality of prescribing
(McGavock, 2001). The main problem is that the data cannot be related to
individual prescribing decisions (Cantrill, Sibbald and Buetow, 1998). In order to
assess the appropriateness of changes in prescribing, audit of medical records is
necessary, an approach increasingly advocated (Woodhead, 2004). Thus, while
certain prescribing patterns might suggest either good or poor prescribing, it is
not possible to make a firm judgement on the basis of PACT data. Therefore,
although the results of this analysis may be reliable, their validity could be
questionable.
6.2.3.4. Statistical tests used
In analysing changes at BNF chapter level, a number of statistical tests were done
using the Wilcoxon Test to investigate changes in prescribing costs between
intervention and control practices. Repeated tests of this type, if uncorrected for
the number of tests, can artificially inflate statistical significance. This is known
as "Fishing and the Error Rate Problem" (Shadish, Cook and Campbell, 2002).
Since correction for the number of tests was not carried out, caution is needed in
the interpretation of these results. However, it must be remembered that changes
at BNF chapter level were secondary prescribing-related outcome measures;
primary-related outcome measures being the changes in overall prescribing
variables.
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6.2.3.5 Questionnaire design
In designing the questionnaire only five of the twenty patients approached agreed
to be interviewed and the sample was not as diverse as hoped for. Although the
questionnaire was piloted on these five patients, in hindsight, it is acknowledged
that much more extensive piloting (with a more diverse sample of patients) was
needed to assess validity and reliability. Due to fmancial and time constraints, it
was not possible to conduct the survey in languages other than English. Therefore
the results are unlikely to include views from those patients from non-English
speaking backgrounds. However, according to the 2001 census (National
Statistics Online, 2004), the percentage of non-white people living in Doncaster
is low (2.3%).
6.2.4 Ways the study could have been strengthened
There are a number of ways the study could have been strengthened and these are
discussed below.
The collection and analysis of PACTline data for a two year period prior to the
intervention would have given greater insight into the growth in costs of both the
intervention and control practices. In addition, it would have been interesting to
look at trends for at least one more year subsequent to the intervention to see
whether relative savings were being maintained by the intervention practices and
whether the trend of rising costs continued in the control practices. The benefits
of the pharmacist intervention may well have been short-lived, as previous
studies have shown a tendency for GPs to revert to old habits after prescribing
intervention has ceased (Harris et al. 1985).
The collection of the additional data was considered by the researcher in the
second year of the project but was not possible due to a number of reasons.
PACTline data for the year September 1994 to August 1995 were not available
from the PPA as only the most current two years' worth of data are kept on
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computer. In terms of collecting PACTline data for the year September 1997 to
August 1998, guidelines on the ethics of using this type of data for research
purposes were changing and it was no longer possible to access this data without
prior ethical committee approval.
The analysis of PACT data at individual practice level showed that some
intervention practices were more successful than others at containing the rise in
prescribing costs. relative to controls. The reasons for this were not explored by
the researcher but by staff at Doncaster Health Authority who took responsibility
for the qualitative aspects of the Prescriber Support Project. This consisted of a
series of interviews with the pharmacists and GPs in the intervention practices
and analysis of the pharmacists' diaries. The results of this work are mentioned in
Appendix 6 but it is acknowledged that my own study could have been
strengthened by including some qualitative aspects in its design. This process of
"triangulation of methods" (Mays and Pope, 2000) would have illuminated the
findings from the quantitative aspects of the study, and given greater insight into
the cost-control strategies used by the intervention practices. However, time and
financial constraints were the major inhibiting factors.
6.3 COMMENTS ON THE RESULTS OF THE STUDY
The majority of the results presented in Chapter 3 and all of the results presented
in Chapter 4 have been presented for combined data for both the intervention
practices and matched controls. Therefore, with the exception of changes in
overall prescribing costs, it is not possible to see the variations between the two
groups of practices. While this information may have been interesting, it would
have been extremely time-consuming to process and analyse the data at practice
level. Also, this process would have produced hundreds of statistical results and
this would have made interpretation of p-values difficult (Shadish, Cook and
Campbell, 2002). Instead, the method of presenting data on each of the two
groups of practices has some advantages. The most important is that it is possible
to see exactly how the groups of practices changed their prescribing costs. For
example, in section 4.4.5, costs (and changes in costs) within BNF therapeutic
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groups add up to give overall costs for each BNF chapter. In turn, the costs (and
changes in costs) for each BNP chapter add up to give overall costs for BNF
chapters 1 to 6, 8 and 10. Thus it is possible to see the impact of changes in costs
in one therapeutic group on overall prescribing costs.
The results of the study are discussed below in answer to the research questions
posed at the start of the project. Policy implications and recommendations arising
from the study are also discussed.
6.3.1 Did intervention practices make savings in their prescribing costs?
6.3.1.1 Changes in overall prescribing variables
Compared with their matched controls, the intervention practices made relative
savings of more than twice the amount that the project cost in terms of the
employment and training of the practice-based pharmacists. Results showed that
there was little difference between the two groups of practices in terms of number
of items prescribed and that the relative savings were due to a reduction in cost
per item. It seems likely that a substantial proportion of these savings were the
result of a significant increase in the growth of generic prescribing.
Figures 3.2 to 3.5 show changes in overall prescribing variables at individual
practice level. With one exception, all the intervention practices managed to
control prescribing costs relative to their matched controls. Although the majority
of intervention practices increased the number of items prescribed per ASTRO-
PU, in general they were better able to control costs per item and increase generic
prescribing compared to controls. The increase in the number of items prescribed
in intervention practices may well have been the result of reducing repeat
prescribing intervals from 2 monthly to monthly. This would have the effect of
dramatically increasing the number of items prescribed without any change in
overall prescribing volume and may in part explain how intervention practice 6
(Figure 3.3) showed a greater than 20% increase in items per ASTRO-PU, yet
managed to control prescribing costs, relative to matched controls.
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6.3.1.2 Changes at BNF chapter level
Statistically significant differences in costs between intervention and control
practices were found in chapters 1 (gastro-intestinal system) and 5 (infections).
For combined data, intervention practices showed a reduction in costs for
chapters 1, 5 and 10 and showed relatively smaller increases in costs than
controls in BNF chapters 2, 3 and 4. Although intervention practices increased
their generic prescribing rates by a greater amount than the controls for each of
the BNF chapters studied, this did not explain how practices controlled
expenditure for gastrointestinal drugs where, at the time of the study, a high
proportion of costs came from drugs that were still within patent. This is
discussed further in section 6.3.3.3.
Relative to controls, intervention practices increased the number of items
prescribed in BNF chapters 2, 3 and 4. These differences were small and once
again the results may be spurious as items are not a reliable measure of
prescribing volume (Bogle and Harris, 1994).
6.3.2 Did savings cover the cost of the intervention?
The study showed that if the cost growth of the intervention practices had been as
great as controls, their total prescribing expenditure would have been around
£347000 higher. Given that the cost of the scheme was £163000, it is estimated
that the project made a net saving of £184000.
Although the project was successful in making savings, it must be noted that the
Prescriber Support Project involved opportunity costs for the Health Authority
and the practices. While Health Authority personnel felt that these costs were
justified in terms of the benefits of the initiative, Primary Care Trusts would need
to be aware of the major commitment required in terms of time and resources to
implement such an intervention. Similarly, practices would need to be aware that
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working with a practice based pharmacist may reduce the time available for other
aspects of practice development.
6.3.3 What changes did intervention practices make in their prescribing
patterns compared with matched controls?
6.3.3.1 Changes in overall prescribing variables
The results from the Optimise analysis of changes in overall prescribing variables
show similar patterns to the results from the PACTline analysis. However, there
were some minor differences. For example, the percentage changes in costs (per
1000 patients) were slightly higher for each group based on the Optimise
analysis. This is because cost growth would have been higher in chapters 1 to 6, 8
and 10 of the BNF compared with the other chapters (Department of Health
Statistical Bulletin, 2004). Interestingly, the percentage changes in prescribing
volume (based on units per 1000 patients or items per ASTRO-PU) were similar
even though the unit of volume was different. As with the PACTline analysis it is
clear that intervention practices made relative savings by controlling the cost per
unit volume.
According to the analysis of PACTline data, intervention practices achieved a
significantly higher growth in generic prescribing than controls, despite their
median baseline proportion of generics being higher than controls. The results
of the Optimise analysis are consistent with these findings. They show that
intervention practices had the potential to make savings of £1 271 per 1000
patients by prescribing generically and that they realised 40% of this potential. In
contrast, control practices which had a greater potential to make savings (£1 482
per 1000 patients) only realised 2.6% of this potential.
Optimise software makes it possible to identify potential savings by prescribing
brand-named preparations that are cheaper than either a generic (or brand-named)
equivalent. As mentioned earlier, generics are not always cheaper than brands.
For example, when the tariff generic, co-amilofruse became available, several of
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the brand-named versions of the drug were cheaper than the price set for the
generic in the Drug Tariff. In other cases, there may be differences in costs for
chemically equivalent brand-named drugs (where a generic is not available). In
order to identify these types of preparations it is necessary to have detailed
knowledge of prices (and changes in prices) in the Drug Tariff. The analysis has
shown that although both intervention and control practices made savings by
switching from generic (or branded) preparations to brand-named products that
were cheaper, the extent of savings was much greater for the intervention
practices (21% compared with 7% for controls). This is an important finding
because making savings through these types of substitution requires a
sophisticated approach to cost control.
6.3.3.2 Changes in Audit Commission type categories
New and expensive drugs
Of all the categories examined, "new and expensive drugs" was the most
important in terms of overall prescribing costs and changes in costs. The increase
in costs for these drugs accounted for 73% of the £3 688 rise in overall costs per
1000 patients for intervention practices and 76% of the £5 384 rise for control
practices. Although these proportions are similar, there was a marked difference
between the two groups of practices in terms of the actual change in prescribing
costs between the two years, with intervention practices being more successful at
controlling the rise in costs of these drugs than control practices.
The most important of the new and expensive drugs in terms of percentage
increase in costs between the two years for both groups of practices were lipid-
lowering drugs. This is not surprising given that, for all practices in England, this
section of the BNF (2.12) has shown the largest increase in net ingredient cost for
the three consecutive years 2001 to 2003 (Department of Health Statistical
Bulletin, 2004). Results showed that intervention practices did not restrict their
prescribing of this class of drug; nor did they restrict their prescribing of
oestrogens and HRT. However, with a changing clinical evidence base, the
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benefits of increased prescribing of HRT may now be questionable (Innovative
Health Technologies, 2004). In terms of SSRIs, proton pump inhibitors and
selected new and expensive drugs, intervention practices managed to restrict the
increase in costs to a greater extent than controls.
Expensive hospital-initiated drugs
Expensive hospital-initiated drugs were included in the analysis as it was
considered that they may have contributed to some of the differences in costs
observed between the intervention and control practices. Although intervention
practices had a marked increase in costs for drugs in chapter 8 of the BNF, the
magnitude of the increase was similar for control practices. However,
intervention practices had a 24% increase in costs for some hospital-initiated
drugs in marked contrast to control practices which had a fortuitous 48%
reduction in costs for the same drugs.
Other Audit Commission type categories
In keeping with the results of the Audit Commission Report (1994), intervention
practices made savings in prescribing costs for modified/sustained release
preparations, drugs of limited therapeutic value and topical NSAIDs. The fact
that intervention practices decreased their prescribing costs for these drugs
suggests that the pharmacists were making specific interventions in these areas.
Savings for intervention practices were not apparent for drugs that could be
bought over-the-counter or combination products. However, the rise in costs for
these drugs was minimal (4% and 0.7% respectively).
6.3.3.3 Changes in prescribing costs at BNF chapter level
Findings from the Optimise analysis of changes in prescribing costs at BNF
chapter level are consistent with those obtained from the PACTline analysis, with
the exception of changes in costs for chapter 6 (endocrine system). This is not
unexpected as the PACTline data, unlike the Optimise data, were weighted for
patient characteristics such as gender, an important factor in this class of drugs.
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Overall, intervention practices managed to restrict the rise in costs to a greater
extent than control practices for chapters 1 (gastro-intestinal system), 2
(cardiovascular system), and 3 (respiratory system). In contrast to control
practices, intervention practices reduced costs for chapter 10 (musculoskeletal
and joint diseases) and although both intervention and control practices reduced
their costs for chapter 5 (infections), intervention practices did so to a much
greater degree.
It is noteworthy that intervention practices managed to control costs for gastro-
intestinal drugs at a time when the rise in the use of proton pump inhibitors was
having a substantial impact on prescribing costs (Jones et al. 2001). This was
achieved by substantially reducing prescribing costs for H2-receptor antagonists.
Also the reduction in costs for drugs used for infections is important given that
GPs have been criticised for the volume and cost of the antimicrobial agents that
they prescribe (Little et al. 1997; Woodhead, Fleming and Wise, 2004).
Similarly, reductions in costs for drugs used for musculoskeletal and joint
diseases (mainly NSAIDs) in the intervention practices, would be in keeping with
attempts to persuade GPs to reduce their prescribing of NSAIDs for reasons of
safety and cost.
6.3.3.4 Changes in prescribing costs for selected therapeutic groups
As shown in Table 4.17, changes in costs for 20 therapeutic groups were
responsible for 87% (£3 956) of the difference between the two groups of
practices in their changes in costs between 1995/6 and 199617. It is worth noting
that of the 20 therapeutic groups listed in Table 4.17, the "top 10" were
responsible for 80% of the differences seen between the two groups.
Data on changes in prescribing in specific therapeutic groups are shown in
section 4.4.6 and a summary of the changes in different therapeutic groups is
shown in Tables 4.51 to 4.52. It is not intended to repeat this information in the
discussion but rather to focus on the types of changes that occurred in prescribing
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patterns (with examples) in order to draw out key strategies that may have been
employed by the intervention practices.
Changes in intervention practices
The types of changes that enabled intervention practices to reduce prescribing
costs are shown below (with examples):
• reductions in prescribing volume:
- H2-receptor antagonists
- drugs used to treat infections (penicillins and macrolide antimicrobial
agents)
- adrenoceptor stimulants (mainly salbutamol)
• reductions in cost per volume:
- drugs used to treat infections (penicillins and cephalosporins)
- ACE inhibitors
• switching to less expensive drugs and preparations:
- nizatidine instead of ranitidine
- reduction in use of breath-actuated and dry-powder inhalers
- relative increase in generic beclomethasone inhalers
• "paying" for new and expensive drugs through reductions in other therapeutic
areas:
- Increase in prescribing of proton pump inhibitors offset by reductions in
prescribing of Hs-receptor antagonists
The most important of these factors was the reduction in cost per volume. This is
in keeping with the results of the PACTline data which showed that these
practices significantly increased their rate of generic prescribing relative to
matched controls.
It should be noted that intervention practices did not reduce costs in all
therapeutic areas. In some areas they increased costs, but managed to control
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these increases to a greater extent than control practices. This was achieved in
one of three ways:
• control of prescribing volume:
- alpha-adrenoceptor blocking drugs
- proton pump inhibitors
• reductions in cost per volume:
- nitrates
• switching to less expensive drugs and preparations:
- use of 10mg omeprazole
Changes in control practices
The types of changes that resulted in control practices increasing their overall
prescribing costs included:
• increases in prescribing volume in most therapeutic groups but particularly
for cardiovascular and gastro-intestinal drugs (especially PPIs)
• use of more expensive preparations within specific therapeutic groups:
- isosorbide mononitrate mlr
- dry powder inhalers
- clarithromycin
• increases in cost per volume:
- alpha-adrenoceptor blocking drugs
nitrates
- macrolide antimicrobial agents
• smaller reductions in costs per volume than intervention practice:
- ACE inhibitors
- penicillin antimicrobial agents
cephalosporins
The most important of these factors was the inability of the control practices to
either reduce (or restrict the rise in) costs per unit volume. This is in keeping with
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the overall Optimise results which demonstrated that these practices showed only
a slight reduction in their potential generic savings (2.6%).
It should be recognised however, that while control practices showed
considerable increases in costs between 1995/6 and 199617, there were some
instances where they managed to reduce costs. For example they reduced costs
for chapter 5 (infections) by reducing the volume of prescribing for penicillins
and cephalosporins.
Implications of changes in prescribing costs in specific therapeutic groups
On the basis of the findings presented, it is possible that the pharmacists were
using strategies to help the intervention practices reduce their prescribing costs.
The elements of these possible strategies are outlined below.
Controlling prescribing volume
There are a number of ways in which prescribing volume (per 1000 patients)
might fall. These include:
• a decrease in morbidity
• prescribing more appropriately
• minimising drug wastage through improving the monitoring of drugs
• withholding drugs that patients need
• a spurious result due to a fall in list size
Although some of the reductions in prescribing volume for the intervention
practices may have been spurious, it is possible that much of the change was as a
direct result of specific efforts on the part of the pharmacists. Analysis of the
pharmacists diaries by Doncaster Health Authority showed that the pharmacists
were using a range of strategies which could account for the changes seen in the
analysis of the PACT data and these have been summarised in Appendix 6.
However, while the pharmacists may have been responsible for instigating most
of the changes that influenced prescribing costs in the intervention practices, it is
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likely that the GPs made some independent changes in their day to day
prescribing.
Given that the researcher did not have data on morbidity in the study practices, it
is not possible to tell whether or not the reductions in prescribing volume were
appropriate or not. However, there were reductions in prescribing volume in
areas where it has been suggested that there may be benefits from less prescribing
e.g antimicrobial agents (Little et al. 1997; Woodhead, Fleming and Wise, 2004).
Conversely, there were increases in volume for drugs where it has been suggested
that there may be benefits from greater prescribing by GPs e.g. lipid-lowering
drugs (Scandinavian Simvastatin Survival Study Group, 1994; Oliver, 1995;
Shepherd et al, 1995).
Controlling cost per unit of volume
Practices can control cost per unit of volume by:
• an appropriately cautious use of new and expensive drugs
• an appropriately conservative use of premium price preparations including:
combination products
- modified release products
expensive inhaler delivery systems
- relatively expensive drug choices in different therapeutic groups
• a fortuitous reduction in patients on expensive medications (particularly
hospital-initiated drugs)
• failure to prescribe expensive medications that patients may need
• failure to prescribe premium price preparations when they might have
considerable benefits over existing medication.
One of the limitations of using PACT data for this type of analysis is that it is not
possible to know the reason why a specific drug is prescribed; or whether the
changes in cost per unit volume are appropriate or not. However, the findings
would suggest that the intervention practices were being appropriately cautious in
their use of new and expensive drugs and conservative in their use of premium
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price preparations. In addition, the use of therapeutic substitution to reduce costs
was evident e.g. the increased use of nizatadine over ranitadine (Dutton, 1996)
6.3.3.5 Changes in potential generic savings
Potential generic savings are the savings that could have been made if a practice
had prescribed a brand-named drug generically (where this would have saved
money). Therefore a reduction in potential generic savings between two years
implies that practices have reduced prescribing volume for the brand-named
drugs in question. This analysis makes it possible to say whether these reductions
in prescribing volume have been accompanied by increases in prescribing generic
(or brand-named) equivalent preparations, or by a general reduction in
prescribing volume. This type of analysis is important as it points to the type of
strategy that might have been employed by the practices.
Table 4.38 showed that, for intervention practices, there was a substantial
reduction in potential generic savings between the two years. Over 80% of this
came from reductions in the prescribing of 10 brand-named drugs. This suggests
that in order to make sizeable generic savings, it may be important to focus on a
small number of brand-named drugs where there is the greatest potential for
making savings through generic substitution (Audit Commission, 1994).
Table 4.53 summarises the results of the analysis of how intervention practices
reduced prescribing of certain brand-named preparations. It can be seen that for
some preparations, generic switching was the most important method. For others,
there was an overall reduction in prescribing volume for all equivalent
preparations. These results are discussed inmore detail below.
Intervention practices reduced their prescribing of certain brand-named inhalers
by switching to generics and other brands. There was an overall reduction in
prescribing volume for these preparations (when brands and generics were added
together). The analysis showed that brand to brand switches were towards
Salamol Easi-breathe (salbutamol) and Beclazone (beclomethasone) preparations.
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This is in keeping with the fact that these preparations were heavily marketed to
GPs during the time of the study.
The generic switches that occurred for Volterol 50mg, Volterol 25mg and
Colofac 135mg were quite substantial and would suggest that intervention
practices were instituting systematic changes in their prescribing.
For Adalat 10mg, Triludan 60mg and Tagamet 400mg, there were substantial
reductions in volume of prescribing. In the case of Adalat 10mg, there was a
switch away from generic nifedipine to "other brand-named preparations",
specifically Tensipine. These changing in prescribing might well have been
attributed to a number of factors. For short acting nifedipine, there were concerns
that it might increase the risk of cardiac events. Triludan prescribing was hit
massively by highly publicised concerns about potentially life-threatening drug
interactions and it is possible that the reduction in Tagamet prescribing was due
to generic substitution and the use of PPIs instead of H2-receptor antagonists.
In the case of Nitrolingual spray, there was no real reduction in prescribing
volume in intervention practices and switches were being made to a mixture of
other brand-named preparations and generics.
6.3.4 Was the quality of prescribing maintained?
As mentioned in section 4.3.7 there are a number of limitations in the use of
PACT data to assess prescribing quality ((McGavock, 2001; Cantrill, Sibbald and
Buetow, 1998). However, by using PACT data as a proxy measure of prescribing
quality it has been possible to obtain an impression of whether quality of
prescribing was maintained or improved in the intervention practices. A list of
questions pertaining to quality of prescribing was explored using Level 3 PACT
data and the results are discussed below with examples.
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Did intervention practices increase their prescribing in areas where this
might be necessary to give patients the drugs that they need?
Intervention practices increased their costs (per 1000 patients) for:
• lipid-lowering drugs (97% increase: see Table 4.10)
• inhaled corticosteroids (0.12% increase: see Table 4.11)
• hormone replacement therapy (7.1% increase: see Table 4.6)
Did intervention practices control or decrease their prescribing in areas
where it has been suggested that GPs may "over-prescribe"?
Intervention practices reduced their prescribing (per 1000 patients) for:
• drugs of limited therapeutic value (15% decrease: see Table 4.5)
• antimicrobial agents (13% decrease: see Table 4.13)
- reductions in prescribing volume for penicillin antimicrobial agents
(3.6%) and macrolide antimicrobial agents (3.4%)
• NSAIDs (5.4% decrease: see Table 4.16)
- reductions in prescribing volume seen for Mefenamic acid (13%),
Naproxen (4.3%), Indomethacin (12%), Piroxicam (17%), Tiaprofenic
(18%) and others (12%) (see Table 4.36)
Did intervention practices control or decrease prescribing costs in areas
where it has been suggested that savings might be made without detriment
to patient care?
Intervention practices made savings or controlled the rise in costs in the
following areas:
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• selected generic substitutions (see Table 4.4)
- reduced their potential for making savings by £507 per 1000 patients
(40%)
- most of these reductions in potential for generic savings came from
reductions in the prescribing of 10 brand-named drugs. In many cases
there was evidence of generic substitution e.g. Voltarol 50mg and 20mg
tablets, Colofac 135mg tablets, Becloforte 250mcg inhaler and Becotide
100mcg inhalers
• selected combination products (see Table 4.5)
- although practices did not mange to reduce costs for these drugs, they did
manage to control the rise in costs which amounted to 0.71%
• selected modified release products (see Table 4.5)
- overall practices managed to reduce the prescribing of these drugs by
4.9%. In some cases, e.g. the use of ISMN mlr, intervention practices
showed a modest increase in prescribing volume (5.3%) compared with
controls (17%)
To summarise, on the basis of these findings it would appear that intervention
practices:
• increased their prescribing in areas where this might be necessary to give
patients the treatment that they need
• decreased their prescribing in areas where it has been suggested that GPs may
"over prescribe" (Audit Commission, 1994)
• decreased their prescribing in areas where it has been suggested that savings
might be made without detriment to patient care (Audit Commission, 1994)
It is worth repeating that the intervention practices appeared to make relative
savings in areas where it is believed that savings can be made without detriment
to patients. These reductions in costs were partly offset by increases in areas
where it has been suggested that GPs may need to increase their prescribing.
There was no suggestion of the practices holding back on their prescribing of
important classes of drug such as inhaled corticosteroids or lipid-lowering agents.
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Although these findings would suggest no major cause for concern, it would have
been interesting to have carried out detailed analysis of prescribing quality in the
intervention practices. An area for future possible research would be to examine
quality of prescribing in general practices and how it changes, as a result of
different pharmacist-led interventions.
6.3.5 What were the views of patients on changes made to their medication?
6.3.5.1 Satisfaction with finding out about the change in treatment
The results of the study showed that communication, or lack of it, was extremely
important to patients in terms of having their medication changed. Levels of
satisfaction were greatest when told about the change face-to-face by either a
pharmacist or GP, or being told by a letter. It is likely that some of the patients'
dissatisfaction could have been avoided with better communication. These
findings are consistent with the findings of the Dowell study (Dowell, Snadden
and Dunbar, 1996), the recent study by Little et al. (2004b) and the findings of
the systematic literature review by Cox et al. (2004).
Being offered a choice about whether the medication was changed was positively
associated with levels of satisfaction; so too was having the opportunity to
discuss their concerns with the GP (or pharmacist). This suggests, as found by
Little et al. (2004b), that satisfaction can be increased by encouraging patients to
raise issues and to discuss symptoms and other health related issues in the
consultation.
From analysis of the free-text comments, concerns often centred around real (or
potential) side-effects. In addition, for the small number of patients who did not
go along with the change in medication, there was the suggestion that initial
compliance was associated with satisfaction with the way in which respondents
were told about the change in treatment. This association has been found in other
studies such as that by Jenkins et al. (2003) which showed that problems in
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communication were more likely to lead to poor outcomes in terms of non-
adherence.
Satisfaction with the way in which patients found out about their changes in
medication was associated with a number of other factors. In common with other
studies, women were more likely to be satisfied (Largey and O'Neill, 1996).
Also, the degree to which patients saw the same GP when visiting the surgery
was an important factor. Increased satisfaction associated with seeing the same
GP always (or often) would fit with the literature suggesting that continuity of
care is important to patients (Baker and Streatfield, 1995; Freeman and Richards,
1993).
6.3.5.2 Satisfaction with the new treatment
The recently published World Health Organisation report (2003) highlights the
need to improve adherence to medications so as to "reduce the global burden of
disease". At the time of the survey, 87% of patients confirmed that they
remained on their new treatment, despite 22% having experienced problems.
Seventy-two percent of responders were either "satisfied" or ''very satisfied" with
their new treatment, and 14% were either "dissatisfied" or "very dissatisfied"
(these figures include patients who decided not to continue with their treatment).
These are important findings as they suggest that the vast majority of patients in
this study were prepared to go along with the types of prescribing changes
mentioned. It is interesting to note that in the study by Jon Dowell and
colleagues, (Dowell, Snaden and Dunbar, 1995) only 70% of patients had
continued with a prescribing change at the time of their survey. The more
favourable results from this study may have been associated with a number of
factors including the types of medication change and the communications
received by patients. Nevertheless, even on the basis of this study, GPs and
pharmacists need to recognise that a significant minority of patients will
experience problems with a change in medication and that most of these will seek
advice.
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Satisfaction with a new treatment was strongly associated with whether patients
felt that they had a choice about their change in treatment. This is an important
finding because it adds support to the contention that patients should be involved
in the decision-making process. The recognition of the need for patient centred
consultations is well documented (Royal Pharmaceutical Society, 1997;
Richards, 1999; Stevenson et al. 2000; Weiss and Britten, 2003). However, as
pointed out by Stevenson et al. (2000) and Jones (2003), the concept of shared
decision making does not always translate into practice.
Other aspects of the way in which patients were told about changes in their
medication were not so important, although telling patients why the change in
treatment was taking place seemed to be valuable. Once again, females were
more likely to be satisfied than males. Other patient characteristics were not
associated with satisfaction with the new treatment. Neither were the length of
time the respondent had been with the practice nor how often they saw the same
GP when visiting the surgery.
In summary it can be seen that the results of the study are consistent with the
body of evidence that suggests that patient satisfaction is positively associated
with increasing levels of communication in the consultation and degree of
involvement in the decision-making process. The fact that they frequently do not
get the information or reassurance they want (Britten et al. 2000) may be
attributed to a number of factors e.g. unvoiced agendas in the GP consultation
(Barry, 2000), patient expectations, GPs' (sometimes inaccurate) perceptions of
their patients, or lack of participation on the part of the patient (Britten et al.
2000). Perhaps practice-based pharmacists, with their knowledge of medications
and "well developed interest in, and awareness, of concordance," (White, 2003)
would be well-placed to provide such information and assurances.
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6.4 POLICY IMPLICATIONS OF THE STUDY
The work presented in this thesis would suggest that the employment of
pharmacists in general practice has the potential to reduce GP prescribing costs
while maintaining or improving the quality of prescribing. The relative savings
made by the intervention practices were largely the result of controlling or
reducing costs per unit volume, although controlling or reducing the volume of
prescribing had an important part to play, especially in the case of new and
expensive drugs (proton pump inhibitors in particular). Itwould appear that large
savings were made from just 10 brand-named drugs by:
• switching to generic preparations (where these were cheaper)
• reducing prescribing volume
• in the case of inhalers, switching to lower cost delivery devices
The implications from this work are that there are a number of quite simple
strategies which might help GPs to control prescribing costs in the future. These
are:
• making systematic switches from brand-named drugs to generics where this
is likely to have an important impact on drug costs.
• having a cautious approach to the introduction of new and expensive drugs
(except where there is very clear evidence to support their benefits compared
with existing products)
• limiting the use of modified release and combination products by reserving
them for patients who really need them
• controlling prescribing volume (without detriment to patients)
Although these strategies could very well be implemented without the need for
pharmacist intervention (Tant, 1999), the reason for the success of this project is
likely to be the fact that the pharmacists had the time, the detailed knowledge, the
motivation and the co-operation required to bring about a change in prescribing
patterns. GPs often do not have the necessary time it would take to implement
such strategies (Avery, Walker and Murphy, 1997), but are willing to change
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prescribing behaviour if there is no detriment to patient care (Avery and Heron,
1997).
6.4.1 Information and support
The information and support offered to the pharmacists involved in the project
probably made an important contribution to the success of the initiative. One area
where information and training was seen to be particularly important was with
regard to the use of PACT data (Davis, S. personal communication). Some of the
pharmacists were more experienced than others in dealing with this information
and therefore the level of input required from Doncaster Health varied from
training in basic skills to more complicated analysis. However, skilled
interpretation of prescribing data is essential if pharmacists are to identify
priorities for change in their practices (Jones and Kendall, 2004). Future schemes
need to pay careful attention to training needs in this area and the provision of
appropriate data when it is needed.
6.4.2 Relationships between pharmacists and primary health care teams
The importance of good working relationships between pharmacists and their
respective primary health care teams cannot be underestimated. These
relationships (in which mutual trust is essential) take time to develop. It is
important for pharmacists to fmd effective ways of communicating with GPs and
for managing change with minimum disruption to the practices or patients. The
fostering of good working relationships in the intervention practices may have
been helped by the time commitment given by each of the pharmacists. It is
unlikely that pharmacists working on a sessional basis would have the
opportunity to develop such effective working relationships.
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6.4.3 Patient involvement
The literature has shown the increasing importance of patient involvement in
their medication regimens (Barber 1995; Royal Pharmaceutical Society, 1997;
Richards, 1999; Stevenson et al. 2000; Lewin et a1. 2004). Levels of satisfaction
with health services have been shown to correlate with compliance (Home,
Hankins and Jenkins, 2001). Thus, to improve health outcomes and reduce drug
wastage, it is desirable to increase levels of patient satisfaction.
The results of this study showed that communication between patients and health
professionals is of paramount importance in terms of patient satisfaction,
especially when changes to medications are being made. Recommended
strategies to improve communication include:
• informing patients of changes to their medications at all times. Since the
findings suggest that patients are as satisfied with a letter as they are with
face-to-face contact, then the former may be a more cost-effective way of
proposing medication change to patients
• giving patients the opportunity to discuss their medications and the reasons
for any changes made
• giving patients the option to refuse a change in medication (if reasonable)
• ensuring patients receive continuity of care
6.4.4 Implications for future work
Although this study was completed some years ago, the policy implications are
still relevant today. It could be argued that the scale of the savings seen in the
study as a result of increased generic prescribing would no longer be replicated as
generic prescribing is now more commonplace than it was then. However it is
possible that with an emphasis on the appropriate control of new and expensive
drugs and the avoidance of waste, practice-based pharmacists might continue to
be able to "pay for themselves". An appropriate model might be to have intensive
253
input from a pharmacist for one or two years followed by a "maintenance
programme" where the pharmacist visits once every week or so.
If large scale recruitment of practice-based pharmacists were attempted then it is
unlikely that there would be sufficient numbers of pharmacists to go round. It
would certainly not be possible to recruit large numbers of pharmacists with the
skills and experience of those employed by the practices in this study. These
difficulties might mean that relatively inexperienced pharmacists were employed
on a sessional basis in practices. If this were the case then it would be important
to assess whether these pharmacists were effective at helping to control
prescribing costs (while maintaining or improving quality).
Although there has been much emphasis on prescribing costs in this study, it is
important to recognise that the most important role for practice-based
pharmacists is likely to be in promoting high quality patient-centred prescribing.
There is great potential for the involvement of pharmacists in the reduction of
medication-related problems in general practice (Granas and Bates, 1999; Mackie
et al. 1999)
It is recognised that there is scope for improving prescribing in primary care
(Audit Commission, 2003) and pharmacists are uniquely placed to offer support.
It is clear from the pharmacists' diaries (Appendix 6) and from the Optimise
analysis that quality issues were addressed by having a pharmacist in the practice.
In some instances it seems likely that GPs were addressing quality issues without
the direct intervention of the pharmacists. Further research is needed on which
models of interaction between pharmacists and GPs are likely to be most
effective.
6.5 CONCLUSIONS
This evaluation has shown that the intervention practices made estimated relative
savings of £347000 in its first year of operation. This is more than twice the cost
of employing the pharmacists and providing training and support. Relative
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savings were achieved by controlling both prescribing volume and cost per unit
volume. The important factors associated with cost control were:
• controlling the increased volume of new and expensive drugs (especially
proton pump inhibitors and SSRIs)
• reducing the volume and cost of prescribing (especially for drugs used for
infections and adrenoceptor stimulants)
• generic substitution of brand-named drugs (where this could significantly
reduce prescribing costs)
• reducing costs for modified release preparations
• controlling costs for combination products
The findings suggest that the intervention practices made savings in areas where
it is believed that savings can be made without detriment to patients and appeared
to maintain or improve the quality of their prescribing. In addition, the findings
add support to the contention that patients should be involved in the decision
making process. If patients are as satisfied with a letter as they are with face-to-
face contact, then the former may be a more cost-effective way of proposing
medication change to patients.
On the basis of these findings strategies have been suggested that may help
general practices control prescribing costs in the future. Previous work has
suggested that the majority of GPs are sympathetic to the idea of controlling
prescribing costs where there is no detriment to patients (Avery and Heron,
1997). However the major problem which they face is lack of time (Avery,
Walker and Murphy, 1997). Changes in medication can prove to be time
consuming, particularly when large numbers of patients' notes need to be
reviewed and/or patients need to be invited to specially arranged clinics.
Receiving intensive input from pharmacists may not only help to overcome this
problem, but also bring additional benefits to both patients and the rest of the
primary care team (Wells, 1997).
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In the words of Marinker and Reilly (see Ford and Jones, 1995):
"Primary care pharmacists, based in practices, could become
responsible for the pharmaceutical care of the practice population.
They would also effect liaison with community and hospital
pharmacists, would undertake domiciliary visits where necessary
and would certainly emerge as key players in the primary health care
team of the future"
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APPENDIXl
SEARCH TERMS USED TO IDENTIFY PEER-REVIEWED
LITERATURE
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List of search terms used for the literature review
The following Medical Subject Heading (MeSH) terms were used to identify the
relevant peer-reviewed literature used in this thesis:
Health care professional/setting:
• ambulatory care
• family practice
• pharmaceutical services
• pharmacists
• primary health care
• primary health care research
Patient/consumer:
• adherence
• communication
• communication barriers
• compliance
• consumer satisfaction
• decision making
• outcome assessment
• patient-centred care
• patient compliance
• patient satisfaction
Prescribing:
• budgets
• cost control
• cost-benefit analysis
• cost sharing
• costs and cost analysis
• drugs, generic
• drug costs
• drug therapy
• drug utilization
• formularies
• health care costs
• health care rationing
• health care reform
• health services research
• prescriptions, drug
• physician's practice patterns
• physician's practice patterns
• quality of health care
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Appendix 2.1: Intervention practices
Tests of Nonnality
Kolrncccrcv-smlrnov" Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
actual change in NIC
.157 8 .200* .922 8 .445per ASTRO-PU
actual change in
.311 8 .022 .834 8 .065items per ASTRO-PU
actual change in NIC
.371 8 .002 .662 8 .001per item
actual change in %
.212 8 .200* .900 8 .291generics
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
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Normal Q-Q Plot of actual change in items per ASTRO-PU
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Normal Q-Q Plot of actual change in % generics
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Appendix 2.2: Control practices
Tests of Normality
Kolmoqorov-Smlmov" Shapiro-Wilk
Statistic df Sig. Statistic df Sig.
actual change in
.164 8 .200* .930 8 .516NICper ASTRO-PU
actual change in
.289 8 .047 .895 8 .260items per ASTRO-PU
actual change in NIC
.279 8 .067 .894 8 .255per item
actual change in %
.192 8 .200* .933 8 .542generics
*. This is a lower bound of the true significance.
a. Lilliefors Significance Correction
Normal Q-Q Plot of actual change in NIC per ASTRO-PU
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Normal Q-Q Plot of actual change in items per ASTRO-PU
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Normal Q-Q Plot of actual change in NIC per item
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Normal Q-Q Plot of actual change in % generics
1.5 r----------------------,
/'
1.0 //0
.5 /0
0/"
0.0 /0
iii
-.5
/0/
E
.:0Z""C
-1.0
~ /Q) a
C.
X
-1.5W
-1 0 2 3
Observed Value
Detrended Normal Q-Q Plot of actual change in % generics
.4r---------------------,
a
a
.2
0.0
-.2
iii
-.4E
0
z
E
-.6
.g
>
~ -.8
a
-1 0
Observed Value
a a
a
a
2 3
a
4
286
APPENDIX3
CALCULATION OF SAVINGS
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Calculation of relative savings
Relative savings were calculated by applying the percentage increase in NIC per
ASTRO-PU of control practices to intervention practices for the year September
1995 to August 1996 to give a projected NIC per ASTRO-PU for the year of the
intervention. This figure was then multiplied by the mean number of ASTRO-
PUs for intervention practices for the period September 1996 to August 1997 to
give projected total costs. The actual costs of the intervention practices were then
subtracted from the projected costs to give an estimate of the relative savings
made. Calculations are shown below:
NIC (£) per ASTRO-PU 1995/6 for intervention practices = 27.34
Percentage increase NIC per ASTRO-PU (%) for control practices = 9.17
Projected NIC (£) per ASTRO-PU
for intervention practices
[= 27.34 + (27.34 x 9.17)]
100
= 29.85
Mean ASTRO-PUs 199617 for intervention practices = 217 033
Projected costs (£) for intervention practices [= 29.85 x 217033] = 6 478 435
Actual costs (£) for intervention practices =6131619
Difference between projected and actual cost (£) =346816
Cost of the scheme (£) = 163 000
Net saving (£) = 183 816
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APPENDIX4
CHANGES IN OVERALL PRESCRIBING VARIABLES FOR
INDIVIDUAL INTERVENTION PRACTICES AND MATCHED
CONTROLS
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APPENDIX5
ADDITIONAL INFORMATION RELATING TO PATIENT
SATISFACTION WITH MEDICATION CHANGE
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Appendix 5.1: Letter to GPs involved in Doncaster prescribing scheme
(0115) 970 9386
23 February 1998
«Prefix2» «FirstName2» «LastName2»
«Position2»
«OrganizationName»
«Address»
«Address 1»
«City»
«Postal Code»
Dear «Prefix2» «LastName2»
Evaluation of the Doncaster Prescriber Support Scheme
The Department of General Practice at the University of Nottingham has been
asked to be involved in the evaluation of the Doncaster Prescriber Support
Scheme. As part of this evaluation we have been working with Sandra Briant,
Pharmaceutical Adviser to produce a questionnaire to assess patient satisfaction
with changes in their medication. We have piloted this questionnaire with other
practices and we have found it to be satisfactory from both the patients' and
practices' point of view. We would be grateful if you would have a look at the
enclosed letter and questionnaire and give your approval for its use in your
practice as part of the evaluation of the Prescriber Support Scheme.
Please note the following:
1 The questionnaire is designed to assess how patients feel about having
their medication changed so that any lessons can be learnt for the future.
This will be the focus of our analysis: we do not plan to judge practices
on the basis of the results of the questionnaire.
2 We would like the pharmacist attached to your practice to send out the
questionnaires to a sample of patients who have had their medication
changed. We believe that it is very important that the questionnaire
comes with a (pre-prepared) letter from the practice as this will:
a) ensure patient confidentiality is maintained
b) maximise the response rate
3 Envelopes and postage will be provided for the purposes of the survey
and we will be able to reimburse the costs of your headed note paper
should this be required.
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4 When patients return their questionnaires to us we will not know their
identities. Therefore, patient confidentiality will be maintained.
If you are willing for this survey to take place in your practice then please fill in
the reply slip overleaf and return it to Sarah Rodgers in the postage paid envelope
provided.
Yours sincerely
Sarah Rodgers
Research Associate
Tony Avery
Senior Lecturer
.......................................................................................
Evaluation of the Doncaster Prescriber Support Scheme: Reply Slip
Please tick the appropriate box:
1. I am willing for this survey to take place inmy practice 0
If you have ticked this box please fill in your details below and send this reply
slip back using the FREEPOST envelope provided
2. I do not wish for this survey to take place in my practice 0
If you have ticked this box there is no need to fill in your details below. Please
send this reply slip back using the FREEPOST envelope provided
Name: __
Address or practice stamp): _
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Appendix 5.2: Letter sent to patients on behalf of researcher requesting an
interview
Date
Name of patient
Address 1
Address 2
Doncaster
Postcode
Dear patient,
In order to improve the service we provide our patients, we wish to look at the
way in which changes in prescriptions are being handled at our practice. An
important part of this evaluation process is to find out what you think about
changes that we have made to your medication in the last few months. To do this,
we have asked an independent researcher from the University of Nottingham to
conduct interviews with patients, such as yourself. The reason we have chosen
someone from outside the practice to undertake this work is so that patients can
say what they really think about the changes we have made. Any feedback given
to the practice will be done in such a way that individual patients cannot be
identified.
If you agree to be interviewed, we would be grateful if you would complete the
attached reply sheet and send it in the FREEPOST envelope enclosed. Initially,
you will receive a phone call from the Researcher, Sarah Rodgers, who will ask
you to suggest a convenient time for the interview and answer any queries you
may have. If acceptable, the interview will take place in your own home and will
take about one hour.
Sarah would like to tape the interview but only if you are in agreement. This is to
make sure that your comments are accurately recorded, since note taking is
difficult during discussions. Sarah is the only person who will listen to the tape
and once again we would like to stress that anything you say to her will be treated
in the strictest confidence. Should you have any queries regarding the interview,
please feel free to contact Sarah directly on telephone number (0115) 970 9387
ext. 42022.
We would very much appreciate your support and look forward to receiving your
comments.
Yours sincerely,
Signed on behalf of Drs [name of doctors]
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Appendix 5.3: Doncaster patient interview schedule
A: BACKGROUND
KEY THEMES: Demographic data, knowledge of condition, past/current
medication
• How old are you?
• Which practice do you attend?
• How long have you been attending this practice?
• How often do you attend the practice?
• How often do you see your doctor?
• What medication have you been taking?
• Why have you been taking this particular medication?
• How long were you taking it for?
• How has the medication helped you?
• Did it give you any unwanted side-effects?
• Did you always take your medication when you should?
• Do you pay for your prescriptions?
B: CHANGE IN MEDICATION
KEY THEMES: Patients perception of why the change was offered, reasons for
accepting/refusing
• When were you offered a change in your medication?
• Do you know why you were offered a change in your medication?
• What were your reasons for accepting/refusing the change?
• How has your prescription been changed?
• How do you feel about this change?
• Do you feel that your new medication has made you feel better/worse/no
different?
• Does it give you any unwanted side-effects?
• Do you always take your (new) medication when you should?
C: PATIENTS' PERCEPTION OF HOW CHANGE WAS HANDLED
KEY THEMES: How change was handled, opportunity to discuss concerns,
adequate information
• Were you consulted before the change in your medication took place?
• Who was it spoke to you about the change?
• Were you given adequate information?
• Did you have any concerns? What were they?
• Was enough time given to exploring these concerns?
• Are you going to continue taking your new medication?
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D: HOW COULD THINGS BE IMPROVED
• Would you say that you feel satisfied with the way the change was handled?
• Do you think that things could be improved? How?
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Appendix 5.4: Questionnaire
Patient Satisfaction Questionnaire
We are asking for your help in finding out how
patients feel about having their treatment changed. To
do this, we would like you to spend a few minutes
filling in this short questionnaire and sending it to the
University of Nottingham in the FREEPOST envelope
provided
Your practice will not see your answers. Only the
people dealing with the questionnaires at the
University of Nottingham will see your answers and
they will not know who you are. This means that you
arefree to say what you really think!
Your views are very important. What you say may
help improve services to patients in your area and
throughout the rest of the country, so please take the
time to reply.
Thankyouforyourhe~
RefODDOO
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ABOUT YOUR CHANGE IN TREATMENT
As you may remember, you recently had thefollowing change in your treatment:
Thinking about this change please answer the following questions by ticking the
boxes to give your replies. At the end there is space for you to write comments.
1. How were you first told about your change in treatment? (please tick one box)
My GP discussed it with me face-to-face D I
The practice pharmacist discussed it with me face-to-face D2
I received a letter from the practice about the change D3
I received a phone call from the practice about the change D4
Iwas told about the change when Icame to collect a repeat prescription Ds
I cannot remember D6
Other (please give details), _
2. Were you told why your Doctor wanted to change your treatment? (please
tick one box)
No
Yes
Cannot remember
3. Were you given any choice about whether or not your treatment was changed?
(please tick one box)
No
Yes
Cannot remember
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4. Were you given the chance to ask any questions about the change in your
treatment? (please tick one box)
No
Yes
Cannot remember
5. In general, how satisfied were you with the way you found out about the
change in your treatment? (please tick one box)
Very
Satisfied
Reasonably Neither satisfied
satisfied or dissatisfied
Dissatisfied Very
Dissatisfied
6. Did you go along with the change in your treatment? (please tick one box)
No
Yes
Cannot remember
10 now please go to question 11
20 now please go to question 7
30 now please go to question 12
7. Did you have any problems with the change in your treatment e.g. side-effects?
(please tick one box)
No 01
Yes O2
Cannot remember 03
8. If you did experience any problems, did you speak to your GP about them?
(please tick one box)
No 01
Yes O2
Cannot remember 03
9. Have you continued with the change in your treatment? (please tick one box)
No
Yes
301
10. In general, how satisfied were you with your new treatment? (please tick one
box)
D.
Very
Satisfied
Reasonably
satisfied
Neither satisfied
or dissatisfied
Dissatisfied Very
Dissatisfied
11. If you did not go through with the change in your treatment please explain why.
12. Have you gone through with any other changes in treatment in the last 12
months? (please tick one box)
No
Yes
Cannot remember
13. If there is anything else you would like to add, please write in the space below.
continued overleaf
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ABOUT YOU
Please answer all the following questions by ticking the boxes to give
your replies.
14. How old are you? (please give your age in years) _
15. Are you male or female? (please tick one box)
Male Female
16. How long have you been coming to this surgery? (please tick one box)
Less than
6 months
Between 6 months
and 1year
Between 1 year
and 3 years
Between 3 years
and 5 years
More than 5
years
17. When you visit the surgery, how often do you see the same GP? (please tick one
box)
Always Often Sometimes Occasionally Never
18. Do you have to pay for your prescriptions?
Yes No
303
Sarah Rodgers
Division of General Practice
The Medical School
University Hospital
Nottingham
NG72UH
Thank you for your help! !!
Don't forget to return this questionnaire in
the FREEPOST envelope provided (no stamp
required) to:
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Appendix 5.5: Letter sent to patients by pharmacists on practice-headed
paper
Date
Name ofpatient
Address1
Address2
Doncaster
Postcode
Dear patient,
We are asking for your help in fmding out how patients feel about having their
treatment changed. To do this, we would like you to spend a few minutes filling
in a short questionnaire and sending it to the University of Nottingham in the
FREEPOST envelope provided.
We will not see your answers. Only the people dealing with the questionnaires at
the University of Nottingham will see your answers and they will not know who
you are. This means that you are free to say what you really think!
Your views are very important. What you say may help improve services to
patients in your area and throughout the rest of the country, so please take the time
to reply.
Thank you for your help
Yours sincerely
Practice Pharmacist
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Appendix 5.6: Instructions sent to pharmacists regarding survey
administration
Date
Name of Pharmacist
Title
Practice
Address 1
Address 2
Doncaster
Postcode
Dear pharmacist,
Evaluation of the Doncaster Prescriber Support Scheme
Following our previous letter, we would like to outline a proposed method for
administering the Patient Satisfaction Questionnaire:
1. We would like you to send out 25 questionnaires per practice
2. We would like you to consider only those patients who underwent a
change in their medication between 1 October 1997 and 31 January
1998.
3. To avoid bias, the questionnaire will need to be sent to a 1 in N sample of
patients. It has been decided that a third party should choose the sample
and Joanne Etridge has agreed to help. What we would like you to do, is
to send details (anonymised if possible) of all patients who have had a
change in medication between 1st October 1997 and 31st January 1998.
Joanne will then choose the sample and notify you which patients are to
be sent the questionnaire.
4 It will be necessary to write brief details of the medication change in the
box on the first page of each questionnaire (as a reminder for the
patients), and write each patient's name and address on the envelope.
5. A Patient Record booklet (and explanatory notes) has been enclosed to
enable you to keep a record of the patients who have been sent a
questionnaire. Each questionnaire has an arbitrary reference number on
the front and will be used to follow up non-responders. The first 2 digits
refer to each practice (1-13), the middle 2 digits refer to the patient
number (01-25) and the last digit refers to the type of change. We would
be grateful if you could ensure that the patient number on the
questionnaire corresponds with the patient number on the Record booklet.
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6. Enclosed you will find a classification for the type of change in
medication the patient has had. If possible, we would appreciate if you
could decide which category the change falls into and enter the number
corresponding to this category in the far right-hand box of the reference
number on the front page of the questionnaire.
7. When all the questionnaires for each practice have been issued we would
appreciate if you could return the reply slip enclosed in a FREEPOST
envelope. This will help me to know when the questionnaires have been
sent out.
8. Three weeks after the questionnaires have been sent out we will tell you
which patients have replied (based on their reference numbers). We will
send you another batch of questionnaires to be sent to non-responders
with a covering letter.
The appropriate number of questionnaires has been enclosed along with stamped
envelopes, labels, FREEPOST envelopes and a copy of a covering letter which
will need to be photocopied onto your letterhead paper and signed. We will be
able to reimburse the costs of headed note paper should this be required.
We would like to take this opportunity to thank you for your help in
administering the Patient Satisfaction Questionnaire and look forward to
providing you with feedback on the results. Should you have any queries, please
do not hesitate to contact me on the telephone number above.
Yours sincerely,
Sarah Rodgers
Research Associate
Encl.
Tony Avery
Senior Lecturer
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Appendix 5.7: Patient Record Booklet and explanatory notes for
pharmacists
Explanation of Patient Record
No. Refers to patient number (1-25)
Name Name of patient
Ref. Reference number on front of questionnaire (first 2 digits
practice number; middle 2 digits patient number; last digit
classification number for type of change)
MIF Male or female
DoB/Age Date of birth or age
Change Actual medication change
Code Code number for classification for type of change
Date of Change Date when change in medication took place
Q'aire sent (date) Date when questionnaire was sent to patient
Reply (YIN) Nottingham University to notify you whether patient has
replied to initial questionnaire
Reminder sent Date reminder questionnaire was sent to non-respondents
(date)
Reply (YIN) Nottingham University to notify you whether patient has
replied to reminder questionnaire
I would appreciate if the Patient Record could be returned to Nottingham
University after administering the questionnaire. Please detach patient details to
maintain anonymity.
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Appendix 5.8: Variables used in the multivariate analysis shown in Tables
5.7 to 5.8
Satisfaction with change in treatment
Dependent variable was "satisfaction with how the respondent found out about
the change in treatment":
• Very satisfied= 0
• Satisfied= 1
• Neither satisfied nor dissatisfied= 2
• Dissatisfied= 3
• Very dissatisfied= 4
Independent variables were:
• The respondent was over65: dummy variable =1 if the respondent was over
65 and zero otherwise.
• The respondent was female: dummy variable = 1 if the respondent was a
female and zero otherwise.
• The respondentpaidfor prescriptions:dummy variable =1 if the respondent
paid for their prescriptions and zero otherwise.
• The respondent had been coming to the surgery for more than5 years:
dummy variable = 1 if the respondent had been coming to the surgery for
more than five years and zero otherwise.
• The respondent was told why there was a change in treatment:dummy
variable = 1 if the respondent was told why there was a change in treatment
and zero otherwise.
• The respondent was given an opportunity to ask questions:dummy variable
=1 if the respondent was given the opportunity to ask questions and zero
otherwise.
• The respondent felt they had a choice about whether their treatment was
changed: dummy variable = 1 if the respondent felt that they had a choice
about whether or not their treatment was changed and zero otherwise.
• The respondent always seen the same GP the same GP when visiting the
surgery: dummy variable = 1 if the respondent always saw the same GP
when visiting the surgery and zero otherwise.
• The respondent sometimes seen the same GP when visiting the surgery:
dummy variable = 1 if the respondent sometimes saw the same GP when
visiting the surgery and zero otherwise.
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• The respondent was informed of the change in treatment by their GP: dummy
variable = 1 if the respondent was informed of the change in treatment by
their GP and zero otherwise.
• The respondent was informed of the change in treatment by the practice
pharmacist: dummy variable = 1 if the respondent was informed of the
change in their treatment by the practice pharmacist and zero otherwise.
• The respondent was informed of the change in treatment by letter: dummy
variable = 1 if the respondent was informed of the change in their treatment
by letter and zero otherwise.
• The respondent was informed of the change in treatment by phone: dummy
variable = 1 if the respondent was informed of the change in their treatment
by phone and zero otherwise.
Satisfaction with the new treatment
Dependent variable was "satisfaction with the new treatment":
• Very satisfied= 0
• Satisfied= 1
• Neither satisfied nor dissatisfied= 2
• Dissatisfied = 3
• Very dissatisfied= 4
Independent variables were:
• The respondent was over 65: dummy variable =1 if the respondent was over
65 and zero otherwise.
• The respondent was female: dummy variable = 1 if the respondent was a
female and zero otherwise.
• The respondent paid for prescriptions: dummy variable=1 if the respondent
paid for their prescriptions and zero otherwise.
• The respondent had been coming to the surgery for more than 5 years:
dummy variable = 1 if the respondent had been coming to the surgery for
more than five years and zero otherwise.
• The respondent was told why there was a change in treatment: dummy
variable = 1 if the respondent was told why there was a change in treatment
and zero otherwise.
• The respondent was given an opportunity to ask questions: dummy variable
=1 if the respondent was given the opportunity to ask questions and zero
otherwise.
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• The respondent felt they had a choice about whether their treatment was
changed: dummy variable = 1 if the respondent felt that they had a choice
about whether or not their treatment was changed and zero otherwise.
• The respondent always seen the same GP the same GP when visiting the
surgery: dummy variable = 1 if the respondent always saw the same GP
when visiting the surgery and zero otherwise.
• The respondent sometimes seen the same GP when visiting the surgery:
dummy variable = 1 if the respondent sometimes saw the same GP when
visiting the surgery and zero otherwise.
• The respondent was informed of the change in treatment by their GP: dummy
variable = 1 if the respondent was informed of the change in treatment by
their GP and zero otherwise.
• The respondent was informed of the change in treatment by the practice
pharmacist: dummy variable = 1 if the respondent was informed of the
change in their treatment by the practice pharmacist and zero otherwise.
• The respondent was informed of the change in treatment by letter: dummy
variable = 1 if the respondent was informed of the change in their treatment
by letter and zero otherwise.
• The respondent was informed of the change in treatment by phone: dummy
variable = 1 if the respondent was informed of the change in their treatment
by phone and zero otherwise.
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APPENDIX6
KEY FINDINGS FROM THE ANALYSIS OF THE PHARMACIST
DIARIES BY DONCASTER HEALTH AUTHORITY
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Actions taken by the pharmacists as recorded in their diaries
As mentioned in the introduction to the thesis, the pharmacists were asked to fill
in record sheets to note down any actions that they or their practice took to
review or alter prescribing during the course of the study. Doncaster Health
Authority personnel analysed these diaries and it can be seen from the types of
interventions shown below, that the pharmacists were using a number of
strategies which may have accounted for some of the changes seen in the analysis
of the PACT data.
1. Repeat prescription review
Repeat prescription review was undertaken in at least five of the practices and
interventions included review of patients receiving multiple medications
(polypharmacy), 28 day prescribing, incompatible amounts prescribed and ulcer
healing drugs.
2. Generic substitution
This took place in at least six of the practices. In many cases the pharmacist
identified the areas where greatest savings would be made from switching from
brand-narned drugs to generics. After discussions with the practice, the
pharmacist often made the generic substitutions on the practice computer for
patients receiving repeat medication.
3. Nursing and residential home reviews
These took place in at least five of the practices with the emphasis being on
review of medication to determine whether prescribing regimes could be
rationalised.
4. Formulary review
This took place in at least five of the practices. As a result, several practices
agreed to specific therapeutic substitutions:
• Topical NSAIDs changed to Movelat
• PPIs changed to Lansoprazole
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• Beconase changed to Nasobec
• Opticrom changed to Haycrom
• Capoten changed to Captopril
5. Gastro-intestinal drugs
Review of these drugs took place in at least six practices with pharmacists
tending to set up clinics in order to review patients. The types of changes
undertaken were:
• H.pylori eradication (two practices)
• Changing PPls to lower doses, less expensive preparations or alternative
drugs (three practices)
• General review of patients taking ulcer healing drugs ( two practices)
6. Cardiovascular disease
Review of these drugs took place in at least five practices. Types of review
included:
• lipids audit to maximise treatment of patients with ischaemic heart disease
(two practices)
• hypertension clinic audit (one practice): the notes of 862 patients were
reviewed by the pharmacist and assessments were made of the most
appropriate treatments
• diuretic review (two practices): in both practices a clinic was set up for
changing patients' medication (in one of these practices 55 out of 85 patients
attended and agreed to change in their medication)
• ACEI review (one practice): 28 out of 55 patients agreed to undergo changes
in their medication
• Review of patients taking peripheral vasodilators (one practice): out of 15
patients, two stopped the drug and three agreed to try stopping it
• Aspirin audit (one practice)
• Diltiazem SR changed to Angitil (one practice)
• Natrilix changed to Bendrofluazide (one practice)
• Indapamide changed to Bendrofluazide (one practice)
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7. Asthma
Changes were reported in six practices and they included:
• The setting up of a pharmacist run asthma clinic
• Becotide and Ventolin prescribed generically
• Some patients switched from Becotide and Becloforte to an Easi-breathe
inhaler
• Drypowder devices switched to Easi-breathe inhalers
• Respirator solutions changed to Sterineb
Some pharmacists commented that changing patients' asthma drugs was a major
undertaking because of the numbers involved. In some practices patients were
sent letters to inform them of the proposed changes. In one practice over ten per
cent of patients asked to be changed back to Vento lin after a switch to Salamol.
8. Other activities
The following took place in at least one of the practices:
• medication review
• review of antidepressant prescribing
• home visits to review medication
• review of monitoring arrangements for patients taking lithium
• medication review of patients taking methotrexate
• identification of high cost drug treatments
• hospital discharge drug checks
• update of diabetic register
• stop smoking clinic
• combination analgesics (Tylex and Solpodol) changed to their separate
ingredients
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General comments
The following additional points came from the pharmacists' diaries:
• the practice-based pharmacists tended to inform the local community
pharmacists about any major changes in their prescribing so that they could
order appropriate drugs in some areas whilst reducing stock in other areas.
• many of the interventions were noted to be time consuming particularly
where large numbers of patients notes had to be reviewed and/or patients
needed to be invited to specially arranged clinics.
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